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Summary 
Granulomatosis with Polyangiitis (GPA) is an ANCA (anti-neutrophil cytoplasmic antibody) 
associated vasculitis. It typically starts in the respiratory tract and the lungs and progresses to 
a generalized life-threatening, relapsing-remitting disease of small blood vessels in multiple 
essential organs such as the lungs and kidneys. GPA is strongly associated with the presence 
of autoantibodies, so-called ANCA, which are mainly directed against the neutrophil serine 
protease proteinase 3 (PR3). Despite numerous attempts to determine the role of ANCA at the 
onset and during progression of GPA, the pathogenicity of ANCA remains still unclear. The 
aim of this thesis was to explore the mechanisms by which ANCA contribute to the 
development of GPA and influence disease progression and severity. 
The induction of small-vessel vasculitis by the action of ANCA was investigated using a 
newly developed humanized mouse model. Transfer of monoclonal antibodies (mAbs) against 
human PR3 (hPR3) into a hPR3 knock-in mouse was planned to provide new insights into the 
pathogenicity of ANCA. Expression and functionality of hPR3 in the neutrophils of the newly 
generated mouse line was observed. Active hPR3 was transported to the surface of the 
neutrophils and was thus accessible to antibodies. Based on the literature, antibodies, which 
are able to inhibit the proteolytic activity of PR3, were thought to have the highest pathogenic 
potential and to influence the development of relapses. Characterization of mAbs indeed 
revealed one mAb, MCPR3-7, as inhibiting for PR3 and this mAb even impaired the 
interaction of PR3 with its natural inhibitor, α1-proteinase inhibitor. This antibody, however, 
could not be used for transfer experiments, due to its inability to bind to membrane-bound 
PR3. Analysis of a large GPA patient cohort confirmed the existence of ANCA with 
inhibitory capacity towards PR3. Inhibitory ANCA, however, were not restricted to samples 
from relapsing patients, but occurred also during remission phases. No correlation of 
inhibitory ANCA with disease outbreak, relapses or severity could be detected. Therefore, 
instead of transferring inhibitory PR3 antibodies, non-inhibitory antibodies of different IgG 
subclasses were evaluated in hPR3 knock-in mice. One mAb was indeed able to induce a 
strong inflammatory response in the mice, proofing their pathogenic potential. After 
recruitment of immune cells, activation and degranulation of neutrophils led to vasculitis-like 
and pulmonary lesions. IgG2a antibodies were able to elicit a stronger inflammatory response 
than IgG2b, suggesting that the development of a GPA-like phenotype seems to be dependent 
on the IgG subclass.  
   
 
 
Zusammenfassung 
Granulomatose mit Polyangiitis (GPA) ist eine ANCA (Anti-Neutrophile Cytoplasmische 
Antikörper) assoziierte Vaskulitis. Nach anfänglichen Problemen in den Atemwegen und der 
Lunge, entsteht im fortgeschrittenen Stadium eine generalisierte, lebensbedrohliche, 
schubförmig wiederkehrende Vaskulitis kleiner Blutgefäße in essentiellen Organen wie der 
Lunge oder den Nieren. GPA ist eng mit dem Vorkommen von Autoantikörpern, den 
sogenannten ANCAs, assoziiert. Diese richten sich gegen die Neutrophilen-Serinprotease 
Proteinase 3 (PR3). Trotz vieler Versuche, den Einfluss der ANCAs auf den Ausbruch und 
den Verlauf der Krankheit zu bestimmen, konnte die Pathogenität der ANCAs noch nicht 
bewiesen werden. Das Ziel dieser Arbeit war es, den Einfluss der ANCAs auf die Entstehung, 
den Verlauf und den Schweregrad von GPA zu erforschen. 
Die Fähigkeit von ANCAs eine Vaskulitis kleiner Gefäße auszulösen wurde mit einem neuen 
humanisierten Mausmodell untersucht. Transfer monoklonaler Antikörper (mAk) gegen 
humane PR3 (hPR3) in hPR3 Knock-in-Mäuse sollte neue Einsicht in deren Pathogenität 
gewähren. Humane PR3 wurde in der neuen Mauslinie exprimiert und war funktionell. Durch 
Transport der aktiven PR3 auf die Oberfläche der Neutrophilen war diese zugänglich für 
Antikörper. Nach bisher publizierten Daten sollten Antikörper, die die proteolytische 
Aktivität von PR3 inhibieren, die höchste Pathogenität aufweisen und Rückfälle auslösen. 
Durch Charakterisierung verschiedener mAk konnte ein Antikörper identifiziert werden, der 
PR3 inhibiert und die Interaktion von PR3 mit ihrem natürlichen Inhibitor (α1-Proteinase 
Inhibitor) vermindert. Verwendung dieses Antikörpers für Transferexperimente war allerdings 
nicht möglich, da er membrangebundene PR3 nicht erkennt. Die Analyse einer großen GPA-
Patienten-Kohorte bestätigte die Existenz von inhibitorischen ANCA. Diese ANCAs kamen 
jedoch auch während Remissionsphasen vor. Eine Korrelation von inhibitorischen ANCAs 
mit Krankheitsausbruch, Rückfällen oder Schweregrad der Krankheit konnte nicht detektiert 
werden. Statt inhibitorischer Antikörper wurden deshalb nicht-inhibitorische Antikörper 
unterschiedlicher IgG Subklassen transferiert. Einer der mAk löste eine starke Entzündungs-
reaktion in den humanisierten Mäusen aus. Immunzellen wurden rekrutiert und durch die 
Aktivierung und Degranulierung von Neutrophilen entstanden Vaskulitis-artige und 
pulmonale Läsionen. Da der Transfer von IgG2a Antikörpern eine stärkere Entzündungs-
reaktion auslöste als IgG2b Antikörper, scheint die Entwicklung des GPA-ähnlichen 
Phänotyps von der IgG Subklasse abzuhängen. 
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1. Introduction 
1.1 Anti-neutrophil cytoplasmic autoantibody associated 
vasculitis (AAV) 
Anti-neutrophil cytoplasmic autoantibody (ANCA) associated vasculitis (AAV) is a systemic 
autoimmune disease, which is characterized by necrotizing inflammation of blood vessel 
walls. In adults it is the most frequent form of primary small-vessel vasculitis. Predominantly 
small vessels like arterioles, capillaries and venules are affected. Furthermore, AAV is 
strongly associated with the development of autoantibodies, so-called ANCA. These ANCA 
are mainly directed against proteinase 3 (PR3) and myeloperoxidase (MPO). PR3-specific 
ANCA occur mainly in patients suffering from Granulomatosis with Polyangiitis (GPA, 
previously called Wegener’s granulomatosis), whereas MPO-ANCA are a hallmark for 
microscopic polyangiitis (MPA). Besides GPA and MPA the group of AAV further comprises 
idiopathic necrotizing crescentic glomerulonephritis and the Churg-Strauss syndrome (CSS) 
(Kallenberg et al., 2006).  
1.2 Granulomatosis with Polyangiitis (GPA) 
GPA, formerly also known as Wegener’s granulomatosis, was first described by Heinz 
Klinger in 1931. In 1936 Friedrich Wegener observed a similar clinical presentation of 
necrotizing granulomas in the respiratory tract in three additional patients. The hallmarks of 
GPA, necrotizing granulomatous lesions in the upper and lower respiratory tract, necrotizing 
glomerulonephritis and systemic vasculitis of small blood vessels, were established and 
accepted a few years later (Olivencia-Simmons, 2007). 
GPA is a rare disease with a worldwide prevalence of 23.7 – 156.5 per million (Mahr, 2009). 
The annual incidence was estimated to 3.0 – 14.4 per million (Reinhold-Keller et al., 2005). It 
affects both genders equally and occurs typically in adults between 40 and 55 years of age 
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(Langford and Hoffman, 1999). As GPA is a multi-system disorder, symptoms manifest 
individually in the patients and diagnosis proves to be difficult. Mostly patients present with 
upper and lower airway symptoms. Only in its generalized form GPA leads to an involvement 
of the kidneys and the vessels. The most common clinical symptoms of patients with GPA 
unfold in the following order. In about 95% of patients involvement of the upper respiratory 
tract occurs in the early stage of disease. Characteristic symptoms therefor are for instance 
cough, rhinitis and sinusitis (Almouhawis et al., 2013). Pulmonary manifestations occur in 
about 85% of patients throughout the course of disease. This also leads to nonspecific 
symptoms like for example cough or dyspnea. The most common lesions in the lungs are 
nodules, which can be observed in about 70% of patients with lung involvement (Delèvaux et 
al., 2005). Further complications in the lungs can be formation of granulomas, vasculitis or 
alveolar hemorrhage. About 77% of patients are affected by renal disease (Olivencia-
Simmons, 2007). The most serious renal manifestation is the glomerulonephritis. If left 
untreated, glomerulonephritis can lead to complete renal failure. Renal involvement is 
indicated by hematuria, azotemia and proteinuria. Other important clinical manifestations of 
GPA are furthermore inflammation of the vessel walls, mainly affecting small and medium-
sized vessels, and cardiac manifestations. According to disease severity two different forms of 
GPA are discriminated; severe and limited disease. Limited disease is defined as a disease, 
which is not ultimately threatening the life of the patient or the function of vital organs and is 
normally confined to the upper respiratory tract and lungs (Stone and The Wegener’s 
Granulomatosis Etanercept Trial Research Group, 2003). Severe disease is mostly 
characterized by rapidly progressing glomerulonephritis and alveolar hemorrhage and 
represents an imminent threat on the life of the patient. The differentiation between those two 
disease forms is as well important for the choice of therapeutic agents (Wung and Stone, 
2006). Therapy of GPA consists of two phases, the remission induction therapy and the 
maintenance of remission. In general the therapy is performed by using a combination of 
corticosteroids and immunosuppressants. Combination of those two agents enables 
prolongation of remission. The choice of therapeutic agent depends on disease severity. For 
treatment of severe disease therapeutics with higher toxicity are applied (cyclophosphamide 
and glucocorticoids), whereas less toxic agents are used for patients with limited disease 
(methotrexate and glucocorticoids) (Wung and Stone, 2006). 
GPA is strongly associated with the presence of autoantibodies, so called anti-neutrophil 
cytoplasmic antibodies (ANCA). Thus GPA is assigned to the group of autoimmune diseases 
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(Hewins et al., 2000). The target antigen of ANCA in GPA is proteinase 3 (PR3). Strong 
association of GPA with ANCA, which are directed against PR3 (PR3-ANCA), leads to the 
assumption that ANCA play an important role in the pathogenesis of GPA. In the following 
chapters PR3, ANCA and their role in GPA are introduced in detail. 
1.3 Proteinase 3 – the target autoantigen in GPA 
1.3.1  Neutrophil granulocytes 
Granulocytes (polymorphonuclear leukocytes) are myeloid cells, which are characterized and 
named according to their high content of densely packaged granules in their cytoplasm. There 
are three different types of granulocytes, the neutrophil granulocytes, in the following called 
neutrophils, the eosinophil and the basophil granulocytes. The different types are classified 
according to the staining properties of their granules. Neutrophils represent about 50% to 70% 
of all circulating leukocytes. They are relatively short-lived cells, which only survive a few 
days. One of the characteristic features of neutrophils is the segmented nucleus, which is why 
they are also called polymorphonuclear cells (PMNs). Neutrophils are the first line of host 
defense against a wide range of pathogens. Thus they are produced in increasing numbers 
during the immune response and are the first cells to arrive at a site of inflammation. In 
contrast to the high number of neutrophils, eosinophil and basophil granulocytes are only 
present in the blood in low numbers. Only about 1 to 5% of leukocytes represent the 
eosinophil granulocytes and 0.5 to 1% the basophil granulocytes. 
1.3.2 The neutrophil immune response 
After production of neutrophils in the bone marrow, the cells circulate in the blood for a few 
hours before they are recruited to injured or infected tissue. At these peripheral extravascular 
sites they form the first line of cellular immune defense. The neutrophils reach the site of 
inflammation via the blood stream and enter the tissue by a process called neutrophil 
extravasation. This process consists of the attachment of neutrophils to the endothelial cells, 
rolling along the endothelium and firm attachment to the endothelial cells followed by 
transmigration into the tissue (Ley et al., 2007; Zarbock and Ley, 2008). During recruitment 
neutrophils are activated by selectin bound chemokines, which are produced by endothelial 
cells, by integrins and G-protein coupled receptors. Furthermore activation of neutrophils is 
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possible through Fcγ receptors (FcγR), the receptors for IgG immune complexes. Crosslinking 
of antibodies to FcγRs leads to an activation of the cellular functions of neutrophils 
(McKenzie and Schreiber, 1998). After reaching the site of infection, the main function of 
activated neutrophils is the elimination of pathogens. This is mainly carried out by 
phagocytosis of the pathogen. In the endosome pathogens are killed by the production of 
highly toxic reactive oxygen species (ROS), generated by the NADPH-oxidase and by 
hypochlorous acid, which MPO produces from hydrogen peroxide. Furthermore fusion of the 
granules with the pathogen-containing endosome and release of the granule content 
(bactericidal peptides and proteases) into the endosomal lumen leads to the destruction of the 
engulfed pathogens. Neutrophil activation can also lead to an extracellular release of the 
granule content after fusion of the granules with the plasma membrane. This fusion can cause 
further neutrophil recruitment. Additionally, activation of neutrophils can result in the 
formation of neutrophil extracellular traps (NETs), an extracellular mechanism of bacterial 
killing. Here the pathogen is killed by the release of chromatin fibers which are decorated 
with antimicrobial peptides and enzymes (Brinkmann et al., 2004). 
1.3.3 Neutrophil serine proteases (NSPs) 
Besides the three neutrophil serine proteases (NSPs) proteinase 3 (PR3), neutrophil elastase 
(NE) and cathepsin G (CG), which are already known since over 30 years (Baggiolini et al., 
1978), a fourth NSP, the neutrophil serine protease 4 (NSP4), was recently discovered (Perera 
et al., 2012). The genes for PR3 (PRTN3) and NE (ELA2/ELANE) are tightly linked together 
and form a gene cluster together with complement factor D (adipsin, AND or CFD) and 
azurocidin (AZU1) on the short arm of chromosome 19 (19p13.3) (Zimmer et al., 1992). The 
gene for NSP4 (PRSS57) is also located on the short arm of chromosome 19 (19p13.3), but 
outside of the AZU1-PRTN3-ELANE-CFD cluster (Perera et al., 2012). The CG gene 
(CTSG) belongs to a different gene cluster on chromosome 14 (14q11.2), containing the 
genes for chymase, granzyme H and granzyme B (Caughey et al., 1993). All four NSPs are 
synthesized as inactive zymogens. Only upon cleavage of the propeptide by the dipeptidyl 
aminopeptidase I (cathepsin C) NSPs are converted into a mature enzyme and adopt an 
enzymatically active conformation. After cleavage, the now accessible new N-terminus Ile16 
can interact with Asp194 in the interior of the molecule and substrates can productively 
interact with the substrate binding pockets, in particular the S1 pocket (Freer et al., 1970). 
After biosynthesis, transport through a slightly acidic compartment and conversion by 
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cathepsin C, NSPs are stored as mature enzymes in the azurophilic granules in the neutrophil 
(Adkison et al., 2002; Korkmaz et al., 2010; Perera et al., 2013).  
NSPs are released from azurophilic granules into the phagolysosome after phagocytosis of 
bacteria and neutrophil activation. In this way NSPs can participate in intracellular killing of 
pathogens in the pathogen-containing phagolysosome (Kobayashi et al., 2005). NSPs can 
further be involved in the extracellular killing after release of the granule content into the 
extracellular space. Here they can build a defense barrier against fungi, Gram-positive and 
Gram-negative bacteria. The important role of NSPs in the defense against pathogens has 
been confirmed in several studies. It could for instance be shown that NE and CG deficient 
mice are more susceptible to infections (Reeves et al., 2002). Furthermore NSPs are involved 
in the regulation of inflammation by proteolytic cleavage of chemokines, cytokines, growth 
factors and cell surface receptors. The proform of the inflammatory cytokines TNFα and IL-
1β, for example, can be cleaved and released via PR3 (Coeshott et al., 1999; Robache-Gallea 
et al., 1995). PR3, besides MMP-8 and MMP-9, also processes the pro-inflammatory cytokine 
IL-8 (Padrines et al., 1994). In addition PR3 and NE are able to proteolytically cleave the anti-
inflammatory progranulin. This cleavage abolishes the anti-inflammatory effect of 
progranulin and thus has an enhancing effect on inflammation (Kessenbrock et al., 2008). 
1.3.4 Protease specificity – The Schechter and Berger nomenclature 
The degradation of proteins by proteases is limited by the specificity of the respective 
protease. This specificity is determined by the amino acid sequences of substrates that are 
cleaved by the protease. A nomenclature for the interaction of a protease and its substrates 
was introduced by Schechter and Berger (Schechter and Berger, 1967). To guarantee a 
successful cleavage of the peptide bond (scissile bond), a close interaction of the peptide and 
the active site cleft of the protease is necessary. Thus the active site of the protease mediates 
both the binding of the substrate as well as the catalyzing reaction, the cleavage of the amide 
peptide bond. The active site cleft in serine proteases contains the catalytic triad His57, 
Asp102 and Ser195 (numbering according to bovine chymotrypsinogen). In the context of the 
active site cleft, the hydroxyl group of the serine 195 is able to attack as a nucleophile the 
carbonyl carbon of the scissile peptide bond of the substrate, resulting in the hydrolysis of the 
peptide bond (Blow et al., 1969). The amino acid residues of the peptide, which are flanking 
the scissile bond, are designated as P-residues. The peptide is cleaved between the P1 and P1´ 
residue (scissile bond). The residues, which are located on the N-terminal side of the scissile 
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bond are called P1, P2, P3, P4 etc. and the residues on the C-terminal side P1´, P2´, P3´, P4´ 
etc. The subsites in the protease close to the active site cleft, which take up the amino acids 
are numbered accordingly S1, S2, S3, S4 and S1´, S2´, S3´, S4´ etc. (Figure 1.1). 
 
Figure 1.1: Schechter and Berger nomenclature. A tight interaction between the active site cleft of 
the protease and its substrate is necessary for proteolytic cleavage. The amino acid residues of the 
substrate, which are close to the cleavage site (scissile bond), are designated as P-residues. The P-
residues on the N-terminal side of the scissile bond are called P1, P2, P3 etc.; on the C-terminal side 
the amino acids are called P1´, P2´, P3´ etc. Cleavage takes place between the P1 and the P1´ residue. 
The respective subsites in the protease, which interact with the amino acid residues of the substrate, 
are numbered accordingly S1, S2, S3, S1´, S2´, S3´ etc. 
1.3.5 Proteinase 3 (PR3) 
PR3 is a multifunctional serine protease, formerly also known as p29b (Campanelli et al., 
1990) and myeloblastin (Bories et al., 1989). It is a protein of 29 kDa. The crystal structure of 
PR3 consists of two β-barrels (Fujinaga et al., 1996), which is typical for serine proteases. 
After biosynthesis and cleavage of the propeptide by the dipeptidyl aminopeptidase I, PR3 is 
stored in azurophilic granules of neutrophils. Upon neutrophil activation in response to for 
instance infections, it is released into the phagolysosome or into the extracellular space. There 
it is involved in the clearance of pathogens with its antimicrobial activity. Additionally it is 
expressed on the surface of neutrophils (Halbwachs-Mecarelli et al., 1995). This surface 
expression occurs via a hydrophobic patch on the surface of the molecule, which can bind to 
the NB1 (CD177) receptor on neutrophils (Korkmaz et al., 2008). Besides antimicrobial 
activity, PR3 also exhibits proteolytic activity. Initially PR3 was described as a elastin 
degrading protein, which can cause pulmonary emphysema in hamsters (Kao et al., 1988). 
Apart from elastin, it is able to degrade matrix proteins, such as laminin, vitronectin, 
fibronectin and collagen type IV (Rao et al., 1991). Activity studies revealed an elastase-like 
P1 specificity of PR3 for small aliphatic residues like Ala, Val, Ser or Met (Rao et al., 1991). 
The proteolytic activity of PR3 is regulated by specific endogenous inhibitors, like α1-
proteinase inhibitor (α1PI), elafin and α2-macroglobulin.  
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Besides the role in emphysema, PR3 is associated with a number of other human diseases. 
Most important for this study is the role of PR3 in GPA. PR3 is the target antigen of ANCA 
(Jenne et al., 1990), which can be detected in the blood of patients with GPA. Additionally 
Bories et al. for example postulated an involvement of PR3 in the growth and differentiation 
of leukemia cells (Bories et al., 1989). 
1.4 Anti-neutrophil cytoplasmic antibodies (ANCA) 
The presence of ANCA has been first reported in patients with necrotizing glomerulonephritis 
in 1982 by Davies and Colleagues (Davies et al., 1982). A few years later van der Woude et 
al. observed a diffuse granular cytoplasmatic staining pattern of PR3-ANCA on ethanol fixed 
neutrophils (cANCA) and characterized PR3-specific ANCA as a clear marker for GPA (van 
der Woude et al., 1985). In contrast, ANCA, which are directed against MPO and associated 
with microscopic polyangiitis, usually display a perinuclear staining pattern (pANCA) (Falk 
and Jennette, 1988). About 80% to 90% of ANCA, found in GPA, are cANCA. As the target 
antigen of cANCA is in most cases PR3, a clear association of PR3-ANCA with GPA has 
been established (Hoffman and Specks, 1998). Due to this PR3-specificity of ANCA in GPA 
patients, PR3 autoantibodies as determined by ELISA are regarded and utilized as a highly 
reliable laboratory biomarker for the diagnosis of GPA. Besides systemic vaculitides, ANCA 
also appear at least transiently and occasionally in a number of other diseases, for example in 
rheumatic autoimmune disease, inflammatory bowel disease, autoimmune liver disease or 
infections (Hoffman and Specks, 1998). 
1.5 The role of PR3, ANCA and the neutrophil immune 
response in GPA 
As already mentioned in chapter 1.3.5 PR3 can be found on the outer membrane surface of 
neutrophils. The amount of surface accessible PR3, however, is heterogeneous and varies 
among individuals. In comparison to healthy control persons a higher proportion of 
neutrophils express PR3 on their surface in patients with GPA and this elevated proportion 
can influence the frequency of relapses (Kallenberg et al., 2006). This minor membrane-
bound fraction of PR3 is the reason why ANCA are able to directly interact with neutrophils. 
ANCA binding then leads to activation of the neutrophils. Especially after priming of 
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neutrophils, for example with TNFα, the membrane expression of PR3 is upregulated 
(Csernok et al., 1994), resulting in an augmentation of ANCA activation (Charles et al., 
1991). Hence, membrane expression of PR3 is able to directly enhance neutrophil activation 
via ANCA. Besides the binding of the Fab (CDR) region of ANCA to PR3, the Fc domain of 
ANCA interacts with FcγRs and activates neutrophils via immunoglobulin receptors. 
Neutrophils express FcγRIIa (CD32) and FcγRIIIb (CD16) on their surface (Kocher et al., 
1998; Porges et al., 1994). Interaction of the Fc domain of ANCA with FcγRIIa, for example, 
triggers neutrophil oxidative burst (Reumaux et al., 1995). Furthermore ANCA stimulation of 
neutrophils increases neutrophil adherence to endothelial cells (Ewert et al., 1992), leads to 
the generation of reactive oxygen species (ROS), the release of proteolytic enzymes (Falk et 
al., 1990) and secretion of proinflammatory cytokines (Brooks et al., 1996). Thus ANCA-
mediated neutrophil activation causes inflammation of the vessel walls and the surrounding 
tissue and results in the development of necrotizing small-vessel vasculitis (Kallenberg et al., 
2006). Besides the histopathological features of a necrotizing vasculitis, GPA is also 
characterized by granuloma formation and the role of ANCA in the development of these 
symptoms is still unclear. In vivo data rather suggest that this granulomatous inflammation is 
caused by cell mediated immune reactions rather than by ANCA-dependent mechanisms 
(Kallenberg, 2011). Furthermore, also microbial factors can play a role in GPA. 60% to 70% 
of patients are chronic carriers of Staphylococcus aureus and display an increased risk for 
relapses (Stegeman et al., 1994). Due to these facts, the role of PR3-ANCA on the 
pathogenesis of GPA still remains a matter of controversy and needs further clarification. 
1.5.1 ANCA with inhibitory capacity towards PR3 
Up to now, there is some disagreement as to whether changes in ANCA levels are a predictor 
for relapses in GPA patients. Rising levels of ANCA were found to be only weakly associated 
with disease activity (Finkielman et al., 2007). Less than 10% of the variation in disease 
activity was shown to be correlated with changes in ANCA titers. A particular subset of 
ANCA, however, seemed to be a more promising indicator for the prediction of relapses. 
Some studies focused on the presence of ANCA, which reduced the catalytic activity of PR3 
and impaired the inhibition of PR3 by α1PI. As a result of these studies, a close correlation of 
disease activity and the presence of inhibitory ANCA was repeatedly postulated (Daouk et al., 
1995; Dolman et al., 1993; van der Geld et al., 2002). The outcome of these previous studies, 
however, has not been widely accepted. ANCA in all these studies clearly interfered with PR3 
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activity or PR3-α1PI-complexation in vitro. Only Daouk et al. reported on data suggesting a 
correlation of inhibitory ANCA and disease activity (Daouk et al., 1995). Dolman et al. 
confirmed the inhibitory properties of ANCA with regard to the complexation of PR3 with 
α1PI (Dolman et al., 1993). In a larger study with more patient samples (van der Geld et al., 
2002), a correlation of ANCA, which interfered with the cleavage activity of PR3 towards 
casein, a macromolecular substrate, and disease activity was noticed. Inhibition of PR3 
activity towards small synthetic substrates, however, did not occur in parallel with phases of 
active disease. Unexpectedly, during stable remission an even stronger inhibitory capacity of 
inhibitory ANCA was observed, indicating that these activity changing ANCA do not 
contribute to the pathogenesis of GPA (van der Geld et al., 2002). In view of these 
inconsistent and contradictory observations the significance of inhibitory ANCA and their 
impact on disease activity, clinical course and prognosis of the disease is still uncertain. 
1.6 The role of protease inhibitors in GPA 
1.6.1 Alpha-1-proteinase inhibitor (α1PI) 
The alpha-1-proteinase inhibitor (α1PI) is an irreversible serine protease inhibitor and belongs 
to the serpin superfamily (serine protease inhibitor). As an acute phase plasma protein, it also 
plays an important role in acute inflammatory responses and immune defense reactions. 
Alpha-1PI consists of nine α-helices, three β-sheets and carries a flexible reactive center loop 
(RCL) on their surface. This loop is formed by 20 amino acid residues and acts as a 
pseudosubstrate for various target proteases (Gooptu and Lomas, 2009). Inhibition of 
proteases can be conducted in three different ways. Initially the protease binds to the RCL of 
the inhibitor and forms a Michaelis complex. In this complex the protease is only reversibly 
bound and is able to dissociate from the inhibitor. This form of complexation is called 
canonical inhibition. After formation of the Michaelis complex, the protease is able to 
catalyze the hydrolysis of the scissile bond in the RCL. After this cleavage, the protease can 
be released from the inhibitor, and is then free to cleave other substrates. In many instances, 
however, the protease is trapped and forms an ester bond with the P1 residue of the RCL after 
cleavage of the RCL. During this productive inhibitory reaction, the protease is translocated 
from one pole of the inhibitor to the other, opposite pole of the inhibitor. While the protease is 
covalently linked to the inhibitor, it undergoes a conformational change and adopts an 
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inactive zymogen-like conformation in the resulting complex. This complex exposes a new 
binding site, which is recognized by members of the lipoprotein receptor family. Protease-
inhibitor complexes are rapidly cleared from the neutrophil membrane and removed from the 
interstitial fluids and the circulation (Gooptu and Lomas, 2009).  
Up to now, more than 100 genetic variants of α1PI have been identified. The most important 
genetic variants are the Z-allele, the S-allele, and the M-allele, which are named according to 
their migration position in a native gel after isoelectric focusing in the pH range between 4.5 
and 5.5. Another well-known variant is the so-called null-variant. Those four alleles are 
associated with three major clinical categories according to their pathogenic potential. The by 
far most prevalent M-allele gives rise to normal plasma levels of α1PI and is not associated 
with any risk for lung or liver diseases. In contrast the Z- and the S-allele are the most 
common deficiency alleles in the Caucasian population and lead to an increased risk for lung 
and liver diseases. Alpha-1PI levels in carriers of these alleles are reduced, but still detectable. 
The last group comprises patients which are homozygous for the null-variant. Here no 
plasma-α1PI levels can be detected and the variant is associated with an increased risk for 
emphysema (Luisetti and Seersholm, 2004). 
1.6.2 The role of α1PI in GPA 
In a recent genome wide association study (GWAS) both the gene locus of PR3 as well as the 
locus for its natural inhibitor, α1PI, were identified as a genetic risk factor for GPA, but not 
for MPA. In particular, the Z-allele of α1PI was confirmed as a risk factor in this GWAS 
(Lyons et al., 2012), which is consistent with a role of this protease inhibitor in GPA. In 
earlier studies, Segelmark et al. already reported a negative impact of the Z-allele on the 
disease outcome in GPA patients. A more disseminated disease and a worse prognosis in 
patients with the Z-allele, and thus with lower levels of functional α1PI, was observed 
(Segelmark et al., 1995). Such a protease-antiprotease imbalance could also be detected in 
other studies on patients with GPA and thus a pathogenic role of α1PI deficiency in 
conjunction with ANCA has been postulated (Esnault et al., 1993; Griffith et al., 1996; Savige 
et al., 1995). While inherited defects of the α1PI gene were identified as a risk factor for 
GPA, PR3-ANCA acquired as a result of unknown environmental factors were also found to 
weaken the biological function of α1PI. In both settings the PR3-α1PI complexation reaction 
is affected. On the one hand ANCA can interfere with the complexation of PR3 with α1PI, 
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which was found to be positively correlated with disease activity (Dolman et al., 1993). On 
the other hand low levels of α1PI favor the binding of ANCA to surface-bound PR3 and thus 
neutrophil-mediated tissue damage. These observations are the basis of our current view about 
a beneficial effect of normal α1PI levels in GPA patients (see e.g. Rooney et al., 2001). 
1.7 Animal models for GPA 
The pathogenesis of GPA is still a topic of controversial discussions. The significance of 
ANCA for the development of GPA, as well as their capacity to trigger GPA is still uncertain. 
The high mortality rate of GPA patients and limited treatment options has prompted many 
researchers to clarify the pathogenic basis of the disease process in GPA patients. Several 
animal models have already been developed, to study the pathogenicity of ANCA in vivo. 
Considering the differences in the structure and expression pattern of human and murine PR3, 
developing appropriate mouse models for GPA turned out to be difficult. On one hand, 
antibodies against human PR3 (hPR3) did not crossreact with murine PR3 (mPR3) (Jenne et 
al., 1997). On the other hand, the mPR3 molecule, in contrast to hPR3, was not found on the 
surface of naïve and primed mouse neutrophils (Pfister et al., 2004). In line with these 
findings, transfer of mouse PR3-specific antibodies, which were generated in PR3/NE 
deficient mice, into wildtype mice did not induce pathological changes (Pfister et al., 2004). 
Immunization of wildtype mice with a chimeric human/mouse PR3 molecule led to the 
production of antibodies against the chimeric PR3, but did not result in vascular lesions (van 
der Geld et al., 2007). To overcome the species barrier between human and murine 
neutrophils, a few models with humanized mice were evaluated. One approach was to 
reconstitute immunodeficient mice with the human immune system by injecting human 
hematopoietic stem cells. Transfer of PR3-specific antibodies from GPA patients into these 
mice did indeed lead to a mild pauci-immune proliferative glomerulonephritis, supporting the 
pathogenicity of ANCA in GPA (Little et al., 2012). However, expression of hPR3 at protein 
level and the presence of hPR3 on the neutrophil surface were not demonstrated in this model. 
Hence the mechanism for the development of glomerulonephritis in these mice remained 
unclear and obscure. Another humanized model was generated by Relle et al. Here the hPR3 
cDNA was expressed with the help of the podocin promotor in transgenic mice. Expression of 
hPR3 was restricted to the kidneys. Injections of hPR3-specific antibodies, however, did not 
elicit renal pathology in these mice (Relle et al., 2013).  
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1.8 Objective 
Despite numerous attempts to determine the role of ANCA at the onset and during 
progression of GPA with the help of animal models and large patient cohorts, the 
pathogenicity of ANCA is still a controversial topic. The aim of this thesis was to explore the 
mechanisms by which ANCA contribute to the development of GPA and influence disease 
progression and severity. For this purpose, two different approaches were chosen.  
On one hand, the induction of small-vessel vasculitis by the action of ANCA was investigated 
using a newly developed humanized mouse model. As all initial attempts to generate an 
animal model of PR3-ANCA induced systemic vasculitis were inconclusive, a new mouse 
model on the basis of an hPR3 knock-in mouse was created. Transfer of mAbs and ANCA 
from patients should provide new insights into the pathogenicity of ANCA in GPA. Before 
transfer of antibodies into the humanized mouse line, expression of hPR3 in the knock-in 
mice had to be characterized. Removal of the neomycin cassette after insertion of the 
humanized PR3 locus was planned to improve the expression of the hPR3. However, this step 
necessitated the backcrossing of the knock-in mice onto a pure background. Furthermore the 
binding properties of different PR3-specific mAbs had to be analyzed to evaluate their 
potential as transfer antibodies. Antibodies of different subclasses were transferred into the 
hPR3 knock-in mice, to establish the animal model, and their potential to induce vasculitis-
like and pulmonary lesions was explored. 
In the second part of this thesis the question as to whether distinct subtypes of ANCA are able 
to modulate the activity of PR3, determine relapses, overall disease activity and organ 
involvement was addressed. The influence of ANCA, which inhibit PR3 activity, on the 
course of disease was often postulated. To determine if a relationship between activity 
modulating ANCA and disease activity exists, a large GPA patient cohort was analyzed. 
Therefore a new small scale approach to analyze the inhibitory properties of ANCA directly 
with small volumes of serum or plasma from GPA patients was developed. The activity 
modulating capacity of ANCA in the plasma samples from the patient cohort was determined 
with this new approach and correlated to disease severity and organ involvement. Furthermore 
potential activity modulating mechanisms of these ANCA were determined. 
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2. Material and Methods 
2.1 Material 
2.1.1 Chemicals and consumables 
Chemicals were purchased from the companies Biozym (Hessisch Oldendorf, Germany), 
Merck (Darmstadt, Germany), Millipore (Billerica, MA, USA), Roth (Karlsruhe, Germany) 
and Sigma-Aldrich (St. Luis, MO, USA), unless mentioned otherwise. Consumables such as 
pipette tips, centrifuge tubes, reaction tubes and microwell plates were obtained from BD 
Biosciences (Franklin Lakes, NJ, USA), Biozym, Eppendorf (Hamburg, Germany), Millipore 
and Nunc/Thermo-Scientific (Waltham, MA, USA). Cell culture flasks were procured from 
Corning (Corning, NY, USA) and cell culture media from Gibco® Life Technologies 
(Carlsbad, CA, USA). 
2.1.2 Plasmids 
Plasmid Construct Origin 
PR3-precursor(human)-pcDNA5 SigIgκ-proPR3-H6 Angelika Kuhl, AG Jenne 
PR3-inactive(human)-pTT5 ΔhPR3-S195A Heike Kittel, AG Jenne 
The vector maps are provided in the Appendix (7.1). 
2.1.3 Cell lines 
The cell line HEK 293EBNA-1 was purchased from the NRC Biotechnology Research 
Institute, which is part of the National Research Council in Montreal, Canada. 
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2.1.4 Recombinant and purified proteins 
Protein Origin 
α1PI, human Athens Research & Technology (Athens, GA, USA) 
Elafin, human Proteo Biotech AG (Kiel, Germany) 
Neutrophil elastase, human Elastin Products (Owensville, MO, USA) 
Neutrophil elastase, mouse Therese Dau, AG Jenne 
Proteinase 3, human Diarect AG (Freiburg, Germany) 
Proteinase 3, mouse Therese Dau, AG Jenne 
2.1.5 Antibodies 
Primary Antibodies 
Antigen /  
Isotype control 
Species Clone Provider Cat. No. 
Human PR3 Mouse MCPR3-2 
MCPR3-3 
MCPR3-7 
CLB-12.8 
4B12 
5B11 
7D12 
Ulrich Specks, Rochester, USA 
Ulrich Specks, Rochester, USA 
Ulrich Specks, Rochester, USA 
Sanquin 
AG Jenne/AG Kremmer IMI 
AG Jenne/AG Kremmer IMI 
AG Jenne/AG Kremmer IMI 
- 
- 
- 
M9050 
- 
- 
- 
Human PR3-biotin Mouse WGM2 Hycult Biotech HM217BT 
Human PR3-FITC Mouse WGM2 Hycult Biotech HM217F 
Mouse PR3 Goat α-mPR3 AG Jenne/Animal facility MPI - 
IgG1 Isotype Mouse - BD Biosciences 349040 
IgG1 Isotype-FITC Mouse - MACS Miltenyi Biotech 130-098-847 
Mouse Ly6G-FITC Rat RB6-8C5 BD Biosciences 553126 
IgG2b Isotype-FITC Rat - BD Biosciences 553988 
 
Secondary Antibodies 
Antigen Species Label Provider Cat. No. 
Mouse IgG+IgM Goat Peroxidase Pierce (Thermo Scientific) 31444 
Mouse Ig Goat  Dako Z0420 
Goat IgG Mouse Peroxidase Chemicon AP186P 
Human ƙ-light chain Goat Peroxidase Sigma-Aldrich A-7164 
 
Other 
Protein Label Provider Cat. No. 
Avidin Peroxidase Invitrogen, Life Technologies 434423 
 
Material 
 
15 
 
2.1.6 Synthetic substrates 
FRET substrates 
Sequence Cleaving protease Provider 
Abz-YYAbu-ANBNH2 PR3, NE Adam Lesner, Gdansk, Poland 
Abz-VADCADRQ-EDDnp PR3 Brice Korkmaz, Tours, France 
TAMRA-VADnVVADYQ-Dap(CF) PR3, NE EMC Microcollections 
TAMRA-VADnVRDYQ-Dap(CF) PR3 EMC Microcollections 
 
Lipid anchored FRET substrate 
Sequence Cleaving protease Provider 
TAMRA-doo-VADnVRDRQ-doo PR3 EMC Microcollections 
 
SBzl substrates 
Sequence Cleaving protease Provider 
Boc-APnV-SBzl PR3, NE Bachem 
For-AAPAbu-SBzl PR3, NE Bachem 
 
pNA and ONp substrates 
Sequence Cleaving protease Provider 
Ahx-PYFA-pNA PR3 Brice Korkmaz, Tours, France 
Boc-A-ONp PR3, NE Sigma-Aldrich 
 
2.1.7 Oligonucleotides 
Oligonucleotides were synthesized by Metabion (Martinsried, Germany).  
DJ3446 5’-TTA GCT GTG TGG CTT CAT GC-3’ 
DJ3447 5’-TAC CTT GAA CCT GGG AGG TG-3’ 
DJ3465 5’-TAC ACC CGC TGT GACCAT AA-3’ 
DJ3466 5’-AGC CAT GCT GGA CTC CTC TA-3’ 
DJ3467 5’-GTG GCT AGC TTG AGG TTT GG-3’ 
DJ3468 5’-CTG TGC AGA GCT TCA AAA CG-3’ 
DJ3536 5’-AGC TAC CCA TCC CCC AAG-3’ 
DJ3538 5’-ATG GCC AGG CAC TGG GT-3’ 
mActin-fw 5’-CTG GGC CGC CCT AGG CAC CA-3’ 
mActin-rev 5’-TGG CCT TAG GGT TCA GGG-3’ 
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2.1.8 Mouse strains 
Mouse strain Background Origin 
129S6/SvEv wildtype 129S6/SvEv - 
PR3/NE knockout 129S6/SvEv Markus Moser, MPI Biochemistry 
hPR3 knock-in 129S6/SvEv Markus Moser, MPI Biochemistry 
 
2.1.9 Laboratory equipment 
Balances PM 4800 Delta Range, Mettler Toledo, Columbus, OH, USA 
XS205 Dual Range, Mettler Toledo, Columbus, OH, USA 
Centrifuges 5417R, Eppendorf, Hamburg, Germany 
5417C, Eppendorf, Hamburg, Germany 
Rotana 460R, Hettich, Tuttlingen, Germany 
Rotana/R, Hettich, Tuttlingen, Germany 
Flow Cytometer BD LSRII, BD Biosciences, Franklin Lakes, NJ, USA  
FPLC ÄKTAprimeTM, GE Healthcare, Chalfront StGiles, Great Britain 
Gel electrophoresis 
chambers/power supplies 
 
Bio-Rad, Amersham-Pharmacia, MPI workshop 
Incubation shaker HAT Multitron, Infors, Bottmingen, Switzerland 
Incubator Heraeus B6, Thermo Scientific, Waltham, MA, USA 
Ice machine Ziegra, Isernhagen, Germany 
Magnetic Stirrer KMO2 basic, IKA, Staufen, Germany 
RCT basic IKAMAG, IKA, Staufen, Germany 
Microplate reader FLUOStar Optima, BMG Labtech, Offenburg, Germany 
SunriseTM, TECAN, Maennedorf, Switzerland 
Microscope Leica DM IL, Leica Microsystems, Wetzlar, Germany 
Molecular Imager ChemiDocTMXRS+, Bio-Rad, Hercules, CA, USA 
PCR cycler T3 Thermocycler, Biometra, Göttingen, Germany 
Rotator Fröbel Labortechnik, Lindau, Germany 
Semidry Blotter FastBlot, Biometra, Göttingen, Germany 
Shakers KS 260 basic, IKA, Staufen, Germany 
Polymax 1040, Heidolph, Schwabach, Germany 
Spectrophotometer BioPhotometer, Eppendorf, Hamburg, Germany 
Stirring Cell MPI workshop 
Thermoblock Thermomixer 5436, Eppendorf, Hamburg, Germany 
Ultrasonic bath Sonorex digital 10P, Bandelin, Berlin, Germany 
Water bath incubator MA6, LAUDA, Lauda-Königshofen, Germany 
Water preparation Milli Q Advantage, Millipore, Billerica, MA, USA 
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2.2 Molecular biological methods 
 
2.2.1 Plasmid DNA purification from E.coli  
Purification of Plasmid DNA from 2-5 ml overnight culture of E.coli was carried out with the 
QIAprep Spin Miniprep Kit from Qiagen. After alkaline lysis of the bacterial cells the DNA 
was bound to a silica membrane in high salt. For the purification of higher amounts of 
Plasmid DNA out of larger overnight cultures the PureYield™ Plasmid Maxiprep System 
(Promega) was used. Here the DNA was also bound to a silica membrane after alkaline lysis 
of the bacterial cells. Furthermore this purification procedure included an endotoxin removal 
step to remove protein, RNA and endotoxin contaminants from the DNA preparation. Both 
kits were used according to the manufacturer’s instructions. The purified and endotoxin free 
Plasmid DNA was used for transfection of mammalian cells (HEK 293EBNA) in cell culture. 
Removal of endotoxin was necessary to avoid reduced transfection efficiency. 
2.2.2 Polymerase chain reaction (PCR) 
Polymerase chain reaction (PCR) is a method to amplify defined short DNA fragments from a 
larger DNA fragment. Therefor two oligonucleotides are used, flanking the two ends of the 
DNA strand, which should be amplified. These two primers contain a free 3´-OH at one end, 
ensuring the synthesis of the new strand in only one direction. The synthesis is carried out by 
a polymerase, which is adding and linking new nucleotides to the primers, generating the 
amplificate. One PCR cycle consists of denaturation of the DNA strand, in which the double 
helix is separated into single stranded DNA, annealing of the primers to the single strands and 
extension of the primers by the DNA-polymerase to generate the new strand. Replication of 
this cycle leads to an amplification of the required DNA fragment. For all PCRs the 
HotStarTaq DNA Polymerase from Qiagen was used. 
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HotStarTaq PCR reaction (25 µl): 1× PCR buffer (Qiagen) 
 0.2 mM dNTP-mix 
 0.4 µM forward primer (10 pmol absolute) 
 0.4 µM reverse primer (10 pmol absolute) 
 0.2 µl HotStarTaq DNA polymerase 
 1-2 µl DNA template 
  H2O to 25 µl 
 
Touchdown HotStarTaq PCR program:     
 15 min 95 °C  Denaturation  
 30 s 94 °C  Denaturation  
 30 s *  Annealing 3 cycles 
 30 s 72 °C  Extension  
 30 s 94 °C  Denaturation  
 30 s **  Annealing 3 cycles 
 30 s 72 °C  Extension  
 30 s 94 °C  Denaturation  
 30 s ***  Annealing 21 cycles 
 30 s 72 °C  Extension  
 10 min 72 °C   Extension  
  *     primer specific annealing temperature + 6 °C 
**   primer specific annealing temperature + 3 °C 
*** primer specific annealing temperature 
 
2.2.3 Agarose gel electrophoresis 
Due to their negatively charged backbone, DNA fragments can be separated in a gel matrix in 
an electric field according to their size. Depending on the size of the fragments the density of 
the agarose gels ranged from 0.7 to 2.0% (w/v). To visualize the DNA strands on the gels 
under UV (λ = 254-366 nm) SYBR safe (Life Technologies) or ethidium bromide was used. 
The agarose gels were prepared in TAE-buffer, adding SYBR safe 1:10 000 or 1 µg/ml 
ethidium bromide. After addition of DNA loading buffer, the samples were loaded into the gel 
slots and the gel was run in TAE-buffer at 80 V. To determine the size of the DNA fragments, 
the bands were compared to a molecular weight standard (Gene Ruler 1kb, Fermentas, 
Thermo Fisher Scientific). 
Recombinant protein expression 
 
19 
 
            TAE-buffer (50 ×): 242 g  Tris 
 100 ml  0.5 M EDTA pH 8.0 
 57.1 ml  acetic acid 
   H2O to 1 l 
   
            DNA loading buffer (10 ×): 0.25% (w/v)  bromphenol blue 
 0.25% (w/v)  xylene cyanol 
 50% (v/v)  glycerol 
2.2.4 Restriction digest 
DNA can be cleaved at specific recognition sites with restriction endonucleases. One unit of 
these restriction enzymes is defined as the amount of enzyme needed to digest 1 µg of DNA 
in one hour at an optimal temperature. The restriction enzymes were purchased from New 
England Biolabs (Ipswich, MA, USA) and the digests were carried out according to the 
manufacturer’s instructions. 500 ng DNA were digested in a total volume of 20 µl for one 
hour at the temperature optimum of the respective enzyme. 
2.3 Recombinant protein expression 
Expression of the two different PR3-constructs was carried out in the HEK 293EBNA-1 
(HEK 293E) cell line. This cell line carries a plasmid with the Epstein Barr Virus gene 
EBNA-1. The EBNA-1-gene is able to activate the episomal replication of plasmids, which 
carry the EBV origin of replication oriP, e.g. pTT5 (Durocher et al., 2002). Furthermore the 
plasmid contains a geneticin resistance marker (G418) for maintenance of this plasmid within 
the cell. The cells were cultured in suspension in HEK 293E medium in Erlenmeyer flasks at 
37 °C, 8% CO2 and 110 rpm in the incubation shaker. 
        HEK 293E medium: 1 ×  FreestyleTM 293 Expression Medium (Invitrogen) 
 0.1% (v/v) Pluronic® F-68 
 25 µg/ml Geneticin® G418 
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2.3.1 Transfection of HEK 293E 
Prior to transfection HEK 293E cells were diluted to a concentration of 1 × 106 cells/ml in 
HEK 293E medium. Complexes of Polyethylenimin (PEI) and DNA were prepared in 
OptiPROTM serum-free medium (Gibco® Life Technologies). Therefor 1 µg DNA and 2 µg 
PEI were used for 1 ml of cell culture suspension. Both were prediluted in OptiPROTM. The 
PEI dilution was added to the DNA dilution, incubated for 20 min at room temperature and 
then added to the cell suspension. After 5 to 24 hours Lactalbumin was added as an amino 
acid supply to a final concentration of 0.5%. The supernatant of the cells was harvested after 
four days.  
2.4 Protein analysis 
2.4.1 Purification of recombinant proteins 
Proteins were purified from supernatants of transfected HEK 293E cells. Cell suspensions 
were centrifuged for 15 min at 2400 × g and 4 °C. The supernatant was filtered through a 
0.22 µm membrane (Millipore), concentrated fivefold in a stirring chamber under nitrogen 
pressure (2.5 × 105 Pa) using an ultrafiltration membrane with 10 kDa cutoff and dialyzed in 
binding buffer overnight at 4 °C. Purification of 6 × His-tagged ΔhPR3S195A and SigIgκ-
proPR3-H6 was employed via nickel-affinity chromatography. HisTrap HP columns (GE 
Healthcare) were equilibrated in binding buffer. The protein solution was applied, the column 
washed with binding buffer and the proteins were eluted using a linear imidazole gradient 
ranging from 10 mM to 1 M imidazole in binding buffer. Fractions were collected and 
analyzed by SDS PAGE and silver staining to detect the protein of interest. Protein fractions 
were pooled and concentrated. 
            Binding buffer: 20 mM  Na2HPO4 
 500 mM NaCl 
 10 mM imidazole 
  pH 7.4 
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2.4.2 Determination of protein concentration 
Spectrophotometric determination of protein concentration 
To determine the protein concentration spectrophotometrically the absorbance of the protein 
solution was measured at λ = 280 nm and calculated with the following equation: 
    c = (A280 × MW) / (ε280 × l) 
(c, concentration; A, absorption; MW, molecular weight; ε, extinction coefficient; l, length of 
solution). To determine the extinction coefficient of each protein the program ProtParam 
(http://us.expasy.org/tools/ protparam.htm) was used according to the respective amino acid 
sequence. 
Determination of protein concentration by bicinchonic acid (BCA) assay 
Protein concentration by BCA assay was determined by using the Uptima MicroBC Assay kit 
(Interchim, Montluçon Cedex, France) according to the manufacturer’s instructions. 
2.4.3 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS 
PAGE) 
Discrimination of proteins according to their size was carried out by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS PAGE). A discontinuous gel system was used, 
consisting of a stacking gel and a resolving gel. The stacking gel is slightly acidic and has a 
relatively low acrylamide concentration. Thus the protein sample is forming a thin sharp band 
before entering the resolving gel. In the resolving gel the higher concentration of 
polyacrylamide and a more basic pH lead to the separation of the proteins according to their 
size. The samples as well as the gels and the running buffer contained the detergent SDS. 
Binding of SDS to proteins unfolds their secondary structure. Furthermore it charges the 
proteins negatively according to their length, enabling a discrimination of the proteins relative 
to their size. The samples furthermore contained β-mercaptoethanol for the reduction of 
disulfide bridges. Prior to loading the samples were taken in sample buffer and boiled at 
95 °C for 5 min. For comparison of protein sizes a molecular weight standard was used 
(Prestained Protein Marker, Broad Range, New England Biolabs). 
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8 SDS polyacrylamide gels (15%) 
 stacking gel resolving gel 
H2O 13.6 ml 9.4 ml 
30% polyacrylamide 3.32 ml 20 ml 
1 M Tris HCl, pH 6.8 2.56 ml  
1.5 M Tris HCl, pH 8.8  10 ml 
20% SDS 100 µl 200 µl 
bromphenol blue 20 µl  
TEMED 14 µl 16 µl 
10% APS 200 µl 400 µl 
 
Sample buffer (4 ×), reducing: 200 mM  Tris HCl, pH 6.8  
 40% (v/v) glycerol 
 10% (w/v) SDS 
 30% (w/v) β-mercaptoethanol 
 0.2% (w/v) bromphenol blue 
   
Running buffer (10 ×): 250 mM Tris HCl 
 1.92 M glycine 
 1% (w/v) SDS 
  
2.4.4 Protein detection 
Silver nitrate staining 
For detection of proteins after SDS PAGE by silver nitrate staining, the gel was incubated in 
fixation solution for one hour while shaking. After three washes in 50% ethanol for 20 min, 
the gel was sensitized in thiosulfate solution for 1 min, rinsed with water three times and 
incubated in silver nitrate solution for 20 min. Before development the gel was again washed 
in water three times. The gel was kept in developer solution until the protein bands became 
visible, shortly washed in water and then the reaction was stopped in 50% methanol and 12% 
acetic acid. Afterwards it was fixated in 50% methanol for 20 min. 
Fixation solution: 50% (v/v)  methanol 
 12% (v/v) acetic acid 
 0.5 ml/l 37% formaldehyde 
   
Thiosulfate solution: 0.2 g/l Na2S2O3 × 5 H2O 
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Silver nitrate solution: 2 g/l AgNO3 
 750 µl/l 37% formaldehyde 
   
Development solution: 60 g/l Na2CO3 
 4 mg/l Na2S2O3 × 5 H2O 
 0.5 ml/l 37% formaldehyde 
 
Coomassie staining 
After SDS PAGE proteins were detected by staining the gels in Coomassie Blue staining 
solution for at least 30 min. To remove unspecific staining the gel afterwards was incubated in 
Coomassie Blue destaining solution until the protein bands became visible. 
Coomassie Blue staining solution: 0.25% (w/v) Coomassie Brilliant Blue 
 45% (v/v) methanol 
 10% (v/v) acetic acid 
   
Coomassie Blue destaining solution: 45% (v/v) methanol 
 10% (v/v) acetic acid 
 
   
2.4.5 Processing of proPR3 by enterokinase 
ProPR3 was converted into its active conformation by calf enterokinase (Roche, Basel, 
Switzerland). After dialysis of the proteins against enterokinase buffer, the proteins were 
cleaved at an enzyme/substrate ratio of 1/40 at room temperature overnight. 
             Enterokinase buffer: 20 mM  Tris HCl 
 50 mM NaCl 
 2 mM CaCl2 
 
 
 pH 7.4 
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2.4.6 Measurement of enzymatic activity 
FRET-based activity assay 
Activity of PR3 was measured over time by diluting PR3 to a final concentration of 50 nM in 
the respective buffer. After adding antibodies at a 2- to 15-fold molar excess the FRET-
substrates were added and fluorescence was measured over time in the FLUOStar optima. For 
the substrate Abz-YYAbu-ANBNH2 the proteins were diluted in Tris-HCl buffer, the FRET 
substrate was added at a concentration of 800 nM and the fluorescence was measured at 
λEx = 320 nm and λEm = 405 nm. TAMRA-VADnVVADYQ-Dap(CF) or TAMRA-
VADnVRDYQ-Dap(CF) was measured in activity assay buffer. 5 µM of the FRET substrates 
were used and the fluorescence was determined at λEx = 485 nm and λEm = 520 nm. 
Measurements with the substrate Abz-VADCADRQ-EDDnp (5 µM) were carried out in 
activity assay buffer, and fluorescence was obtained at λEx = 320 nm and λEm = 405 nm. 
Absorbance-based activity assay 
The activity of 50 nM PR3 in activity assay buffer was measured in absence and presence of a 
three-fold molar excess of MCPR3-7. Prior to measurement 1 mM Ahx-PYFA-pNA, Boc-A-
ONp, Boc-APnV-SBzl or For-AAPAbu-SBzl were added and absorbance was determined at 
λAb = 405 nm. In case of the thiobenzyl ester substrates 500 µM 5,5´-dithiobis(2-
nitrobenzoic acid) was added to the samples before measurement. 
              Tris-HCl buffer: 100 mM  Tris 
 500 mM NaCl 
 0.01% (w/v) Brij 39 
  pH 7.5 
   
Activity assay buffer: 50 mM Tris 
 150 mM NaCl 
 0.01% (v/v) Triton X-100 
  pH 7.4 
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2.5 Mouse model analysis 
2.5.1 Isolation of genomic DNA from mouse tails 
Tail biopsies (2-5 mm of the distal tail) were taken from mice at the age of 4-5 weeks. DNA 
was isolated out of these biopsies by Phenol/Chloroform extraction. After a Proteinase K 
digestion in 500 µl Tails buffer with 1 mg/ml Proteinase K overnight at 56 °C while shaking, 
the DNA was precipitated by adding 1 volume of Roti®-Phenol/Chloroform/Isoamyl alcohol, 
mixing and centrifugation at 20 000 × g for 10 min. The DNA was precipitated out of the 
aqueous phase by adding 1 ml 100% ethanol. After centrifugation at 20 000 × g for 10 min 
the DNA was washed with 400 µl 70% ethanol and again pelleted. The pellets were dried 
briefly at 37 °C and solved in 100 µl Tails buffer at 56 °C for 30 min while shaking. 
              Tails buffer: 20 mM  Tris 
 150 mM NaCl 
  pH 7.5 
2.5.2 Mouse-genotyping 
After isolation of the DNA from mouse tail biopsies the genotypes were analyzed by PCR 
with HotStarTaq DNA polymerase (see chapter 2.2.2). With the primers DJ3446 and DJ3447 
the hPR3-allele was amplified at the annealing temperatures 59 °C, 56 °C and 53 °C, 
represented by a band of 400 bp. The wildtype mPR3-allele was amplified with the primers 
DJ3467 and DJ3468 leading to a band of 450 bp (annealing temperatures: 61 °C, 58 °C and 
55 °C). After cre-recombination the successful deletion of the neomycin cassette was verified 
with the primers DJ3465 and DJ3466, with 3 cycles at 59 °C, 3 cycles at 56 °C and 30 cycles 
at 53 °C. The result of this amplification was a band with 400 bp. 
2.5.3 Isolation of bone marrow leukocytes  
Bone marrow leukocytes were isolated from mouse femurs. After sacrificing the mice by CO2 
inhalation, both femurs were dissected, the ends of the bones were cut off and the bone 
marrow cells were flushed out of the bone with 5 ml PBS by using a syringe with a 21-gauge 
needle. After centrifugation (500 × g, 5 min) the erythrocytes were lysed in 10 ml erythrocyte 
lysis buffer for 1-3 min at room temperature. The remaining bone marrow cells were again 
pelleted and then washed with 10 ml PBS.   
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      Erythrocyte lysis buffer: 9 ml  0.8% NH4Cl 
 1 ml 0.2 M Tris HCl, pH 7.5 
 
2.5.4 Isolation of neutrophils 
Neutrophils were purified out of bone marrow cells from 2-4 mice. Therefor the bone marrow 
cells were flushed out of the femurs as described above with 5 ml RPMI 1640 (Gibco®, Life 
Technologies). The bone marrow solution was sent through a cell strainer to disperse the 
cells. The cell suspension was underlaid with 62.1% Percoll (GE Healthcare) in 3 × HBSS 
and centrifuged for 30 min at 500 × g and 4 °C without brake. The cell pellet, containing 
PMNs and erythrocytes, was resuspended in 10 ml erythrocyte lysis buffer (see chapter 2.5.3) 
and after 1-3 min at room temperature centrifuged for 5 min at 500 × g and 4 °C. The 
remaining PMNs were washed with RPMI 1640. 
            62.1% Percoll (15 ml): 5.69 ml  10 × HBSS 
 9.32 ml  Percoll (GE Healthcare) 
2.5.5 Reverse transcriptase (RT) PCR 
Isolation of mRNA 
After isolation of bone marrow leucocytes from mice, the cells were resuspended in 1 ml 
TRIzol® (Life Technologies) and incubated for 5 min at room temperature. 200 µl 
Chloroform were added to the solution, the solution was mixed and incubated at room 
temperature for 15 min. After centrifugation for 10 min at 13 000 × g and 4 °C, 500 µl of 
isopropanol were added to the aqueous phase. The solution was incubated at room 
temperature for 15 min. Afterwards it was centrifuged for 10 min at 13 000 × g and 4 °C, the 
pellet was resuspended in 1 ml 70% ethanol and again centrifuged for 5 min at 5000 × g and 
4 °C. The pellet was dried for 10 min and then resolved in 20 µl RNase free water. To 
determine the RNA concentration, absorbance at λ = 260 nm was measured. For storage the 
RNA was frozen at – 80 °C. 
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Reverse transcription of mouse bone marrow mRNA 
The transcription of mouse bone marrow mRNA into cDNA was carried out with the Verso 
cDNA synthesis kit (Thermo Fisher Scientific). One µg of mRNA and 0.5 µM reverse primer 
(Oligo dT) in a total volume of 12 µl were incubated at 65 °C for 10 min. Afterwards the 
solution was immediately chilled on ice. After adding 4 µl of 5 × synthesis buffer, 2 µl 
20 mM dNTPs, 1 µl RT-Enhancer and 1 µl Verso enzyme mix the transcription was 
performed at 42 °C for 30 min followed by 2 min at 95 °C. 
PCR of mouse bone marrow cDNA 
A homologous mouse/human PR3 transcript from bone marrow cDNA of heterozygous hPR3 
knock-in mice was amplified by PCR as described in chapter 2.2.2. The HotStarTaq PCR was 
carried out with 1 µl of cDNA and the primers DJ3536 and DJ3538. The amplification 
consisted of 3 cycles at 58 °C annealing temperature, 3 cycles at 55 °C and 30 cycles at 52 °C. 
As a positive control β-actin was amplified with mouse β-actin primers. Here the program 
consisted of 3, 3 and 24 cycles with annealing temperatures at 65 °C, 62 °C and 59 °C.  
2.5.6 Transfer of mAb into hPR3+/+ mice 
Monoclonal antibodies against hPR3 were injected into 12-14 week old hPR3+/+ mice, to 
evaluate the potential of hPR3 antibodies to induce a GPA-like phenotype. Groups of three 
mice were used for each antibody. 300 µg anti-hPR3 mAb or isotype control antibody in 
200 µl PBS were injected into the mice intraperitoneal. An hour later a mild inflammation 
was induced in the lungs of the mice by administration of LPS. Therefor the mice were 
anesthetized with isoflurane and 3 ng LPS in 50 µl PBS were applied intratracheally. At this 
concentration LPS alone or in combination with the isotype control did not induce an 
inflammatory phenotype. Seven days after the LPS administration the mice were sacrificed 
and the extent of inflammation in the lungs was analyzed. The antibody injection and the 
following analysis of the mice were carried out by André Tittel (Institutes of Molecular 
Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms Universität, Bonn, 
Germany). 
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2.5.7 Immune cell analysis after mAb transfer 
Seven days after injection of the mAbs and LPS the mice were sacrificed and the lungs were 
dissected. The lung tissue of the left lung was used for the analysis of immune cell infiltration 
by flow cytometry. The tissue was digested in collagenase/DNase digestion media for 45 min 
at 37 °C. The solution was filtrated through a 100 µm filter and centrifuged at 300 × g and 
4 °C for 5 min. All following centrifugation steps were carried out under these conditions. 
The cells were washed in FACS-buffer and the erythrocytes were lysed by incubation in 
RCB-buffer for 3 min. After another washing step 10% of the cells were used for FACS 
staining. The FcγR were blocked with 5 µg/ml Fc-block (2.4G2 hybridoma) for 15 min at 
4 °C. The cells were washed and stained for 15 min at 4 °C with 100 µl antibody-dilution 
(1:200). A list of the used antibodies, labels and target cells is given below. After another 
washing step the cells were taken in 300 µl FACS-buffer and 20 000 APC-beads were added 
for correlation of the cell count. Data were collected at a BD Cantoll or BD Fortessa (BD 
Bioscience) and analyzed with the FlowJo software. Analysis of the immune cell infiltration 
was carried out by André Tittel (Institutes of Molecular Medicine and Experimental 
Immunology, Rheinische Friedrich-Wilhelms Universität, Bonn, Germany). 
Antibodies: FITC-MHCII B cells, monocytes, macrophages, 
dendritic cells, activated T cells 
 PE-F4/80 macrophages 
 PE-Cy7-CD19 B cells 
 PerCP-Cy5.5-Ly6C macrophages and granulocytes 
 APC-Ly6G granulocytes 
 APC-Cy7-CD45 hematopoietic cells 
 BV421-CD11c macrophages, dendritic cells, 
granulocytes, NK cells, T cells, B cells 
 FITC-TCRβ T cells 
 PE-CD4 CD4+ T cells 
 PerCP-Cy5.5-NK1.1 NK cells 
 APC-CD8 CD8+ T cells 
 BV421-CD45 hematopoietic cells 
  Antibodies were purchased from eBioscience or Biolegend. 
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Collagenase/DNase digestion media: 1 × RPMI 1640 
 0.5 mg/ml collagenase 
 100 µg/ml DNase 
 20 mM HEPES 
 2 mM L-Glutamine 
 10% (v/v) FCS 
 0.1% (w/v) β-mercaptoethanol 
 105 U Penicillin 
 0.1 g/l Streptomycin 
   
RCB-buffer: 145 mM NH4Cl 
 12 mM NaHCO3 
 127 µM EDTA disodium salt 
  pH 7.3 
   
FACS-buffer: 1 × PBS 
 1% (v/v) FCS (heat inactivated) 
 0.5% (w/v) NaN3 
2.5.8 Periodic acid-Schiff (PAS) staining of lung slices 
Seven days after injection of mAbs and LPS the mice were sacrificed, the lungs were 
dissected and the right lung was used for histology. The right lung was rinsed in PBS to 
remove the spilled blood and then fixated in 10% formalin for 2-3 days. The fixated tissue 
was embedded into paraffin cassettes and rinsed under running water for 2-3 hours. After 
dehydration of the organs with an ethanol row (50%, 75%, 96%, 100%) they were 
paraffinized. The paraffin blocks were cut with the microtome. The resulting slices were dried 
overnight to prevent solubilization of the slices during the staining process. For the PAS-
staining the slices were incubated in xylol for 15 min and rehydrated with a decreasing 
ethanol row (100%, 96%, 75%, 50%). After one minute in water the slices were oxidized by 
0.5% periodic acid for 5 min. The generated aldehyde groups were stained with Schiff reagent 
for 10 min. In the following the slices were incubated for 5 min in sulfite water, 5 min under 
running cold water, 5 min in hematoxylin and 5 min under running warm water. After shortly 
rinsing the slices in water they were again dehydrated with an increasing ethanol row and 
afterwards incubated in xylol for 5 min. After the staining the slices were mounted with 
Histomount, dried overnight and then analyzed with an IX71 microscope (Olympus). Staining 
and analysis were carried out by André Tittel and Magdalena Esser (Institutes of Molecular 
Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms Universität, Bonn, 
Germany). 
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2.6 Cell biological methods 
2.6.1 Determination of cell count and viability 
To determine the number of viable cells a hemocytometer (Neubauer-improved) was used. 
Cells were mixed in a 1:1 ratio with trypan blue solution. Trypan blue is able to enter 
perforated membranes of dead cells enabling discrimination of living and dead cells. The cells 
in the four quadrants of the hemocytometer were counted, the average was build and 
multiplied with the dilution factor. As the volume of one quadrant equates 100 nl the result 
was multiplied with 104 to determine the concentration of cells/ml. 
Trypan blue solution: 0.1% (w/v) trypan blue 
 1 × PBS pH 7.4 
2.6.2 Isolation of PMNs from human blood 
Blood was taken from volunteering healthy donors into 9 ml EDTA tubes to prevent clotting. 
The blood was transferred into a 50 ml tube and PBS was added to a total volume of 40 ml. 
The solution was carefully underlaid with Pancoll human (Pan Biotech, Aidenbach, 
Germany). After gradient centrifugation for 20 min at 500 × g and 20 °C without brake, the 
PMNs and erythrocytes can be found at the bottom of the tube. Plasma, thrombocytes, and 
peripheral blood mononuclear cells (PBMCs) remain on top of the Pancoll layer. Plasma, 
thrombocytes, PBMCs and Pancoll were removed and the tube was filled with PBS to 40 ml. 
The solution was mixed with 8 ml of 6% dextran in PBS to sediment the erythrocytes. After 
30 min incubation at room temperature, the PMNs in the supernatant were taken and 
centrifuged for 5 min at 500 × g. The remaining erythrocytes in the pellet were lysed by 
adding 5 ml 0.2% NaCl for 1 min. Five ml 1.6% NaCl were added for another minute. Then 
the solution was filled with PBS to 30 ml and again centrifuged for 5 min at 500 × g. PMNs 
were resuspended in PBS. 
2.6.3 Preparation of total cell lysates 
To lyse neutrophils isolated from mouse bone marrow or human blood, the cell pellets were 
resuspended in cold RIPA-buffer. 60 µl of RIPA-buffer were used for 5 × 106 cells. The cells 
were transferred into thin-walled PCR-tubes and incubated five-times for 5 min in the 
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ultrasonic bath. In between the solution was incubated on ice for 1 min. Afterwards cell debris 
and DNA was pelleted for 10 min at 20 000 × g and 4 °C.  
RIPA buffer: 50 mM Tris 
 150 mM NaCl 
 0.5 M EDTA 
 0.5% (w/v) deoxycholic acid 
 0.1% (w/v) SDS 
 0.5% (w/v) Nonidet P-40 
  pH 8.0 
2.7 Immunological methods 
2.7.1 Western blot 
Western blot analysis provides a method to detect specific proteins after SDS PAGE by 
applying specific antibodies. After separation of proteins according to their size by SDS 
PAGE, the proteins were transferred on a PVDF membrane by semidry electroblotting. The 
PVDF membrane was activated for 15 seconds in 100% methanol and then the gel and the 
membrane were equilibrated in western transfer buffer for 5 min. The transfer was carried out 
between four sheets of blotting paper, soaked in western transfer buffer. Proteins were 
transferred for 30 min at 5 mA/cm2. After the transfer the membrane was washed in H2O and 
blocked to avoid unspecific binding. Therefor the membrane was incubated in blocking milk 
for one hour at room temperature. After three washing steps in PBS with 0.05% Tween 20 
(PBS-T), the first antibody was applied in PBS-T at 4 °C overnight. The membrane was 
washed three times with PBS-T and incubated for one hour at room temperature in the 
secondary antibody while shaking. The secondary antibody was coupled to horseradish 
peroxidase (HRP) and diluted in PBS-T. After another washing step the bound HRP-
conjugates were visualized with chemiluminescence substrate (SuperSignal West Pico 
Chemiluminescent Substrate, Pierce). For development the ChemiDoc imaging system was 
used (Bio-Rad). 
Antibody dilutions: Goat anti-mPR3 1:1000 
 Mouse anti-goat-HRP 1:1000 
Further information on antibodies is provided in 2.1.7. 
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Western transfer buffer: 10% (v/v) methanol, p.a. 
 150 mM glycine 
 35 mM Tris 
  pH 8.3 
   
Blocking milk: 1 × PBS-T 
 5% (w/v) Non-Fat Dry Milk Blocker, Bio-Rad 
  pH 7.4 
 
2.7.2 Enzyme-linked immunosorbent assay (ELISA) 
ELISA with His-tagged proteins 
The detection of His-tagged proteins or protein complexes was carried out by using nickel-
coated 96-well plates. Proteins were coated in PBS with 0.05% Tween 20 (1 µg/ml; 
100 µl/well) overnight at 4 °C. Between all following steps, the plates were washed three 
times with washing-buffer (Utecht & Lüdemann). All incubation steps were carried out by 
room temperature. The primary antibody was diluted in diluent-buffer (Utecht & Lüdemann) 
and incubated for one hour. After washing, a secondary, HRP-coupled antibody was added, 
also diluted in diluent-buffer and incubated for one hour. The reaction was developed using 
ABTS® peroxidase substrate (KPL, Gaithersburg, MD, USA) and OD values were obtained at 
λAb = 405 nm. 
Capture ELISA 
For the detection of antigen in solution a capture ELISA approach was used. An antigen 
specific antibody was coated on 96-well maxisorp plates. The antibody was diluted in coating 
buffer, yielding a concentration of 100 ng/well and incubated overnight at 4 °C. Between all 
following steps, the plate was washed three times in PBS with 0.05% Tween 20 and all 
incubation steps were carried out at room temperature. To prevent unspecific binding the 
wells were blocked for one hour in blocking buffer. The solution containing the antigen was 
diluted in blocking buffer and incubated for one hour. Afterwards the primary antibody 
(1 µg/ml in blocking buffer) was added and also incubated for one hour. As primary antibody 
a biotinylated antibody was used, to enable discrimination of coating antibody and primary 
antibody. Avidin-HRP was added and incubated for one hour. The reaction was developed 
with ABTS® peroxidase substrate (KPL, Gaithersburg, MD, USA) and OD values were 
measured at λAb = 405 nm.  
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Antibody dilutions: MCPR3-2 1:5000 
 MCPR3-7 1:200 
 CLB-12.8 1:1000 
 IgG1 Isotype control 1:50 
 WGM2-biotin 1:700 
 Goat anti-mouse-HRP 1:2500 
 Human ƙ-light-chain-HRP 1:1000 
 Avidin-HRP 1:20000 
       Further information on antibodies is provided in 2.1.7. 
Coating buffer: 10 mM Na2CO3 
 10 mM NaHCO3 
  pH 9.4 
   
Blocking buffer: 140 mM NaCl 
 3 mM KCl 
 8 mM Na2HPO4 
 1 mM KH2PO4 
 0.05% (v/v) Tween 20 
 2% (w/v) BSA 
  pH 7.4 
2.8 Flow cytometry 
2.8.1 Cell surface staining of PR3 
Neutrophils isolated from human blood or mouse bone marrow were stained for PR3 
expression on their surface. 2 × 105 cells were taken in 200 µl PBS. After centrifugation for 
10 min at 300 × g and 4 °C the cells were activated by adding 10 ng/ml TNFα or 200 ng/ml 
PMA for 15 min at 37 °C. Prior to activation with PMA cells were incubated with 
cytochalasin B (5 µg/ml) for 5 min at 37 °C. The primary antibody, diluted in PBS, was added 
and incubated for 30 min at 4 °C. Cells were washed three times in PBS. The FITC-coupled 
secondary antibody was diluted in PBS, added to the cells and incubated in the dark for 
30 min at 4 °C. Cells were washed again in PBS and then fixated in PBS with 2% PFA. 
Between all steps cells were centrifuged for 10 min at 300 × g and 4 °C. Until measurement, 
fixated cells were kept in the dark at 4 °C. Data were collected at LSRII (BD Bioscience) and 
analyzed with the FlowJo software. 
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2.8.2 Measurement of PR3 activity on the cell surface 
For measurement of PR3 activity on the surface of PMNs, a FRET substrate bound to a lipid-
anchor was inserted into the membrane of the cells. Cleavage of the FRET substrate by 
membrane-bound PR3 results in a fluorescence signal on the cell surface. First 2 × 105 freshly 
isolated neutrophils were activated with 10 ng/ml TNFα for 15 min at 37 °C or with 5 µg/ml 
cytochalasin B for 5 min at 37 °C followed by 200 ng/ml PMA for 15 min at 37 °C. The cells 
were centrifuged at 300 × g and 4 °C for 10 min and 1 µM lipidated FRET substrate in PBS 
was added on ice. The cells were incubated in the dark for 30 min at 4 °C or 37 °C. After 
another centrifugation step, the cells were washed with PBS and fixated in PBS with 2% PFA. 
Until measurement at LSRII fixated samples were kept at 4 °C in the dark. 
2.9 Thermophoresis 
2.9.1 Fluorescent labeling of proteins 
Proteins were labeled with the fluorescent dye NT-647 by attaching the dye via its N-
hydroxysuccinimide ester to primary amines of lysine residues. Prior to labeling proteins were 
dialyzed overnight at 4 °C in PBS. Labeling was carried out by adding a 6.5-fold molar excess 
of NT-647 to the protein and incubation for 30 min at room temperature. Free dye was 
removed afterwards by dialyzing in PBS overnight at 4 °C. 
2.9.2 Thermophoretic quantification 
Thermophoretic quantification was carried out together with Susanne A. I. Seidel (Systems 
Biophysics and Functional Nanosystems, Ludwig-Maximilians-Universität München, 
Germany). By thermophoresis movement of molecules along a temperature gradient can be 
measured. Thus changes in charge or size can be detected, enabling the measurement of 
binding affinities between different molecules. To quantify affinities between two proteins or 
protein complexes, a dilution series of the unlabeled protein was prepared. The dilution series 
always started at a concentration above the estimated affinity constant of the two proteins of 
interest. Consistent amounts of labeled protein were added to the samples of the dilution 
series and the samples were filled into standard treated enhanced gradient capillaries 
(NanoTemper Technologies, Munich, Germany). To avoid adsorption to the capillary walls, 
BSA was added to all samples at a final concentration of 1% (w/v). Measurements were 
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performed at a constant ambient temperature of 20 °C on a Monolith NT.115 system 
(NanoTemper Technologies). Analysis of the obtained data was carried out by Susanne A. I. 
Seidel as recently published (Seidel et al., 2013). 
2.10 Patient material analysis 
2.10.1 Precipitation of total IgG from plasmapheresis material 
Purification of IgGs from plasmapheresis material was carried out by ammonium sulfate 
precipitation. Plasmapheresis material from GPA patients was mixed with a saturated 
(NH4)2SO4 solution to a final concentration of 50%. Precipitation of immunoglobulins takes 
place at a final ammonium sulfate concentration of 40-50%. For precipitation the solution was 
stirred one hour at room temperature. Afterwards the precipitated antibodies were pelleted for 
20 min at 4000 × g. The pellet was resuspended in PBS and dialyzed in dialysis tubes with 50 
kDa cutoff in PBS for 72 hours at 4 °C. During the first 24 hours PBS was exchanged every 
4-6 h and dialysis was carried out without stirring. After 24 hours the buffer was only 
exchanged every 8-12 hours and the solution was stirred. The antibody solution was 
concentrated three-fold in a stirring chamber under nitrogen pressure (2.5 × 105 Pa) using an 
ultrafiltration membrane with 100 kDa cutoff. 
2.10.2 Affinity purification of PR3-specific ANCA 
Chemical biotinylation of PR3 
N-hydroxysuccinimide ester coupled biotin (NHS-biotin) was used for the labeling of 
recombinant PR3. NHS-biotin reacts with primary amines and labels proteins for example by 
binding to the side-chain of lysine residues. Prior to labeling recombinant PR3 was dialyzed 
in PBS at 4 °C overnight. The NHS-biotin was added to the protein in a 20-fold molar excess, 
and the solution was incubated for two hours on ice. Unbound NHS-biotin was removed by 
another dialysis step in PBS at 4 °C overnight. 
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Affinity purification 
Total IgG solutions, precipitated from plasmapheresis material of patients with GPA (see 
chapter 2.10.1), were used to extract PR3-specific ANCA. To remove precipitated proteins 
from the IgG solutions, the IgGs were ultracentrifuged for one hour at 166 880 × g and 
filtered through a 0.5 µM syringe filter. All solutions were kept at room temperature during 
the purification, to avoid further precipitation of proteins. Purification of PR3-specific ANCA 
was carried out by streptavidin-affinity chromatography. HiTrap Streptavidin HP columns 
were equilibrated in solubilization buffer. Biotinylated PR3 was taken in solubilization buffer, 
by adding 1/10 volume 10 × solubilization buffer and bound to the columns. After washing 
the column the IgG solution was applied after adding 1/10 volume 10 × solubilization buffer. 
Another washing step was carried out before PR3-specific ANCA were eluted from the 
column with 0.1 M Glycin/HCl pH 2.5. Eluted antibodies were immediately neutralized by 
adding 1/4 volume Tris HCl pH 9.0. Presence of PR3 reactive antibodies in the elution 
fractions was tested via ELISA. 
Solubilization buffer (10 ×): 5% (w/v) Na-deoxycholate 
 10% (v/v) NP-40 
 0.2% (w/v) NaN3 
  in PBS pH 7.4 
2.10.3 Protein G purification of antibodies from patient plasma 
For the purification of total IgGs out of patient plasma, the plasma was mixed with 1 volume 
of PBS with 0.05% Tween 20 (PBS-T). One µl magnetic Protein G dynabeads (life 
technologies) per 2.5 µl patient plasma was added. After rotation of the mixture for one hour 
at room temperature the beads were washed three times with PBS-T. IgGs were eluted from 
the beads by adding 0.1 M Glycin/HCl pH 2.5. The amount was geared to the original plasma 
volume, enabling an estimation of the IgG concentration in the eluted fractions. 9/10 volume 
Glycin/HCl of the original plasma volume was used for the elution. After incubation for one 
minute the fluid was separated from the beads with a magnetic rack. The pH of the elution 
fraction was neutralized by adding Tris HCl, pH 9.0 (1/10 volume of the original plasma 
volume). 
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2.10.4 Measurement of inhibitory capacity of ANCA from patient plasma 
The effect of ANCA from patient material on the activity of PR3 was measured with the 
FRET-substrate TAMRA-VADnVRDYQ-Dap(CF) (2.5 µM; λEx = 485 nm, λEm = 520 nm). 
PR3 was diluted in activity buffer to a concentration of 10 nM. The concentration of total 
IgGs in our elution fraction was similar to the IgG concentration in plasma. Thus the 
concentration of total IgGs was estimated to be 100 µM. Based on the assumption, that 
approximately 0.1% of the total IgGs are PR3-specific ANCA, the expected concentration of 
ANCA in our IgG fraction was 100 nM. ANCA were added to PR3 at an about four-fold 
molar excess. As control IgGs purified from healthy control persons were used. The relative 
PR3 activity was calculated in relation to PR3 activity in presence of control IgGs, which was 
set to 1. To reduce the amount of patient sample needed for the assay the measurements were 
carried out in black 384-well plates. All tests were performed in duplicates and the inter- and 
intra-assay variances were calculated.  
              Activity buffer: 50 mM Tris 
 150 mM NaCl 
 0.01% (v/v) Triton-X100 
  pH 7.4 
2.11 Statistical analysis 
Results are given as the average with the standard error of the mean (SEM) or in case of the 
thermophoretic measurements as the mean with standard deviation (SD). In case of the patient 
data, the median values of BVAS and PR3 inhibition were calculated and displayed with the 
range of the respective values. Statistical differences of the groups of patient samples were 
tested by Mann-Whitney U-test. The statistical differences in the activity assay approach with 
proPR3 were determined with OneWayAnova. Correlation between ANCA binding to PR3 
and PR3-elafin complexes was analyzed by the Spearman rank correlation test. The level of 
significance was 0.05. Calculations were carried out with the GraphPad Prism software. 
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3. Results 
 
3.1 Generation of hPR3 knock-in mice 
To investigate the in vivo role of human autoantibodies in the development and progression of 
GPA a new transgenic mouse line was generated. In this line, the endogenous murine gene 
segment for PR3 was replaced by a human genomic fragment with four human exons 
covering the mature reading frame. This so-called hPR3 knock-in mouse line was created by 
homologous recombination of a targeting construct in murine embryonic stem cells. By 
transferring PR3-specific antibodies from patients (ANCA), as well as monoclonal antibodies 
(mAbs) against PR3 into these knock-in mice, new insights in their pathogenicity can be 
obtained.  
The first step in the generation of the hPR3 knock-in mice (hPR3+/+ mice) was the design of a 
humanized PR3/NE targeting vector. This was already carried out by Leopold Fröhlich and 
Therese Dau prior to the work presented here. In the humanized PR3/NE locus exon 2 to 5 of 
the mPR3 were replaced by the hPR3 gene (Figure 3.1). To ensure the expression of hPR3 
under natural conditions the humanized locus still consists of the promoter region up to exon 
1 and the major portion of intron 1 of the wildtype murine gene. As the exon 1 only contains 
the murine signal peptide, the resulting protein represents the complete human proform of the 
hPR3 gene. At the 3´ end of the humanized PR3 gene segment a neomycin cassette was 
inserted. The neomycin cassette was flanked by two loxP sites, enabling a later removal of the 
cassette by cre-recombinase. The first chimeric founder animals were generated by Markus 
Moser (Max Planck Institute of Biochemistry, Munich, Germany) and then bred by me to 
homozygosity. Initial attempts to detect the expressed PR3 protein in these hPR3+/+ knock-in 
mice were made, but only very low levels were found (carried out by Therese Dau). 
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Figure 3.1: Humanized knock-in locus, used for the generation of hPR3+/+ mice. In the wildtype 
genomic PR3 and NE locus exon 2 to exon 5 was replaced by the human PR3 gene locus. The 
promotor region up to exon 1 still consists of the murine gene in the humanized locus, to ensure 
expression of hPR3 under wildtype conditions. A neomycin cassette flanked by two loxP sites was 
inserted downstream from the humanized PR3 gene.  
3.1.1 Removal of the neomycin and backcrossing to 129S6/SvEv 
background 
To improve the expression of hPR3 in the knock-in mice, the neomycin cassette was removed 
via cre-mediated recombination at an early embryonic cell stage. For this purpose C57BL/6 
mice with an X-linked cre-recombinase gene were mated to the homozygous hPR3+/+ 
129S6/SvEv mice. These pairings only resulted in heterozygous female offspring, carrying the 
rearranged hPR3 knock-in locus. The reason for this gender bias is that male offspring with 
the cre-recombinase locus on the X chromosome is not viable. Due to this crossing with a 
C57BL/6 mouse line, the knock-in locus was on a mixed background. The females with the 
rearranged hPR3 knock-in locus were, therefore, crossed back to wildtype 129S6/SvEv mice, 
to obtain heterozygous knock-in mice of both genders. This first breeding step was the first in 
a series of backcrossing steps, in order to receive mice on a pure 129S6/SvEv background. In 
total the mice were backcrossed to 129S6/SvEv wildtype mice for seven generations. The 
heterozygous offspring of the seventh generation on an almost pure 129S6/SvEv background 
were then bred to homozygosity and maintained as an inbred line. 
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3.2 Characterization of hPR3 expression in hPR3+/+ mice 
3.2.1 Human PR3+/+ mice express hPR3 
To examine, if hPR3 is expressed in hPR3+/+ mice to the same extend as the endogenous 
murine PR3 gene (mPR3) in wildtype mice, RNA transcription in heterozygous knock-in 
mice was determined. RNA isolated from bone marrow cells was transcribed into cDNA and 
a highly homologous part of mPR3 and hPR3 was amplified with primers that perfectly 
matched both the murine and the human sequence. With an hPR3 specific digest the amount 
of human and mouse DNA could be compared (Figure 3.2 A). The 440 bp amplificate was 
digested with SacI, resulting in two bands of 270 bp and 170 bp, representing the hPR3. The 
mPR3 gene remained uncut. In comparison to undigested DNA, the amount of uncut mPR3 
after SacI digest equaled about half the amount of undigested DNA. Furthermore the two 
digested bands of hPR3 when taken together made up approximately the same amount of 
DNA as the uncut mPR3 band. In Figure 3.2 B the expression of hPR3 in knock-in mice at 
protein level was compared to the expression of hPR3 in human PMNs (hPMNs) and mPR3 
in wildtype murine PMNs (mPMNs). Using recombinant hPR3 and mPR3 as protein 
standards, the PR3 amount in hPMNs and wildtype mPMNs was determined semi 
quantitatively by western blotting. Human PR3 from hPR3+/+ PMN lysate could not be 
detected by western blotting. The antibody used for detection of PR3 by western blotting, was 
originally raised against mPR3. Therefore cross reactivity with hPR3 was weaker and 
detection of low amounts of hPR3 was not possible. For that reason protein expression of 
hPR3 in hPR3+/+ mice was analyzed by capture ELISA. PR3 from hPR3+/+ PMN lysates was 
captured with a PR3-specific antibody and then detected with a biotinylated PR3-specific 
antibody. For quantitative comparisons a specified quantity of recombinant hPR3 was 
captured. The total amount of PR3 in lysates obtained from 1 × 106 cells was calculated in all 
three cases. This comparison revealed much higher protein expression in humans (1.5 µg/1 × 
106 cells) than in wildtype mice (500 ng/1 × 106 cells). Moreover, the expression of the hPR3 
knock-in gene in mice was found to be reduced further in comparison to the endogenous 
mouse protein, mPR3. Only 75 ng hPR3 were detected in 1 × 106 cells. 
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Figure 3.2: Human PR3 is expressed in hPR3+/+ PMNs. A, RNA isolated from neutrophils of 
heterozygous hPR3 knock-in mice was translated into cDNA and a homologous genomic segment of 
440 bp was amplified. Differences in transcription of human and mouse PR3 were detected by SacI 
digestion. SacI solely digests the human fragment, resulting in two smaller bands (270 bp and 170 bp). 
Total amounts of mouse and human cDNA have been compared. One example of three independent 
experiments is shown. B, Expression levels of hPR3 in hPMNs and mPR3 in wildtype mPMNs were 
determined by western blotting. Freshly isolated neutrophils were lysed and analyzed by SDS PAGE 
and immunoblotting. Human and mouse PR3 were detected with a goat anti-mPR3 polyclonal 
antibody. Expression levels were determined semi quantitatively in comparison to increasing amounts 
of recombinant human PR3. PR3 expression in hPR3+/+ PMNs was examined by ELISA. PR3 from 
neutrophil lysates was captured with immobilized MCPR3-2 and detected via WGM2-biotin. The 
amount of PR3 in 1 × 106 PMNs was calculated in all three cases in comparison to specified amounts 
of recombinant human PR3 (n = 3, ± SEM). (M, molecular weight standard) 
3.2.2 Human PR3 expressed in hPR3+/+ mice is catalytically active 
Successful generation of an animal model for GPA not only demands expression of hPR3 in 
neutrophils of the knock-in mice but also correct folding, integrity and functionality of hPR3 
in mouse neutrophils. The hPR3 expressed in hPR3+/+ knock-in PMNs was tested for its 
catalytic activity in an in vitro activity assay. Cleavage of the PR3-specific FRET substrate 
Abz-VADCADRQ-EDDnp by PR3 was determined in different neutrophil lysates prepared 
for human and mouse neutrophils (Figure 3.3). Added to lysates of human PMNs the substrate 
was cleaved rapidly, due to the high amount of hPR3 present in human PMNs. Besides hPR3, 
mPR3 is also able to cleave the FRET substrate. However, mPR3 cleaves the substrate with 
more than ten-fold lower efficacy. Hence, a fluorescence signal was also obtained by adding 
the FRET substrates to a lysate of 129S6/SvEv wildtype PMNs. But more importantly, the 
hPR3 present in lysates of homozygous hPR3+/+ PMNs also cleaved the FRET substrate, 
indicating the presence of a catalytically active human enzyme. The fluorescence detected in 
hPR3+/+ lysates, however, was only slightly higher than the signal in 129S6/SvEv lysates, 
despite the better cleavage by hPR3. This result is explained by the much lower expression 
levels of hPR3 in hPR3+/+ PMNs in comparison to mPR3 in 129S6/SvEv PMNs as 
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demonstrated in Figure 3.2 B. As negative control, lysates of PR3/NE double knock-out 
PMNs (PR3/NE-/-) were used, to exclude cleavage of the substrate by other proteases. 
 
Figure 3.3: Human PR3 in hPR3+/+ PMNs is catalytically active. Functional activity of PR3 from 
hPR3+/+ mice was assessed with a PR3 specific FRET substrate (Abz-VADCADRQ-EDDnp, 
λEx = 320 nm, λEm = 405 nm). Five µM of FRET substrate were added to 50 nM PR3 and to lysates 
of 1 × 105 hPMNs or 5 × 105 mPMNs. PR3 activity was measured over time (n = 3, ± SEM). The 
fluorescence signal obtained in 129S6/SvEv mice can be traced back to mPR3 activity. Murine PR3 is 
also able to cleave this FRET substrate, but with much lower efficacy than hPR3.  
3.2.3 Human PR3 in hPR3+/+ mice is transported to the neutrophil surface 
ANCA binding to PR3 on the surface membrane of neutrophils is thought to be one of the key 
steps for the pathogenicity of ANCA in GPA. In humans PR3 is clearly expressed on the 
surface of unprimed and primed neutrophils. Flow cytometry analysis revealed a surface 
signal of PR3 in about 90% of unstimulated hPMNs after purification (Figure 3.4 A). TNFα 
did barely increase the proportion of cells, expressing PR3 on their surface in comparison to 
unstimulated cells (Figure 3.4 B). Stimulation with PMA, however, led to activation and 
stronger membrane exposure of PR3 in all neutrophils (Figure 3.4 C and D). 
 
Figure 3.4: Human PR3 is strongly expressed on the surface of hPMNs. Surface expression of 
PR3 in hPMNs was analyzed by FACS staining. Unstimulated PMNs (A), TNFα-primed (B) and 
PMA activated (C) PMNs were stained for PR3 with WGM2-FITC (black line). As negative control, 
cells were stained with a FITC-labelled IgG1 isotype control antibody (gray curve). One representative 
example for each condition is shown. D, Geometric mean fluorescence (gMFI) of PR3 positive cells 
was calculated (n = 3, ± SEM). 
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Due to a lack of mPR3 on the surface of mPMNs (Pfister et al., 2004), the question arises as 
to whether hPR3 in hPR3+/+ mice is able to bind to the plasma membrane of mouse 
neutrophils. Human PR3 is known to bind to the NB1 receptor on the neutrophil surface and 
to lipid bilayers via a hydrophobic patch on the surface of hPR3 (Goldmann et al., 1999; 
Korkmaz et al., 2008). In mice, surface expression of hPR3 was tested by FACS analysis. No 
hPR3 could be detected on the surface of unstimulated or TNFα-primed hPR3+/+ PMNs 
(Figure 3.5 A and B). In PMA stimulated cells hPR3 was detected on the surface (Figure 3.5 
C), but the antigen levels were much lower than those on the surface of hPMNs. To ensure 
correct gating of the cells, neutrophils were stained with anti-Ly6G as a positive control. 
 
Figure 3.5: Surface expression of hPR3 on hPR3+/+ neutrophils after PMA stimulation. PR3 
expression on the surface of hPR3+/+ PMNs was detected by FACS analysis. PR3 was stained with 
WGM2-FITC (black line) on the surface of unstimulated (A), TNFα-primed (B) and PMA activated 
(C) PMNs. An IgG1-FITC isotype control antibody (gray curve) was used as negative control. One 
representative example of three independent experiments is shown. D, Differences in fluorescence 
signals were obtained by calculating the geometric mean fluorescence (gMFI) of the PR3 positive cells 
(n = 3, ± SEM).  
3.2.4 PR3 on the surface of hPR3+/+ neutrophils is active 
For membrane binding of PR3 and exposure of conformational epitopes it is not only 
important, that the PR3 antigen is detectable on the surface of the hPR3+/+ neutrophils. The 
protease on the surface should also be folded as a catalytically active, mature serine protease, 
exposing conformational epitopes. First of all the activity of PR3 on the surface of hPMNs 
was analyzed (Figure 3.6). For this purpose a FRET substrate linked to a lipid anchor was 
used. The lipid anchor of this substrate inserts into the membrane of neutrophils. Active PR3 
on the neutrophil surface can then cleave the attached FRET substrate and thus a fluorescence 
signal associated to the cellular surface can be measured. On hPMNs a fluorescence signal 
could be detected in unstimulated, as well as in stimulated cells (Figure 3.6 A to C), indicating 
catalytic activity of membrane-bound PR3 in hPMNs. In PMA stimulated cells, active PR3 on 
the cell surface was reduced (Figure 3.6 E). Stimulation with PMA induces oxygen radicals 
and may lead to the inactivation of PR3 on the surface. Despite the possibility of recognizing 
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PR3 on the surface after PMA stimulation (see Figure 3.4 C), catalytic activity was probably 
reduced due to that fact. As a control the FRET substrate was incubated on unstimulated cells 
at 37 °C. Incubation at 37 °C leads to an internalization of the FRET substrate. Fluorescence 
signal obtained in these cells, reflects the expression of active PR3 in the cell. A high 
fluorescence signal could be obtained under these conditions (Figure 3.6 D).  
 
Figure 3.6: Human PR3 on the surface of hPMNs is catalytically active. To determine activity of 
membrane-bound PR3 on hPMNs, a FRET substrate with a lipid anchor was used (TAMRA-doo-
VADnVRDRQ-doo). The FRET substrate anchors in the neutrophil membrane and cleavage by active 
PR3 on the cell surface leads to a fluorescence signal measurable by FACS analysis (λEx = 485 nm 
and λEm = 520 nm). The lipid anchored FRET substrate (1 µM) was bound to the membrane of 
unstimulated (A), TNFα-primed (B) and PMA activated (C) hPMNs (black line) at 4 °C. As negative 
control neutrophils without FRET substrate were used (gray curve). D, Incubation of the FRET 
substrate at 37 °C leads to internalization and active PR3 in the neutrophils could be detected (one 
representative example for the different conditions shown). E, Geometric mean fluorescence (gMFI) 
for each experiment is given (n = 3, ± SEM). 
To determine the catalytic activity of hPR3 on the surface of hPR3+/+ PMNs, freshly isolated 
neutrophils were incubated with the lipid anchored FRET substrate. In unstimulated cells only 
a relative low amount of PMNs with PR3 activity on their surface could be detected (Figure 
3.7 A). The highest expression of active PR3 was obtained in TNFα-primed cells (Figure 3.7 
B). In PMA activated cells the amount of active PR3 was slightly reduced in comparison to 
TNFα−primed PMNs (Figure 3.7 C and E). Despite the high signal for PR3 obtained with the 
surface staining (see Figure 3.5 C), the signal for active PR3 on PMA activated cells was 
reduced. These findings are consistent with the activity measurements on the surface of 
hPMNs after PMA-stimulation, suggesting a damage of catalytic PR3 activity by PMA. After 
incubation at 37 °C and subsequent internalization of the FRET substrate, a high fluorescence 
signal could be detected (Figure 3.7 D). With these experiments hPR3 expression and 
functionality detected in the lysates of hPR3 expressing mPMNs (see Figure 3.2 and 3.3) 
could be confirmed. 
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Figure 3.7: Catalytic activity of hPR3 on hPR3+/+ neutrophils. PR3 activity on the surface of 
hPR3+/+ PMNs was determined by FACS analysis with the lipidated FRET substrate TAMRA-doo-
VADnVRDRQ-doo (λEx = 485 nm, λEm = 520 nm). The FRET substrate was attached to the 
membrane of unstimulated (A), TNFα-primed (B) and PMA activated (C) hPR3+/+ PMNs (black line) 
at 4 °C. As a negative control the FRET substrate was inserted in the membrane of PR3/NE-/- PMNs 
(gray curve). D, Activity of PR3 in hPR3+/+ PMNs was detected after incubation of the FRET substrate 
at 37 °C, which leads to internalization of the substrate (one representative example of each condition 
shown). E, The geometric mean fluorescence (gMFI), representing catalytically active PR3, is shown 
for the different conditions (n = 3, ± SEM). 
3.3 Characterization of monoclonal antibodies for transfer 
experiments 
The impact of ANCA in general and of different subpopulations or subclasses in particular, on 
the pathogenesis of GPA is still uncertain. An animal model expressing hPR3 in mouse 
neutrophils should help solve this question. By transfer of monoclonal antibodies (mAbs) to 
these mice, the influence of antibodies on disease development and progression should be 
assessed. But which antibodies can be used for these transfer experiments? To answer this 
question, the binding properties of the mAbs MCPR3-2, MCPR3-7 and CLB-12.8 were 
examined in the following. 
3.3.1 Interference of mAbs with catalytic activity of PR3 
Some former studies suggest the hypothesis, that antibodies, which inhibit the activity of PR3, 
could be associated with disease development and progression (Daouk et al., 1995; van der 
Geld et al., 2002). Comparison of inhibitory with non-inhibitory antibodies in transfer 
experiments should answer the question as to how ANCA types determine the course and 
severity of the disease. Thus the inhibitory potential of mAbs was analyzed (Figure 3.8). 
Increasing amounts of mAbs were added to 50 nM PR3 and cleavage of Abz-YYAbu-
ANBNH2 (800nM) was measured. Whereas MCPR3-2 and CLB-12.8 did not influence the 
activity of PR3, MCPR3-7 strongly inhibited PR3. Already at a 1:1 ratio an effect on PR3 
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activity could be detected. At a three-fold molar excess of MCPR3-7 PR3 was completely 
inhibited. 
 
Figure 3.8: Interference of mAbs with catalytic PR3 activity. Influence of mAbs on the activity of 
PR3 was measured in a FRET-based activity assay. Cleavage of 800 nM FRET substrate (Abz-
YYAbu-ANBNH2, λEx = 320 nm, λEm = 405 nm) by PR3 (50 nM) was measured in the presence of 
increasing concentrations of three different mAbs (0 – 750 nM) (n = 3, ± SEM). 
3.3.2 Interaction of mAbs with PR3 inhibitor complexes 
Inhibition of PR3 plays an important role in the pathogenesis of GPA. In a recent genome 
wide association study, besides a SNP in the PR3 gene, a SNP in the gene of the alpha-1 
proteinase inhibitor (α1PI) was confirmed as risk allele for GPA (Lyons et al., 2012). As 
already outlined in the introduction (see chapter 1.6.1), binding of α1PI to PR3 first leads to 
the formation of a canonical complex and after cleavage of the reactive center loop PR3 is 
covalently linked to the inhibitor. The covalent association with α1PI induces a 
conformational change in PR3 resulting in an inactive zymogen-like conformation. As 
interaction of PR3 with its physiological inhibitors, plays an important role in the immune 
response, antibodies have to be able to interact with this PR3-inhibitor complexes to unfurl a 
pathogenic effect. Therefore the binding capability of mAbs to different PR3-inhibitor 
complexes was examined. 
Covalent PR3-inhibitor complexes were formed using α1PI and an AAPV-chloromethyl 
ketone (CMK). Furthermore canonical complexes were generated with elafin and α1PI. To 
form the canonical α1PI-PR3 complex the catalytically inactive PR3 variant ∆hPR3-S195A 
(labeled as PR3*) was used. In nearly all these complexes PR3 is present in its active 
conformation. Only covalent complexation to α1PI leads to a conformational change of PR3 
as described above and displays PR3 in a precursor-like conformation. The PR3 complexes 
were formed by adding a ten-fold molar excess of inhibitor to PR3 and incubation at 37 °C for 
one hour. After immobilization on nickel-plates via the 6 × His-tag of PR3, the binding of 
mAbs to the different complexes was detected (Figure 3.9). MCPR3-7 (Figure 3.9 A) showed 
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a much stronger binding capability towards proPR3 in comparison to mature PR3. 
Furthermore MCPR3-7 was only able to bind to the covalent PR3-α1PI complex. No binding 
to the other PR3-inhibitor complexes was observed. The strong binding to proPR3 and PR3-
α1PI complexes indicated a preferential binding of MCPR3-7 to the inactive conformation of 
PR3. In contrast CLB-12.8 (Figure 3.9 B) was able to bind to all different PR3-variants and 
complexes, except for the covalent PR3-α1PI complex. The epitope of CLB-12.8, which lies 
close to the active site cleft (Silva et al., 2010), probably becomes inaccessible after binding 
of the inhibitor and the following conformational changes. As MCPR3-2 (Figure 3.9 C) is 
able to bind to all PR3-variants, it was chosen as an appropriate coating control. Thus equal 
coating of the different variants could be ascertained. No binding of the isotype control 
antibody to the different PR3-variants could be observed. 
 
Figure 3.9: Binding of mAbs to different PR3 inhibitor complexes. Binding of mAbs to different 
PR3-inhibitor-complexes was assessed in an ELISA. Inhibitors were added to PR3 in solution at a ten-
fold molar excess and incubated for one hour at 37 °C. The covalent PR3-α1PI complex represents 
PR3 in its inactive conformation. In contrast the covalent complex with the AAPV-chloromethyl 
ketone (CMK) and the two canonical complexes PR3-Elafin and PR3*-α1PI contain PR3 in its active 
conformation. The complexes, proPR3 and active PR3 were immobilized on nickel plates via the 
6 × His-tag of PR3 and binding of MCPR3-7 (A), CLB-12.8 (B) and MCPR3-2 (C) was determined 
with a HRP-conjugated goat-anti-mouse antibody. The recognition of the PR3 variants was normalized 
to the signal obtained with proPR3, which was set to 100% (n = 3, ± SEM). As MCPR3-2 binds to the 
different PR3 variants at a similar level, MCPR3-2 was used as a coating control. (PR3*, catalytically 
inactive PR3) 
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3.3.3 MCPR3-7 impairs α1PI-PR3 complexation 
As already mentioned, inhibition and clearance of PR3 by α1PI plays an important role in 
neutrophil-mediated tissue damage. Antibodies, which interfere with the complexation of PR3 
with α1PI, could reduce PR3 clearance and thus intensify the immune response. With regard 
to our animal model, it was important to investigate, wether mAbs with such properties exist. 
Transfer of such mAbs into hPR3+/+ mice could lead to an exaggerated immune response. 
Therefore PR3 complexation with α1PI was analyzed in the presence of mAbs by SDS PAGE 
and silver nitrate staining. First, complex formation of PR3 (800 nM) and α1PI (4 µM) 
without mAbs was determined at different timepoints (Figure 3.10 A). Already after 
5 seconds PR3-α1PI complexes could be detected. PR3 was completely covalently attachted 
to α1PI at this timepoint. To assess the influence of mAbs, PR3 was preincubated with a 
three-fold molar excess of MCPR3-7 (Figure 3.10 B), CLB-12.8 (Figure 3.10 C) and MCPR3-
2 (Figure 3.10 D). In case of CLB-12.8 and MCPR3-2 the first complexes were detected in 
the gel after 5 seconds and after 15 seconds the reaction was completed. In contrast, MCPR3-
7 delayed the complexation. Formation of the first complexes could only be observed after 15 
seconds. It took about 3 minutes until the complexation reaction was completed and all PR3 
was covalently attached to α1PI. These findings clearly indicate that binding of MCPR3-7 to 
PR3 influences and impairs the covalent complexation with α1PI. 
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Figure 3.10: MCPR3-7 delays covalent PR3-α1PI complexation. A, Covalent PR3-α1PI 
complexation was observed over time by adding α1PI at a five-fold molar excess to 800 nM PR3 and 
incubation at 37 °C. B to D, To detect the effect of mAbs on the covalent complexation 800 nM of 
PR3 were preincubated with a three-fold molar excess of MCPR3-7 (B), CLB-12.8 (C) or MCPR3-2 
(D) for one hour at room temperature. Alpha-1PI was added at a five-fold molar excess to the PR3-
mAb complexes and incubated at 37 °C. At different timepoints 10 µl of the solutions were taken and 
analyzed by SDS PAGE and silver nitrate staining. Representative examples of three technical repeats 
are shown (M, molecular weight standard; IgGH, IgG heavy chain; IgGL, IgG light chain). 
3.3.4 Influence of mAbs on non-covalent α1PI-PR3 complexation 
Covalent complexation of PR3 with α1PI leads to clearance of PR3 from the neutrophil 
membrane. To determine if only this type of complexation, or also the canonical interaction, 
is affected by mAbs, the non-covalent complex formation was examined by thermophoresis 
measurements. Catalytically inactive PR3, ∆hPR3-S195A, expressed in HEK 293E cells and 
purified via nickel-chromatography, was used for this approach. After preincubation with 
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mAbs, NT647-labeled α1PI was added to a dilution series of ∆hPR3-S195A in presence or 
absence of mAbs and the binding was measured by thermophoresis (Figure 3.11). The 
thermophoretic analyses were performed together with Susanne A. I. Seidel (Systems 
Biophysics and Functional Nanosystems, Ludwig-Maximilians-Universität München, 
Germany). In the absence of antibodies α1PI bound to ∆hPR3-S195A with a KD of 
1.9 ± 1.1 µM. For the measurements in presence of MCPR3-7 no saturating amounts of 
MCPR3-7 could be used, due to the low initial antibody concentration. Hence, the ∆hPR3-
S195A-antibody solution contained ∆hPR3-S195A-MCPR3-7 complexes and free ∆hPR3-
S195A. The binding affinity measured with α1PI accordingly consisted of the binding of 
α1PI to ∆hPR3-S195A-MCPR3-7 complexes and to free ∆hPR3-S195A. Regardless, an 
inhibiting impact of MCPR3-7 on the canonical interaction of ∆hPR3-S195A and α1PI could 
be detected (KD = 5.6 ± 1.0 µM). As this inhibition could already be observed at relatively 
low antibody concentrations, a more pronounced decrease can be expected with higher 
antibody concentrations. In contrast to MCPR3-7, pre-incubation with CLB-12.8 did not alter 
the affinity of ∆hPR3-S195A and α1PI. The curve displaying the binding of α1PI to ∆hPR3-
S195A-CLB-12.8 complexes is a nearly perfect overlay to the curve without antibodies. The 
determined KD of 1.8 ± 0.8 µM did not differ significantly from the KD measured without 
antibodies.  
 
Figure 3.11: Non-covalent PR3-α1PI complexation is impaired in the presence of MCPR3-7. 
Thermophoretic quantification was used to determine the influence of mAbs on non-covalent PR3-
α1PI complex formation. A dilution series of ∆hPR3-S195A was prepared starting at a concentration 
of 12 µM. Each sample of the dilution series was mixed 6:1 with PBS with or without mAbs, to yield 
an antibody concentration of 670 nM. After one hour incubation at room temperature, NT647-labelled 
α1PI was added (880 nM). In the absence of antibodies thermophoresis revealed a KD of 1.9 ± 1.1 µM 
(blue rectangles). The presence of CLB-12.8 did not change the affinity of α1PI to PR3 (KD = 1.8 
± 0.8 µM; grey triangles), whereas the affinity was decreased three-fold by preincubation with 
MCPR3-7 (KD = 5.6 ± 1.0 µM; red circles). Thermophoretic measurements were performed together 
with Susanne A. I. Seidel (Systems Biophysics and Functional Nanosystems, Ludwig-Maximilians-
Universität München, Germany). Results of three technical repeats are shown (n = 3, ± SD). 
Characterization of monoclonal antibodies for transfer experiments 
 
51 
 
3.3.5 Characterization of the MCPR3-7 epitope 
As MCPR3-7 is the only known mAb, which interferes with PR3 activity and influences the 
complexation between PR3 and α1PI, the binding site and the inhibition mechanism of this 
antibody was further characterized. In an activity assay approach with human and gibbon PR3 
variants it could be shown that inhibition by MCPR3-7 is sequence dependent. Gibbon PR3 
(gibPR3) is hardly inhibited in the presence of MCPR3-7 in comparison to hPR3 (Figure 3.12 
A and B). To localize the MCPR3-7 binding sequence two human/gibbon PR3 chimeras were 
used. One chimera consisted of the human amino-terminal β-barrel and the gibbon carboxy-
terminal β-barrel (h/gibPR3, Figure 3.12 C). The other contained the gibbon amino-terminal 
and the human carboxy-terminal β-barrel (gib/hPR3, Figure 3.12 D). Only the gib/hPR3 was 
strongly inhibited by MCPR3-7, whereas the h/gib PR3 still showed activity in presence of 
MCPR3-7. Thus MCPR3-7 binding could be mapped to the carboxy-terminal β-barrel of PR3. 
 
Figure 3.12: Localization of the MCPR3-7 binding epitope on the carboxy-terminal β-barrel of 
PR3. To determine the MCPR3-7 binding region two gibbon/human PR3 chimeras were tested in an 
activity assay approach in the presence of MCPR3-7. The h/gibPR3 variant consists of the human N-
terminal β-barrel and the gibbon carboxy-terminal β-barrel. In contrast the gib/hPR3 variant contains 
the gibbon N-terminal and the human carboxy-terminal β-barrel. PR3 activity was measured with the 
FRET substrate Abz-YYAbu-ANBNH2 (λEx = 320 nm, λEm = 405 nm). Cleavage of 800 nM FRET 
substrate by 50 nM hPR3 (A), gibPR3 (B), h/gibPR3 (C) or gib/hPR3 (D) was measured in the 
absence or presence of a two-fold molar excess of MCPR3-7. The fluorescence signal is displayed in 
relative fluorescence units (RFU) and one representative example of three technical repeats is shown. 
Strong inhibition of the hPR3 and the gib/hPR3 variant but not the gibPR3 and the h/gibPR3 variant 
by MCPR3-7 indicated binding of the antibody to the carboxy-terminal β-barrel. 
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3.3.6 MCPR3-7 is unable to bind to PR3 in its active conformation 
In Figure 3.9 a preferential binding of MCPR3-7 to the proform of PR3 could be detected. To 
further characterize the binding affinities of MCPR3-7 to proPR3 and mature PR3, 
thermophoretic measurements were performed. Thermophoretic quantification was performed 
together with Susanne A. I. Seidel (Systems Biophysics and Functional Nanosystems, 
Ludwig-Maximilians-Universität München, Germany). Binding of MCPR3-7 to proPR3, PR3 
and PR3-CMK (AAPV-chloromethyl ketone) complexes was measured. MCPR3-7 was 
labeled with NT647 and added to the samples of a dilution series of the different PR3-
variants. To generate PR3-CMK complexes the CMK was added to PR3 at a ten-fold molar 
excess and incubated for one hour at 37 °C. In this complex PR3 is held in its active 
conformation, whereas mature PR3 in free solution is able to switch from the active 
conformation into an inactive zymogen-like conformation. Thus PR3 in free solution exists in 
an allosteric equilibrium of molecules between two extreme conformations, one fully 
accessible to a substrate (active conformation) and the other with an occluded active site 
(inactive conformation) (Pozzi et al., 2012). Binding of MCPR3-7 to proPR3 revealed a KD 
below 10 nM. In contrast no binding of MCPR3-7 to PR3 in its active conformation, 
stabilized by binding to CMK, could be detected (Figure 3.13 A). These findings indicate that 
MCPR3-7 selectively recognizes the zymogen conformation of PR3. Binding to mature PR3 
in free solution, however, was detectable (Figure 3.13 B). The binding affinity measured with 
mature PR3 (KD = 0.4 ± 0.2 µM), was about 40-fold lower, than with proPR3. Recognition of 
mature PR3 by MCPR3-7 is probably due to an allosteric switch from the active into the 
inactive zymogen-like conformation and shifts the equilibrium in the direction of the inactive 
conformation.  
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Figure 3.13: MCPR3-7 does not bind to the active PR3 conformation. Affinity of MCPR3-7 to 
PR3 in different conformations was measured by thermophoresis. Binding of MCPR3-7 to proPR3 
was compared to binding of MCPR3-7 to PR3 complexed with AAPV-chloromethyl ketone (CMK) 
(A) or to PR3 in free solution (B). PR3 in free solution is able to adopt different conformational stages 
and displays an equilibrium between active and inactive conformations. In contrast PR3 in complex 
with CMK is held in its active conformation. Complexation was carried out by the addition of a ten-
fold molar excess of CMK to PR3 and incubation for one hour. For the affinity measurements a 
dilution series of the different PR3 variants was prepared, starting at a maximum concentration of 
2.5 µM. NT647-labeled MCPR3-7 was added to the dilution samples at a final concentration of 
50 nM. MCPR3-7 revealed a strong binding affinity to proPR3 (KD ≤ 10 nM, blue rectangles). Active 
PR3 was bound with a much lower affinity (KD = 0.4 ± 0.2 µM, red circles), whereas no binding to the 
mature conformation of the PR3-CMK could be detected (grey triangles). The thermophoretic 
quantification was measured together with Susanne A. I. Seidel (Systems Biophysics and Functional 
Nanosystems, Ludwig-Maximilians-Universität München, Germany). Results of three technical 
repeats are shown (n = 3, ± SD).  
3.3.7  Binding of MCPR3-7 alters the peptide binding pocket 
The results of the thermophoretic quantification revealed a better binding of MCPR3-7 to the 
zymogen conformation of PR3 (see Figure 3.13). As MCPR3-7 furthermore inhibits active 
PR3, alteration of the active PR3 conformation is probably the mechanism by which MCPR3-
7 is able to interfere with PR3 activity. To characterize these conformational changes upon 
MCPR3-7 binding, activity of PR3 towards different substrates in presence and absence of 
MCPR3-7 was measured. Therefore substrates with different amino acids at position P1 and 
with leaving groups of different sizes at P1´ were used. Cleavage of the substrate with the best 
fit non-natural residue at P1, Abz-YYAbu-ANBNH2 (Figure 3.14 A) was strongly inhibited 
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by MCPR3-7. Usage of an optimized extended peptide substrate, TAMRA-VADnVVADYQ-
Dap(CF) also revealed a strong inhibitory effect by MCPR3-7 (Figure 3.14 B). Furthermore 
cleavage of the substrate Ahx-PYFA-pNA (Figure 3.14 C), which contains a big leaving 
group in P1´, was also impaired by the presence of MCPR3-7. In contrast substrates with a 
small leaving group in P1´ and amino acids of different sizes in P1, Boc-A-ONp and Boc-
APnV-SBzl (Figure 3.14 D and E), were still cleaved by PR3 in the presence of MCPR3-7. 
Cleavage of For-AAPAbu-SBzl (Figure 3.14 F), which contains a small leaving group in P1´, 
but a larger amino acid in P1, was partly active after binding of MCPR3-7. An activity of 50% 
could be determined in the presence of MCPR3-7. These findings indicate that binding of 
MCPR3-7 mostly affects the S1´ pocket of PR3. Smaller leaving groups in P1´ are still able to 
interact with PR3 in the presence of MCPR3-7, whereas cleavage of substrates with big 
leaving groups in P1´ is completely inhibited. Changes in the P1 position of the substrate did 
hardly alter the effect of MCPR3-7. Thus it is most likely that inhibition of PR3 by MCPR3-7 
is due to an allosteric mechanism, which alters the conformation of the S1´ pocket of PR3. 
 
Figure 3.14: Interference of MCPR3-7 with PR3 activity towards different substrates. The effect 
of MCPR3-7 on cleavage of different PR3 substrates was determined in a FRET-based activity assay, 
to specify the binding mechanism of MCPR3-7. To a 50 nM PR3 solution (A-E) or a 100 nM PR3 
solution (F) a three-fold molar excess of MCPR3-7 was added. Cleavage of 800 nM Abz-YYAbu-
ANBNH2 (A), 5 µM TAMRA-VADnVVADYQ-Dap(CF) (B), 1 mM Ahx-PYFA-pNA (C), 1 mM 
Boc-A-ONp (D), 1 mM Boc-APnV-SBzl (E) and 1 mM For-AAPAbu-SBzl (F) was measured over 
time. The relative activity was determined by normalizing PR3 activity in absence of MCPR3-7 to 1 
(n = 3, ± SEM).  
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3.3.8 MCPR3-7 cannot bind to membrane-bound PR3 
The inhibitory properties of MCPR3-7, as well as the interference of this antibody with 
covalent and non-covalent PR3-α1PI complex formation, as shown above, turn this antibody 
into a potential candidate for transfer experiments in hPR3+/+ mice. To further explore this 
possibility, detection of membrane-bound PR3 by MCPR3-7 was examined by FACS 
analysis. These experiments were carried out by Ulrich Specks (Thoracic Disease Research 
Unit, Mayo Clinic and Foundation, Rochester, MA, USA). Membrane-bound PR3 on freshly 
isolated hPMNs was detected with MCPR3-2 (Figure 3.15 A, continuous black line). A 
bimodal expression pattern representing PR3-positive and PR3-negative PMNs could be 
observed. After stimulation with TNFα, the proportion of PR3-positive cells, detected with 
MCPR3-2 increased (Figure 3.15 B). CD32 staining was used as positive control (dotted line). 
Using MCPR3-7 to detect membrane-bound PR3, only a tiny second population (arrow) with 
marginal MCPR3-7 reactivity could be observed. The vast majority of cells could not be 
detected as PR3-positive with MCPR3-7. PR3 on the neutrophil surface could neither be 
detected by MCPR3-7 after TNFα stimulation. The missing recognition of membrane-bound 
PR3 may be due to conformational reasons. PR3 attached to the membrane forms complexes 
with NB1 (CD177) and/or lipid bilayers via a hydrophobic patch of the activation domain. 
Thus, membrane-bound PR3 is present only in a fixed conformation. As MCPR3-7 binds to 
the activation domain of its proform, membrane-bound PR3 does not appear to fully present 
the epitope of this antibody. These properties of MCPR3-7 are not favorable for transfer 
experiments in hPR3+/+ mice. 
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Figure 3.15: MCPR3-7 cannot detect membrane-bound PR3. To test antibody detection of PR3 on 
the surface, PMNs were isolated from human blood and stimulated with TNFα (B and D). PR3 
(continuous black line) on the surface of unstimulated and TNFα-primed PMNs was stained with 
MCPR3-2 (A and B) and MCPR3-7 (C and D) and visualized with a FITC-conjugated goat anti-mouse 
secondary antibody. As positive control CD32 expression was detected (dotted line). The gray peak 
represents the isotype control. These experiments were carried out by Ulrich Specks (Thoracic Disease 
Research Unit, Mayo Clinic and Foundation, Rochester, MA, USA). 
3.3.9 Generation of new mAbs against PR3 
None of the mAbs available, except MCPR3-7, interfered with PR3 activity or interaction 
with α1PI. As shown above, MCPR3-7 cannot be used for transfer experiments in hPR3+/+ 
mice, due to the lack of recognition of membrane-bound PR3. Thus new monoclonal 
antibodies against PR3 were produced in cooperation with Elisabeth Kremmer (Helmholtz 
Zentrum München). Two mice were immunized with ∆hPR3-S195A and hybridoma 
supernatants of 21 different antibodies were gathered. The affinity of these antibodies to PR3 
was determined in an ELISA and the hybridoma supernatants with the highest affinity were 
chosen for further analysis. To test these antibodies for their inhibitory capacity towards PR3, 
an immune-capture activity assay approach was used. The hybridoma supernatant contains 
FCS and thereby also bovine α1PI. Thus in an activity assay in free solution, PR3 would be 
immediately inhibited by α1PI after adding the supernatants and the effect of the antibodies 
could not be measured. To avoid this problem, the mAbs of the culture medium were captured 
by anti-mouse polyclonal antibodies, which were immobilized on a black maxisorp 96-well 
plate. Thereby all FCS proteins, including α1PI, in the cell culture supernatants were removed 
during the washing steps, before adding PR3. PR3 was then bound to the antibodies, and after 
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adding a FRET substrate, the influence of the immobilized antibody on PR3 activity was 
measured. With this method, three antibodies, with inhibitory capacity towards PR3 could be 
identified (Figure 3.16). The two antibodies 4B12 and 7D12 strongly inhibited PR3. The third 
antibody, 5B11, was only able to inhibit PR3 by about 50%. As positive control the mAb 
CLB-12.8 was captured onto the 96-well plate, as negative control an IgG1 isotype antibody 
was used. 
 
Figure 3.16: Hybridoma supernatants of new mAbs showed inhibitory capacity towards PR3. 
PR3-specific antibodies from hybridoma supernatants were captured on black 96-well maxisorp plates 
with anti-mouse immunoglobulin antibodies (1 µg/well). PR3 was bound to these antibodies 
(100 ng/well) and PR3 activity was measured with a FRET substrate. 800 nM of Abz-YYAbu-
ANBNH2 were added and fluorescence was measured. The fluorescence signal was normalized to the 
signal obtained by PR3 captured with CLB-12.8, which was set to 1 (n = 2; ± SEM). In this way 
inhibitory capacity of PR3-specific antibodies in hybridoma supernatants was determined. 
The contents of the hybridoma supernatants, like for example α1PI, could disturb further 
characterization and transfer experiments. Thus the antibodies were purified from the 
hybridoma supernatants by Elisabeth Kremmer (Helmholtz Zentrum München). After 
purification the inhibitory capacity of the antibodies was again analyzed. An activity assay in 
free solution was performed (Figure 3.17). The antibodies were added to PR3 at increasing 
nanomolar concentrations, exceeding the molar concentration of PR3, and the cleavage of a 
FRET substrate was measured in the presence of these antibodies. Unfortunately, not even a 
20-fold molar excess of the antibody was able to inhibit the PR3 in free solution. Purification 
of the antibodies may have changed their ability to interfere with PR3 activity. What is more 
likely, immobilized PR3 could be more sensitive to inhibition in this immune-capture activity 
assay approach in comparison to the activity assay in free solution. 
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Figure 3.17: New mAbs showed no inhibitory capacity after purification from hybridoma 
supernatants. PR3-specific antibodies were purified from hybridoma supernatants and their inhibitory 
capacity towards PR3 was tested in an activity assay in free solution. Antibodies were added to 50 nM 
PR3 in increasing concentrations (150 – 1000 nM). 5 µM FRET substrate (TAMRA-
VADnVVADYQ-Dap(CF)) were added and fluorescence was detected at λEx = 485 nm and 
λEm = 520 nm. The fluorescence signal was normalized to the signal obtained by cleavage of the 
FRET substrate in the absence of antibodies, which was set to 1 (n = 2; ± SEM). 
3.4 Transfer of mAbs into hPR3+/+ mice 
3.4.1 Infiltration of immune cells in the lungs after antibody injection 
As MCPR3-7, the only inhibitory mAb available at the beginning of my doctoral work, was 
not found suited for transfer experiments as elucidated in chapter 3.3.8, I decided to transfer 
two mAbs of different IgG subclasses. Hence, besides establishing of a new animal model, I 
could evaluate the impact of different antibody subclasses on the development of an 
autoimmune response after antibody transfer into hPR3+/+ mice. The newly generated mAbs 
against PR3 4B12, which belongs to the IgG2a subclass, and 7D12 of the IgG2b subclass 
were used for the transfers. As these were the antibodies, which were generated in 
cooperation with Elisabeth Kremmer (Helmholtz Zentrum München), high amounts of 
antibodies were available. Transfer of the antibodies and the following analysis of the mice 
were carried out by André Tittel (Institutes of Molecular Medicine and Experimental 
Immunology, Rheinische Friedrich-Wilhelms Universität, Bonn, Germany). In patients with 
GPA external factors, for example Staphylococcus aureus infections, are known to initiate 
inflammatory responses and thus can reduce immune tolerance and favor the development of 
autoimmunity (Scully et al., 2012). For that reason LPS was injected into the transgenic mice 
intratracheally, in addition to the antibody transfer, to induce mild inflammation in the lungs. 
LPS was used at a relatively low concentration (3 ng per mouse). Thus after parallel injection 
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of the isotype control antibodies and LPS, no or very little inflammation was observed after 
seven days. The mice were sacrificed seven days after injection and the immune cell 
infiltration in the lungs was analyzed (Figure 3.18). Injection of 7D12 induced a slight 
increase of PMNs in comparison to its isotype control antibody (Figure 3.18 B right panel). 
Furthermore the number of macrophages was slightly elevated in the lungs after 7D12 
injection (Figure 3.18 B right panel). However no difference in T cells and B cells could be 
observed after injection of 7D12 (Figure 3.18 C-E right panels). Injection of the mAb 4D12, 
in contrast, induced a strong infiltration of all types of immune cells in comparison to its 
isotype control antibody (Figure 3.18 A-E left panels). Not only primary immune cells like 
PMNs and macrophages were elevated in the lung tissue, but also T cells and B cells. These 
results indicate a strong, already advanced immune response after 4D12 injection. Based on 
these results it becomes clear that antibodies against PR3 are able to induce an immune 
response in the transgenic mice. Furthermore this immune response seems to depend on the 
antibody isotype, as the reaction to the IgG2a isotype of 4D12 was much more pronounced 
than to the IgG2b antibody 7D12. 
 
Transfer of mAbs into hPR3+/+ mice 
 
60 
 
 
Figure 3.18: Injection of mAbs against hPR3 leads to recruitment of immune cells in the lungs. 
Two different mAbs against hPR3 (4B12, left panels of A-E and 7D12, right panels of A-E) were 
injected into the hPR3+/+ mice. 300 µg of the mAb were administered intraperitoneal one hour before 
induction of a mild inflammation by injection of LPS (3 ng per mouse). As control 300 µg of the 
respective isotype control antibody (IgG2a for 4B12, IgG2b for 7D12) were injected. After seven days 
the lungs of the mice were dissected and the infiltration of the different types of immune cells (PMNs 
in A, macrophages in B, CD8+ T cells in C, CD4+ T cells in D and B cells in E) into the lung tissue 
was analyzed by FACS staining (n = 3 mice ± SEM). The flow cytometry analysis of the immune cells 
was carried out by André Tittel (Institutes of Molecular Medicine and Experimental Immunology, 
Rheinische Friedrich-Wilhelms Universität, Bonn, Germany). 
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3.4.2 Lung vasculitis and pulmonary lesions after antibody injection 
Histopathological analysis was performed to further characterize the immune response to 
PR3-specific antibodies. During the preparation of histological sections macroscopic 
differences of the lung vessels could already be detected in the mice injected with 4B12 in 
comparison to the isotype control injected mice. After injection of 4B12 the vessels showed a 
plump and swollen shape, indicating vasculitis-like changes in the lungs. For further analysis 
of the immune cell recruitment after antibody injection, lung slices were prepared and stained 
by PAS-staining. PAS-staining visualizes glycoproteins and polysaccharides and thus 
granules of infiltrating immune cells are stained and can be detected. The histopathological 
analysis of the lungs was carried out by André Tittel and Magdalena Esser (Institutes of 
Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms 
Universität, Bonn, Germany). Staining of the lung slices revealed a strong immune cell 
infiltration in the lung tissue after transfer of the mAb 4B12 (Figure 3.19 A and B left panels). 
Large dense patches could be observed in the lung tissue in these mice, indicating a strong 
infiltration of neutrophils and a severe inflammation of the lungs. The respective isotype 
control antibodies did not induce an infiltration of immune cells or an inflammatory response 
in the lungs (Figure 3.19 A and B right panels). No histological changes of the lung tissue 
could be observed after transfer of the mAb 7D12 (Figure 3.19 C and D left panels). Here no 
clear differences to the mice, injected with the isotype control antibody could be detected. 
These findings indicate that hPR3-specific antibodies indeed are able to induce lung vasculitis 
and pulmonary lesions in hPR3+/+ mice. The pathogenicity of these antibodies, however, 
seems to be dependent on the subclass of the respective antibody, as only transfer of the 
IgG2a antibody 4B12 induced development of a GPA-like phenotype. 
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Figure 3.19: Injection of the hPR3-specific antibody 4B12 induced a strong inflammatory 
response in the lung tissue. Seven days after injection of hPR3-specific antibodies (300 µg/mouse) 
and LPS (3 ng/mouse) into hPR3+/+ mice, the animals were sacrificed, the lungs of the mice were 
dissected and the immune cell infiltration was analyzed by PAS-staining. A and B, Injection of the 
mAb 4B12 (left panels) led to severe inflammation of the lung tissue. In comparison to the isotype 
control antibody (right panels), large dense patches are visible in the lung tissue, indicating high 
neutrophil infiltration. C and D, No clear differences in the lung tissue after injection of the mAb 7D12 
(left panels) in comparison to the isotype control antibody (right panels) could be observed. 
Preparation and analysis of the lung slices were carried out by André Tittel and Magdalena Esser 
(Institutes of Molecular Medicine and Experimental Immunology, Rheinische Friedrich-Wilhelms 
Universität, Bonn, Germany) (n = 3 mice, one representative example shown for each condition). 
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3.5 Characterization of different types of ANCA in 
patients 
In the second part of this study the presence of inhibitory ANCA in patients with GPA and 
their correlation with disease activity was investigated. The initial question as to whether 
inhibitory ANCA can be identified in GPA samples was answered. Therefor total IgGs from 
plasmapheresis material of GPA patients, kindly provided by the Klinikum Großhadern, were 
precipitated. PR3-specific ANCA were affinity purified from the total IgG solution. Therefore 
biotinylated PR3 was bound to streptavidin columns and the PR3-specific ANCA were 
isolated. The elution fractions were tested for the presence of PR3-specific ANCA by ELISA. 
PR3 was immobilized on nickel-plates and the ANCA in the elution fractions were bound. 
The fractions, which were positively tested for the presence of PR3-specific ANCA, were 
then analyzed in an activity assay for their inhibitory capacity (Figure 3.20). PR3 activity was 
measured in the presence of a three-fold molar excess of ANCA. It was possible to detect 
inhibitory antibodies among the different patient samples. Antibodies, which strongly 
inhibited PR3 activity, could be observed in two patient samples. These findings clearly 
indicated that detection of inhibitory ANCA in patient material is possible and 
characterization of ANCA according to the activity modulating capacity in principle is 
feasible. 
 
Figure 3.20: Inhibitory ANCA exist in patients with GPA. PR3-specific ANCA, were purified from 
plasmapheresis material of patients with GPA by affinity chromatography. Biotinylated PR3 was 
bound to streptavidin columns, the total IgG solution, precipitated from the plasmapheresis material, 
was loaded onto the columns and PR3-specific ANCA were purified. PR3-specific ANCA were tested 
for their inhibitory capacity. Therefore ANCA were added to 50 nM PR3 at a three-fold molar excess 
and PR3 activity towards the FRET substrate TAMRA-VADnVVADYQ-Dap(CF) (5 µM) was 
measured (n = 3; ± SEM). 
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3.6 Detection of activity modulating ANCA in serum from 
patients with GPA 
As the affinity purification of PR3-specific ANCA from plasmapheresis material is very time 
consuming and a high amount of material is needed, a new method was developed, to 
characterize ANCA directly in serum or plasma samples from patients with GPA. The high 
levels of the natural PR3 inhibitor α1PI in serum and the anticipated low concentration and 
low affinity of PR3-specific ANCA, however, were challenging circumstances for the 
development of the new assay. In a standard activity assay PR3 would be immediately 
inhibited by the α1PI present in the serum samples. Different approaches, like heat 
inactivation or depletion of α1PI, were tested, to remove the α1PI from the patient samples. 
But all these attempts did not remove the α1PI completely. A simple, reliable procedure to 
purify IgGs from patient samples was needed. By using protein G coupled dynabeads, an IgG 
solution, which was free of α1PI, could be obtained. Furthermore the low concentration of 
PR3-specific ANCA had to be complemented by a very sensitive activity test. For the 
detection of the inhibitory capacity of these antibodies, they had to be added in quantities to 
generate at least a two-fold molar excess of PR3-specific IgG over PR3. Hence only a very 
low amount of PR3 could be used and a very sensitive FRET substrate was needed. For the 
measurement of the PR3 activity in the presence of ANCA, the used solution contained IgGs 
at relatively high concentrations. Therefore the intrinsic fluorescence (autofluorescence) of 
IgGs generated a relatively high background signal. A standard FRET-substrate, with 
fluorophore-quencher pairs in the short wavelength range was not appropriate, due to the high 
baseline fluorescence of the IgGs. A FRET substrate with a longer excitation and emission 
wavelength was required. Hence, a new FRET substrate was designed, containing an 
optimized peptide sequence for PR3 and TAMRA-fluorescein as a fluorophore-quencher pair. 
Measurements at the optimal wavelength of this substrate did not generate autofluorescence 
of the IgGs. Furthermore the optimized substrate was very sensitive, enabling measurements 
of very low amounts of active PR3. In Figure 3.21 the purification and measurement 
procedure is summarized. After purification of the total IgGs via protein G coupled dynabeads 
in a first step, ANCA were added to PR3 in free solution in an estimated four-fold molar 
excess. Cleavage of the optimized FRET substrate was measured over time. To reduce the 
sample volume, the measurements were carried out in black 384-microwell plates. Hence, 
only 4 µl of patient sample were required for one measurement.  
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Figure 3.21: New approach to detect activity modulating ANCA in patient samples. Total IgGs 
from serum or plasma samples of patients with GPA were isolated via protein G dynabeads. To 
evaluate the amount of PR3-specific inhibitory ANCA, the bound IgGs were taken up in the volume of 
the original serum sample. Total IgGs at concentrations similar to serum concentrations were added to 
10 nM PR3, resulting in an estimated four-fold molar excess of PR3-specific ANCA over PR3. 
Fluorescence was measured after adding 2.5 µM of TAMRA-VADnVRDYQ-Dap(CF).  
To confirm the practicability of this method, the procedure was tested with three serum 
samples containing ANCA with known inhibitory properties. The IgGs of the three serum 
samples R4, R7 and R17 were purified and then tested in the activity assay as described 
above. The samples R7 and R17 clearly inhibited PR3, whereas R4 did not influence the PR3 
activity (Figure 3.22). As a reference for the background, PR3 activity was measured in the 
presence of therapeutic intravenous immunoglobulins (so-called IVIGs). These IVIG 
preparations were used at the same concentration as total IgGs. As the inhibitory capacity of 
R7 and R17 was previously determined in a different way (by Ulrich Specks), the principle 
feasibility of this method could be ascertained with this experiment. ANCA with activity 
modulating capacity can be detected with this method.  
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Figure 3.22: Activity modulating ANCA in patient samples. To verify the new method, plasma 
samples from patients with known ANCA types were tested. Total IgGs were purified from plasma via 
protein G dynabeads. The inhibitory capacity of PR3-specific ANCA in this solution was measured in 
an activity assay with 10 nM PR3 and an estimated four-fold molar excess of ANCA. R7 and R17 
could be confirmed as PR3-inhibiting (n = 2; ± SEM). 
3.7 Correlation of activity modulating ANCA with disease 
progression in GPA 
To study the correlation of activity modulating ANCA with the course of disease in patients 
with GPA the samples gathered within the scope of the Wegener Granulomatosis Etanercept 
Trial (The Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group, 2005) were 
used (kindly provided by Ulrich Specks, Mayo Clinic, Rochester, USA). Baseline samples of 
180 patients, which were taken at enrollment, were used for the following experiments. In 
addition 150 follow-up samples of 13 patients with relapses during the assessment time and 
106 follow-up samples of eight patients without flares were measured. Activity modulating 
capacity of all these samples was determined. As negative controls, IgGs isolated from plasma 
samples of healthy control persons were used. In the patient samples, surprisingly not only 
ANCA with inhibitory capacity, but also ANCA with activity enhancing capacity towards 
PR3 could be detected (Figure 3.23). The samples were divided into three groups according to 
their ANCA type; inhibitory ANCA, neutral ANCA, which did not change PR3 activity, and 
activity enhancing ANCA. The proportion of these groups in relation to the total sample 
number was calculated. The vast majority of ANCA in the baseline samples (Figure 3.23 A) 
as well as in the follow-up samples (Figure 3.23 B) were inhibitory ANCA. Only a relative 
small proportion of ANCA displayed enhancing or neutral influence towards PR3. In the 
following the activity modulating capacity of ANCA is displayed as a percentage (%) of PR3 
inhibition. As the % PR3 inhibition is calculated by subtracting the measured PR3 activity 
from 100%, the values representing activity enhancing ANCA are negative. 
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Furthermore different capture ELISA approaches with all these samples were carried out by 
Ulrich Specks (Thoracic Disease Research Unit, Mayo Clinic and Foundation, Rochester, 
MA, USA), to assess the binding properties of the ANCA in the plasma samples.  
 
Figure 3.23: The majority of ANCA show inhibitory capacity towards PR3. The activity 
modulating capacity of PR3-specific ANCA from patients with GPA was determined in an activity 
assay after isolation of the total IgG fraction with protein G dynabeads. Baseline samples (A), which 
were taken at enrollment of the patients, and follow-up samples (B), which were taken regularly over 
the course of disease, were assessed. The samples were divided into groups according to their ANCA 
type and the proportion in relation to the total sample size was calculated. The vast majority of 
samples contained ANCA with inhibitory capacity. Only a small proportion of ANCA showed 
enhancing or neutral activity towards PR3. 
3.7.1 Inhibitory ANCA in baseline samples do not correlate with disease 
severity 
As a next step the activity modulating capacity of the baseline samples was examined in 
relation to disease severity. Disease severity in GPA is measured by the Birmingham 
Vasculitis Activity Score (BVAS). This score takes the recent disease activity of the previous 
month in consideration. A BVAS of 0 indicates no active disease, whereas a BVAS above 0 
stands for active disease. The BVAS is calculated according to disease severity and severity 
of organ involvement (Luqmani et al., 1994). Activity modulating capacity of ANCA from all 
baseline samples was measured and the samples were divided into four groups according to 
the occurring ANCA type. It was distinguished between ANCA, which inhibited PR3 (PR3 
inhibition between 10% and 50%), ANCA, which strongly inhibited PR3 (PR3 inhibition 
above 50%), ANCA, which did not affect the PR3 activity (PR3 inhibition between -10% and 
10%) and activity enhancing ANCA (PR3 inhibition below -10%). The median BVAS of 
these four groups was calculated and compared (Figure 3.24 A). No significant differences in 
disease activity between these four groups could be observed. As not all patients were newly 
diagnosed at the timepoint of enrollment for the study, the patients were additionally 
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separated into two groups. One group contained the newly diagnosed patients (n = 80), and 
the other group patients, who had recurrent disease at the time of enrollment (n = 99). To see 
if there is a correlation of the occurrence of inhibitory ANCA and disease onset, the median 
percentage of PR3 inhibition in these two groups was calculated. Comparison of the activity 
modulating effect revealed no significant difference (Figure 3.24 B). ANCA did not show a 
stronger inhibitory capacity at the time of diagnosis in comparison to ANCA from patients 
with recurrent disease. Furthermore the patients were divided into groups according to their 
disease severity. Patients with local, organ-restricted manifestations (limited disease: n = 52) 
were compared to patients with systemic, multi-organ manifestations (severe disease: n= 127). 
The median PR3 inhibition of these two groups was calculated (Figure 3.24 C). ANCA from 
patients with severe disease did not display a stronger activity modulating capacity in 
comparison to patients with limited disease. 
 
Figure 3.24: ANCA from baseline samples do not correlate with disease severity. To investigate 
the correlation of activity modulating ANCA with disease severity, baseline samples, which were 
taken at patient enrollment, were analyzed. A, Patients were divided into four groups, according to the 
activity modulating type of ANCA. It was distinguished between ANCA, which showed strong 
(> 50%) or moderate inhibition (10% to 50%), ANCA, that did not change PR3 activity (10% to -
10%) and activity enhancing ANCA (< -10%). The median Birmingham Vasculitis Activity Score 
(BVAS) of these groups was calculated. No significant differences were observed. B, Median PR3 
inhibition of ANCA from patients, which were newly diagnosed at enrollment, was compared with 
median inhibition of ANCA from patients with recurrent disease. No significant differences could be 
observed. C, Patients with multi-organ manifestations, which were characterized as suffering from 
severe disease, were compared to patients with local manifestations, with so-called limited disease. 
The median PR3 inhibition did not differ significantly in those two groups. 
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3.7.2 Presence of inhibitory ANCA is not related to organ involvement 
The BVAS displays only a value for the overall disease activity. To determine the correlation 
of activity modulating ANCA with single organ involvement, patients were divided into 
different groups according to the affected organs. The organs strongly affected by GPA are 
mainly, ear, nose, throat and mucous membrane, the kidneys and the lungs. To compare the 
ANCA types in regard to organ involvement the patients were separated into two groups for 
each manifestation, patients with and without involvement of the respective organ. The 
median PR3 inhibition of ANCA in these groups was calculated and compared. Patients with 
involvement of mucous membrane and/or ear, nose and throat showed no differences in 
comparison to patients without these symptoms (Figure 3.25 A). Patients with or without 
renal manifestations did not disclose differences in PR3 inhibition (Figure 3.25 B). In patients 
with disease of the lungs a slightly decreased PR3 inhibition could be observed, in 
comparison to patients without pulmonary involvement (Figure 3.25 C). These differences, 
however, did not reach statistical significance. To determine the cause for these differences 
patients were additionally analyzed, considering the occurrence of pulmonary nodules in 
patients with pulmonary involvement. The group of patients, which displayed pulmonary 
nodules, was compared to patients without pulmonary nodules. Comparison of these two 
groups revealed a decrease of PR3 inhibition in patients with pulmonary nodules (Figure 3.25 
D). Thus ANCA from patients without pulmonary nodules apparently have ANCA with 
stronger inhibitory potential.  
 
Figure 3.25: Inhibitory ANCA do not correlate with organ involvement. The median PR3 
inhibition of ANCA from baseline samples was calculated regarding involvement of certain organs. A, 
Patients with involvement of mucous membrane and ear, nose and throat where compared to patients 
without symptoms in these organs. The median PR3 inhibition did not differ in these samples. B, 
Comparison of patients with or without renal manifestations revealed no differences in PR3 inhibition. 
C, Median PR3 inhibition was slightly decreased in patients with pulmonary involvement in 
comparison to patients without pulmonary problems. The differences did not reach statistical 
significance. D, Median PR3 inhibition of patients with nodule formation in the pulmonary tract was 
calculated and compared to patients without nodule formation. In patients with pulmonary nodules the 
median PR3 inhibition was slightly decreased. 
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3.7.3 Disease activity does not correlate with activity modulating ANCA  
Correlation of activity modulating ANCA with disease activity over the course of disease was 
assessed using the follow-up samples of 12 patients with relapses and eight patients without 
flares. PR3 inhibition by these ANCA was analyzed considering disease activity at the time, 
the samples were taken. To answer the question, whether similar changes of PR3 inhibition 
occur in different patients, ANCA from baseline, remission and relapse samples were 
compared. No consistent changes in patients with (Figure 3.26 A) and without (Figure 3.26 C) 
relapses could be observed. Samples taken during timepoints of active disease (baseline and 
relapse samples) did not show a higher PR3 inhibition in comparison to remission samples 
(taken three month after enrollment, BVAS = 0). To further characterize the occurrence of 
inhibitory ANCA the PR3 inhibition over the course of disease was correlated to the BVAS of 
the respective patient. One example of this correlation of a relapsing patient (Figure 3.26 B) 
and of a patient without flare (Figure 3.26 D) is shown. In general no correlation of disease 
activity and presence of inhibitory ANCA could be observed. Inhibitory ANCA did also occur 
during remission. Over longer remission periods even a rising increase in PR3 inhibition 
could be observed. This was especially noticeable in patients without flare. In 62.5% of these 
patients such an increase in PR3 inhibition was detectable. In relapsing patients such an 
increase of PR3 inhibition could also be observed during remission phases in 58% of the 
analyzed patients. These findings suggest that there is no direct correlation between disease 
activity and inhibitory ANCA. However, increasing inhibitory capacity of ANCA during the 
remission phase in some patients expired in a relapse. Thus increasing inhibition over time in 
patients in remission could be a sign for future relapses.  
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Figure 3.26: Over the course of disease no correlation with activity modulating ANCA could be 
detected. Follow up samples of patients with relapses (A and B) and of patients without flares (C and 
D) were analyzed, to investigate correlation of PR3 inhibition with disease activity. A, PR3 inhibition 
of baseline samples, samples from patients in remission and from relapse samples is displayed. No 
consistent or significant changes in PR3 inhibition at states of active disease (baseline and relapse) 
could be detected (n = 12). B, PR3 inhibition of ANCA over the course of disease was correlated to 
the BVAS of the respective patient. Relapses did not occur in parallel with inhibitory ANCA. 
However increasing inhibitory potential of ANCA prior to relapses could be detected in 58% of 
patients (n = 13, one example shown). C, In patients without flares PR3 inhibition of baseline samples 
(active disease) was compared to remission samples. No consistent differences could be observed 
(n = 8). D, Correlation of PR3 inhibition in patients without flares with the respective BVAS revealed 
an increase of PR3 inhibition during remission in 62.5% of patients. In general occurrence of activity 
modulating ANCA did not correlate with BVAS (n = 8, one example shown). 
3.7.4 Epitopes of inhibitory ANCA are located on the active site surface of 
PR3 
The localization of the binding region of inhibitory ANCA was determined with two different 
capture ELISA approaches. PR3 was captured onto 96-well plates with the antibodies 
MCPR3-3 or MCPR3-2 and the ANCA binding to PR3 was detected. MCPR3-3 binds to the 
backside of the PR3 molecule. In a capture ELISA with MCPR3-3 ANCA binding to the front 
of the molecule (active site region) could be detected. In the MCPR3-2 capture ELISA all 
available ANCA epitopes are displayed. ANCA from all serum samples are able to bind to 
PR3 in this capture ELISA approach. The ratio of these two measurements was calculated 
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(MCPR3-3/2 ratio) and the relative binding epitope was determined. A high ratio suggests 
binding of the ANCA to the active site region of the molecule. In contrast, a low ratio 
indicates ANCA binding at the remaining epitopes. To map the binding site of the inhibitory 
ANCA the activity modulating effect was correlated to the respective MCPR3-3/2 ratio 
(Figure 3.27). Therefore the follow-up samples of the 13 patients with relapses (Figure 3.27 
A) and of the eight patients without flares (Figure 3.27 B) were used. In both patient groups a 
correlation of PR3 inhibition with the MCPR3-3/2 ratio could be observed. High PR3 
inhibition occurred in parallel to high MCPR3-3/2 ratio values. As this high ratio indicates an 
ANCA binding to the active site region, these results suggest, that inhibitory ANCA mainly 
bind in the active site region of the molecule. 
 
Figure 3.27: Inhibitory ANCA bind to active site surface of PR3. Approximate binding region of 
all ANCA samples from the WGET study were detected by MCPR3-2 and MCPR3-3 capture ELISA. 
The ratio of both capture ELISAs was calculated (MCPR3-3/2 ratio). In the MCPR3-2 capture ELISA 
all available ANCA epitopes are displayed. MCPR3-3 binds to the backside of the molecule and 
enables ANCA binding to the front (active site region). Thus a high ratio indicates binding of ANCA 
to the active site region. A low ratio in contrast suggests binding of ANCA to the remaining epitopes. 
Activity modulating capacity of ANCA from all follow-up samples were determined and correlated to 
the results of the MCPR3-3/2 ratio. In patients, who had relapses during the course of disease (n = 13) 
(A), as well as in patients without relapses (n = 8) (B) the curves for % PR3 inhibition and MCPR3-
3/2 ratio showed a strong correlation (one representative sample shown of each group). Plasma 
samples with high PR3 inhibition in parallel also bound to the active site region of PR3. 
Changes in PR3 activity, however, were not only caused by inhibitory ANCA but also by 
ANCA with enhancing activity. To map the binding region of the activity modulating ANCA 
in general, the samples were divided into two groups, according to their binding epitope. To 
this end the MCPR3-3/2 ratio, obtained in the two capture ELISA formats, was used. Samples 
with a high ratio were taken together in a group, displaying ANCA, which bind to the active 
site region of the molecule. The other samples, with a low ratio, represent ANCA with 
preferential binding to the remaining epitopes. The occurrence of activity modulating ANCA 
in these two groups were calculated (Figure 3.28). A higher proportion of activity modulating 
ANCA (85%) was observed in the group containing the ANCA, which bound to the active 
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site region. ANCA with preferential binding to the other epitopes contained only 75% activity 
modulating ANCA. These findings suggest a more frequent binding of activity modulating 
ANCA to the active site region. 
 
Figure 3.28: Activity modulating ANCA occur more frequently in samples with ANCA binding 
to the active site surface. The follow-up samples of 21 patients were divided into two subgroups 
according to their binding epitope. ANCA binding to the active site region (high MCPR3-3/2 ratio) 
were separated from ANCA which bound to the remaining regions (low MCPR3-3/2 ratio). The 
proportion of activity modulating ANCA in those groups were calculated and compared. ANCA with 
activity modulating capacity occurred more frequently in samples which displayed binding to the 
active site region. 85% of ANCA in this group changed the activity of PR3 in comparison to 75% in 
the samples containing ANCA, which bound to the remaining epitopes. 
3.7.5 Inhibitory ANCA bind not directly into the active site cleft 
In Figure 3.27 it could be shown, that the epitope of the inhibitory ANCA is located at the 
active site region. However the direct binding site as well as the mechanism of inhibition has 
yet to be addressed. To examine, if the inhibitory ANCA bind directly to the active site cleft, 
the active site cleft of PR3 was blocked by elafin. PR3-elafin complexes were formed by 
adding elafin at a ten-fold molar excess to PR3 and incubation for one hour. The complexes as 
well as PR3 alone were immobilized on nickel-plates and ANCA binding to both PR3-
variants was compared by ELISA. For the analysis the 150 follow-up samples of the patients 
with relapses were used. OD measurements revealed a strong binding of ANCA to both, free 
PR3 and PR3-elafin complexes. No differences between the two variants could be observed, 
indicating that binding of elafin to the active site cleft did not obscure the epitope of 
inhibitory ANCA (Figure 3.29). In contrast, ANCA binding to PR3 and PR3-elafin is strongly 
correlated to each other. Despite the mapping of the epitope in the active site region, PR3 
inhibition by ANCA is not carried out by a direct blocking of the active site cleft. Thus 
inhibition of PR3 by an indirect allosteric mechanism is most likely. 
Correlation of activity modulating ANCA with disease progression in GPA 
 
74 
 
 
Figure 3.29: The epitopes of inhibitory ANCA are still accessible in the presence of elafin. 
Binding of ANCA to PR3 and to PR3-elafin complexes was detected in an ELISA. Elafin was added 
to PR3 in a ten-fold molar excess and incubated for one hour at 37 °C. PR3 and PR3-elafin complexes 
were immobilized on nickel plates via the 6 × His-tag of PR3 and the binding of ANCA from plasma 
samples (dilution 1:50) was observed. The 150 follow up samples of the relapsing patients have been 
investigated. ANCA binding to PR3 was strongly correlated to ANCA binding to PR3-elafin 
complexes (r = 0.9466, p < 0.0001). 
3.7.6 Inhibition mechanism of some ANCA resembles MCPR3-7 
inhibition 
To further clarify the inhibition mechanism of ANCA, the extent of epitope sharing with 
MCPR3-7 was analyzed. MCPR3-7 is able to inhibit PR3 by an allosteric mechanism as 
described above (see chapter 3.3.6 and 3.3.7). The question as to whether inhibitory ANCA 
inhibit PR3 by a similar mechanism was answered by employing a MCPR3-7 capture ELISA. 
In this capture ELISA overlapping of ANCA with the MCPR3-7 epitope could be determined. 
A high signal in the MCPR3-7 capture ELISA indicated a different binding epitope, whereas a 
low signal indicated ANCA binding at the same epitope as MCPR3-7. The capture ELISA 
measurements were carried out using the follow-up samples of the 13 patients with relapses 
(Figure 3.30 A and B) and the eight patients without flares (Figure 3.30 C and D). The results 
were than correlated to the PR3 inhibition values of these ANCA. In some graphs the curves 
for PR3 inhibition and the MCPR3-7 capture ELISA correlated strongly to each other (Figure 
3.30 A and C). This means that ANCA, which inhibited PR3 activity, at the same time were 
able to bind to the MCPR3-7 capture ELISA. Thus these ANCA do not bind to the same 
epitope as MCPR3-7. In contrast some patients also showed a negative correlation of the two 
curves (Figure 3.30 B and D). Here samples with inhibitory ANCA could not bind in the 
MCPR3-7 capture ELISA, indicating a similar inhibition mechanism as MCPR3-7. These 
findings suggest a heterogeneous inhibition mechanism of ANCA, which may sometimes be 
mediated by ANCA subpopulations with MCPR3-7-like properties. 
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Figure 3.30: Some inhibitory ANCA bind to the MCPR3-7 epitope. To determine an overlap of the 
epitope from inhibitory ANCA with the MCPR3-7 epitope a MCPR3-7 capture ELISA was 
performed. A low signal in this ELISA strongly indicates a binding epitope similar to MCPR3-7. Thus 
a low signal in the MCPR3-7 capture ELISA, which occurs in parallel with high PR3 inhibition, 
suggests a similar binding mechanism of inhibitory ANCA and MCPR3-7. An overlap of the curves 
for PR3 inhibition and the MCPR3-7 capture ELISA, in contrast, implies no epitope sharing of 
inhibitory ANCA and MCPR3-7. PR3 inhibition of relapsing patients (A and B; n = 13; one sample 
shown for each condition) and of patients without flares (C and D; n = 8; one sample shown for each 
condition) were correlated with the signals obtained in the MCPR3-7 capture ELISA. In some patients 
correlation of both curves was observed (A and C), whereas the curves in other patients where 
negatively correlated (B and D). These findings indicate that only some ANCA inhibit PR3 by a 
similar mechanism as MCPR3-7. 
The overlap with the MCPR3-7 epitope of activity modulating ANCA in general was 
analyzed in Figure 3.31. The samples were subdivided into two groups, according to the 
results of the MCPR3-7 capture ELISA. One group contained the ANCA, which displayed a 
low signal in this ELISA, thus representing ANCA, which shared the MCPR3-7 epitope. The 
other group contained ANCA, which bound to different epitopes than MCPR3-7 and showed 
a high signal in the MCPR3-7 capture ELISA. The occurrence of activity modulating ANCA 
in both groups was calculated. No differences between these two groups could be observed. 
ANCA that bound to the same epitope as MCPR3-7 displayed a proportion of 79% activity 
modulating ANCA. Comparably, 81% of ANCA, which bound to the other epitopes, were 
activity modulating ANCA. A correlation of activity modulating ANCA with the binding to 
the MCPR3-7 epitope could not be observed. 
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Figure 3.31: Activity modulating ANCA do not bind more frequently to the MCPR3-7 epitope. 
The samples were divided into two groups according to their ability to bind to the MCPR3-7 epitope. 
One group consisted of ANCA, which shared the MCPR3-7 epitope, and the other group contained 
ANCA, which bound to the remaining epitopes. The proportion of activity modulating ANCA was 
calculated for both groups. Comparison of both groups revealed no differences in the amount of 
activity modulating ANCA, indicating a low occurrence rate of MCPR3-7 like ANCA in GPA 
patients. 
However, as shown in Figure 3.30 some ANCA apparently bind to the same epitope as 
MCPR3-7. To answer the question if these ANCA also inhibit by the same mechanism as 
MCPR3-7 an activity assay in the presence of an excess of proPR3 was carried out. MCPR3-7 
is able to bind to mature PR3 and inhibit its activity. As already described mature PR3 can 
adopt different conformations and is not held rigidly in its active conformation. Binding of 
MCPR3-7 induces changes in the PR3 conformation, resulting in an inactive zymogen-like 
conformation. However, MCPR3-7 preferably binds to proPR3. By adding proPR3 to a mix 
of PR3 and MCPR3-7 it is able to prevent the inhibition of the mature PR3 (Figure 3.32 A). 
To see if this is also possible in the case of ANCA, three patient samples were chosen (# 117, 
# 125, # 143), which bound to proPR3 at least to the same extent as to mature PR3. An 
activity assay in the presence of a ten-fold molar excess of proPR3 was performed with these 
samples. In two of the three samples (# 117, # 143) the inhibitory capacity towards PR3 was 
decreased in the presence of proPR3 (Figure 3.32 B). These findings suggest that some 
specificities of inhibitory ANCA appear to overlap with that of MCPR3-7. However, the 
majority of ANCA regulate the catalytic activity of PR3 by another, as yet unknown allosteric 
mechanism. 
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Figure 3.32: Inhibition mechanism of some ANCA reflects inhibition by MCPR3-7. A, To reduce 
the inhibitory effect of MCPR3-7 on PR3, a three-fold and a ten-fold molar excess of proPR3 was 
added to the reaction. PR3 (10 nM) was mixed with proPR3 and a four-fold molar excess of MCPR3-7 
was added. After incubation at 37 °C for one hour, PR3 activity was measured with TAMRA-
VADnVRDYQ-Dap(CF) (2.5 µM) (n = 3; ± SEM). B, Three plasma samples (# 117, # 125, # 143), 
which showed strong binding to the proform and to the mature form of PR3 were examined, regarding 
the effect of a ten-fold molar excess of proPR3 on their inhibitory capacity. ANCA from protein G 
purified IgGs were added at a four-fold molar excess to PR3 (10 nM) with proPR3 (100 nM), 
incubated for one hour at 37 °C and activity was measured with TAMRA-VADnVRDYQ-Dap(CF) 
(2.5 µM). As control protein G purified IgGs from a healthy control person were used (# 0). The 
relative PR3 activity was determined by normalizing PR3 activity in presence of the control antibodies 
to 1 (n = 3; ± SEM). Presence of proPR3 resulted in weaker PR3 inhibition in only two samples 
(# 117, # 143). These observations suggest that most inhibitory ANCA do not bind and inhibit PR3 in 
the same way as MCPR3-7.   
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4. Discussion 
4.1 Expression and functionality of PR3 in the humanized 
mouse 
The human promotor region of the PR3 gene contains a TATA-box, a CAAT-box and GC-
rich elements (Jenne, 1994). In contrast, the murine PR3 promotor region includes, besides a 
TATA-box, a c-myb and a PU.1 binding region (Sturrock et al., 1998). To ensure the 
expression of hPR3 in the transgenic mice under natural conditions, the murine sequence of 
the promotor region, exon 1 and large parts of intron1 were maintained in the humanized gene 
locus. Indeed, no differences could be observed in the transcription of the mPR3 and the hPR3 
gene in transgenic mice, which were heterozygous for the humanized gene locus (Figure 3.2 
A). Despite the similar mRNA levels of mPR3 and hPR3 in heterozygous mice, the protein 
expression of hPR3 in the knock-in mice was reduced in comparison to mPR3 in wildtype 
mice (Figure 3.2 B). The propeptide of PR3, which is located at the beginning of exon 2 and 
consists of only two amino acids, is not conserved between the human and the murine PR3. 
The propeptide in hPR3 is Ala-Glu, the propeptide in hNE and mNE is Ser-Glu. In the mPR3 
the propeptide is Ser-Lys. Here the amino acid at the P1 position is changed to a basic amino 
acid and the propeptide is now positively charged (Sturrock et al., 1998). Due to these 
differences, it is unclear, if the human propeptide is effectively cleaved by the murine 
dipeptidyl aminopeptidase I (DPPI). The human DPPI is able to cleave Glu-Lys (Kummer et 
al., 1996). About mouse DPPI, however, it is only known, that it is able to activate neutral 
murine serine proteases in general (Pham et al., 1997). Furthermore DPPI deficiency leads to 
decreased PR3 expression levels in patients with Papillon-Lefèvre syndrome (Pham et al., 
2004). Thus it is possible that a reduced capability of murine DPPI to cleave the propeptide of 
hPR3 causes the lower expression of mature hPR3, in particular as no differences on 
transcription levels could be observed.  
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Surface expression of PR3 is an important factor in the development of GPA. Antibodies 
against PR3 interact with the protein on the neutrophil surface and induce activation of the 
neutrophils, resulting in inflammation of the vessel walls and the surrounding tissue. Thus 
detection of hPR3 on the surface of the mouse neutrophils was crucial for the generation of an 
animal model for GPA. After activation of neutrophils with PMA hPR3 was slightly 
expressed on the surface of knock-in PMNs (Figure 3.5). In contrast to mPR3, which cannot 
be found on the surface of naïve neutrophils (Pfister et al., 2004), hPR3 is able to bind to the 
NB1 receptor on the neutrophil surface via its hydrophobic patch (Korkmaz et al., 2008). 
Besides protein expression, correct folding and catalytic activity of hPR3 in the transgenic 
neutrophils is an important prerequisite for a useful new animal model. A new method, with a 
lipidated FRET-reporter, which is specific for a protease and is targeted to the plasma 
membrane, was the perfect tool, to assess the catalytic activity of PR3 on the membrane 
surface of neutrophils. Local activity of MMP-12 and NE on the cell surface was already 
analyzed with such a lipidated FRET-reporter (Cobos-Correa et al., 2009; Gehrig et al., 2012). 
Similarly the activity of membrane-bound PR3 could be assessed with a PR3-specific 
lipidated FRET-reporter (Figure 3.6 and 3.7). As this method is highly sensitive, active PR3 
was also detected on TNFα-primed neutrophils of knock-in mice (Figure 3.7 B and E). 
Despite the detectable surface expression of PR3 in PMA treated PMNs, PR3 activity on the 
surface of these cells was reduced in comparison to TNFα-primed neutrophils (Figure 3.6 E 
and 3.7 E). Stimulation of neutrophils with PMA leads to a strong degranulation of 
azurophilic and specific granules (Yurewicz and Zimmerman, 1977). Mason et al. 
demonstrated that α1PI, the natural inhibitor of PR3, is not only expressed by hepatocytes, 
but can also be synthesized in neutrophils (Mason et al., 1991). In the neutrophils α1PI is 
localized in the azurophil granules and is thus released after PMA activation. Hence it is 
likely that despite an increased expression of PR3 on the neutrophil surface after PMA 
stimulation, PR3 activity is partly inhibited by α1PI and thus only a reduced activity signal of 
PR3 could be observed.  
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4.2 MCPR3-7, a unique antibody with PR3-inhibiting 
potential 
4.2.1 MCPR3-7 in comparison to other antibodies 
Based on the literature, antibodies with inhibitory capacity towards the proteolytic activity of 
PR3, have a high pathogenic potential (Daouk et al., 1995; Dolman et al., 1993; van der Geld 
et al., 2002) and thus seemed most promising for the transfer into the transgenic mice. The 
inhibitory potential and binding properties of a set of mAbs were characterized to this end. 
One of these antibodies, MCPR3-7, was found to display inhibitory capacity towards PR3 
(Figure 3.8). The other antibodies did not affect the activity of PR3. In case of CLB-12.8 this 
was rather surprising. Due to its binding epitope, which is located in close proximity to the 
active site cleft (Silva et al., 2010), inhibitory capacity of this antibody was expected. In 
addition to the lack of inhibitory capacity of CLB-12.8, it also did not interfere with the 
covalent or canonical complexation of PR3 to α1PI (Figure 3.10 C and 3.11). The binding of 
CLB-12.8 to the covalent PR3-α1PI complex, however, was impaired (Figure 3.9 B). This 
loss of binding ability of CLB-12.8 towards the covalent PR3-α1PI complexes can be 
explained by the conformational transition of the active site cleft of PR3 after covalent 
interaction with α1PI. This conformational change could already be observed with elastase 
and α1PI (Huntington et al., 2000) and in the complex between trypsin and an Arg-mutant of 
α1-antitrypsin (Dementiev et al., 2006). In the covalent complex the P1 residue of the RCL is 
no longer buried in the S1 pocket of the enzyme. Furthermore the autolysis loop 142 – 129, 
the 186 – 190 loop and the four N-terminal residues are disordered resulting in an inactive 
conformation of the protease. These changes probably affect the CLB-12.8 epitope and 
prevent the interaction with the antibody. In case of MCPR3-7, however, which has higher 
binding affinity to the proform of PR3, covalent complexation induces the foundation of the 
MCPR3-7 epitope (Figure 3.9 A). Conversely, binding of MCPR3-7 to the fixed active 
conformation of PR3 was not possible. As MCPR3-7 nevertheless inhibits PR3 activity, it 
apparently is only able to interact with PR3 in an intermediate conformation of the mature 
molecule. For that reason MCPR3-7 is able to inhibit PR3 activity and interaction of PR3 with 
α1PI (Figure 3.10 B and 3.11). The inhibition mechanism of MCPR3-7 is discussed in detail 
in the following chapter. Among the tested antibodies, MCPR3-7 was the only one with 
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inhibitory capacity towards PR3 activity and its complexation with α1PI, turning it into an 
interesting candidate for transfer experiments in hPR3+/+ mice. 
4.2.2 MCPR3-7 and its mechanism of inhibition 
The proform and the mature form of PR3 adopt two different conformations of high structural 
similarity. The only differences detected in those two forms are in the activation domain 
(Fehlhammer et al., 1977). The differential binding of MCPR3-7 to the two conformations, 
which was observed in the course of this thesis, suggests a binding epitope near the activation 
domain. Binding of MCPR3-7 to the stabilized active conformation was not possible. AAPV-
CMK, a mechanism-based small inhibitor, forms a stable covalent complex with PR3 and 
stabilizes the active conformation of the molecule. No binding of MCPR3-7 to these PR3-
inhibitor complexes could be observed in the thermophoretic quantification (Figure 3.13) as 
well as in ELISA experiments (Figure 3.9 A). Consistent with these findings, MCPR3-7 was 
not able to bind to the canonical PR3-α1PI-complexes or the PR3-elafin complexes, which 
both display PR3 in its active conformation. MCPR3-7 appears to be a conformation specific 
antibody, which discriminates between the active and the inactive conformation of PR3. 
Mapping of the MCPR3-7 epitope to the active site region was confirmed in an activity assay 
with human/gibbon chimeras (Figure 3.12). On the carboxy-terminal half, which contains the 
activation domain, the gibbon PR3 has non-conservative residue substitutions (Lys187Gly; 
Trp218Arg; Ala146Thr) (Kuhl et al., 2010). PR3 variants containing this gibbon carboxy-
terminal β-barrel were not inhibited by MCPR3-7, indicating binding of the mAb to the 
carboxy-terminal half of the molecule. These results were consistent with the findings of Silva 
et al. (Silva et al., 2010). Here the MCPR3-7 epitope in mPR3 could be reconstituted with 
human residues, and the binding near to the active site region could be confirmed. 
Despite an inability of MCPR3-7 to bind to the fixed active conformation of PR3, it is able to 
bind to free mature PR3 and to inhibit its activity. Mature PR3 is not held rigidly in its active 
conformation. Even after propeptide cleavage it can adopt a zymogen like conformation 
(Pozzi et al., 2012), enabling MCPR3-7 to interact with the mature form. This interaction of 
MCPR3-7 with the mature PR3, however, was weak and about 40-fold lower than the binding 
to proPR3 (Figure 3.9 A and 3.13). Nevertheless MCPR3-7 strongly inhibited the activity of 
mature PR3 (Figure 3.8). Binding of the antibody probably can force PR3 into an inactive 
conformation, which results in the loss of the S1 binding site and the oxyanion hole. The 
inhibitory effect of MCPR3-7 was first detected with the optimized peptide substrate Abz-
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YYAbu-ANBNH2. The amino acid residues of this substrate occupy the S1 – S3 pockets. In 
addition, the S4 and the S1´ pocket are engaged by the fluorophore-quencher pair. Thus the 
inhibitory effect could not be traced back to a distinct peptide binding pocket on the basis of 
this substrate. Substrates with other leaving groups in the P1´ position, like for example 5-
amino-2-nitrobenzoic acid (ANB-OH), para-nitroaniline (pNA), the benzyl mercaptan from 
SBzl or the para nitrophenol (Boc-L-A-ONp) are known to interact less efficiently with the 
S1´ subsite of PR3, than ANB-NH2 substrates (Wysocka et al., 2008). PR3 was indeed able to 
cleave two such substrates in the presence of MCPR3-7 (Figure 3.14 D and E), indicating that 
MCPR3-7 primarily alters the shape and access of the S1´ pocket. After MCPR3-7 binding 
only smaller and less polar leaving groups were accepted in the S1´ pocket. To exclude an 
influence of MCPR3-7 on the S1 pocket of PR3, substrates with smaller (Ala) and larger 
(nVal) P1 residues were tested. No changes of PR3 activity after variation of P1 residues was 
observed. As elucidated in Figure 4.1, these findings confirm, that besides the preference of 
MCPR3-7 for the proform of PR3 (Z), interaction with mature PR3 (E) is possible, due to the 
ability of mature PR3 to adopt different conformations. Binding of MCPR3-7 to mature PR3 
shifts the equilibrium of the different mature conformations towards the inactive conformation 
(E*), by altering the S1´ pocket. Hence, the presence of MCPR3-7 reduces the activity and 
alters the interaction of PR3 with substrates. Due to the altered accessibility of the active site 
cleft the interaction of α1PI with PR3 in presence of MCPR3-7 is furthermore reduced and 
the complexation delayed (Figure 3.10 and 3.11). 
 
Figure 4.1: Interaction of MCPR3-7 with proPR3 and mature PR3. MCPR3-7 binds preferentially 
to the proform (Z) of PR3. Binding of MCPR3-7 to proPR3 results in slight conformational changes of 
the zymogen (Z*). Mature PR3 occurs in two different conformations, an active (E) and an inactive 
(E*) conformation, which are in equilibrium in free solution. Binding of MCPR3-7 shifts this 
equilibrium towards the inactive conformation (E*). Interaction with the antibody stabilized the 
inactive conformation of PR3 and changed the activity and substrate interaction with PR3. 
Furthermore MCPR3-7 has an inhibitory effect on the complexation of PR3 with α1PI (dotted line). 
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Antibodies, which can interfere with the activity of proteases, can be divided into two 
different groups according to their mode of action (Ganesan et al., 2010). One group contains 
antibodies, like MCPR3-7, which inhibit the protease activity by induction of an allosteric 
switch in the protease. These antibodies do not compete directly with the substrate for the 
active binding pocket. In contrast, they bind a region at the periphery of the substrate binding 
cleft and cause a conformational switch of surface loops, which determine the size and the 
shape of the binding pockets. Such antibodies are able to reduce, alter or completely suppress 
the catalytic activity of proteases. The second group of antibodies inhibits the protease 
activity by direct binding to the active site cleft. The surface loops of these antibodies insert 
directly into the substrate binding pockets. Thereby the access of the substrate to the active 
site is blocked. This form of antibodies is rarely found in mammals and hardly induced by 
immunizations. These previous observations are consistent with our findings, indicating that 
MCPR3-7 inhibited PR3 by an allosteric effect. The autolysis loop, as well as the 187-190 
loop, are loops, which shape the S1, S1´and S2´ pockets (Fujinaga et al., 1996). Thus these 
loops are good targets for allosteric regulation of enzyme activities. Binding of MCPR3-7 is 
probably facilitated by partial rearrangement of these loops in the mature enzyme and this 
interaction then results in changes in substrate recognition and interactions of PR3 with the 
RCL of α1PI. 
4.2.3 Limitations of MCPR3-7 
Despite the interesting properties of MCPR3-7, utilization of this mAb for transfer 
experiments proves to be difficult. Detection of membrane-bound PR3 with MCPR3-7 was 
not possible (Figure 3.15). The epitope of MCPR3-7 was mapped to a region, which lies near 
the hydrophobic patch of PR3 (Silva et al., 2010). Korkmaz et al. identified this hydrophobic 
patch as the region of PR3, which interacts with the NB1 receptor (CD177) on human 
neutrophil membranes. Binding of PR3 to the neutrophil membrane most likely obscures the 
epitope of MCPR3-7 (Korkmaz et al., 2008) and prohibits the detection of membrane-bound 
PR3 by MCPR3-7. Thus neutrophil activation by MCPR3-7, which was crucial for disease 
induction in mice, is not possible. Activation of neutrophils via MCPR3-7-PR3 immune 
complexes would be another possibility to provoke an inflammatory response. The low 
affinity of MCPR3-7 for mature PR3 (Figure 3.9 and 3.13), however, makes the formation of 
such immune complexes unlikely. Hence, transfer of MCPR3-7 into the hPR3 knock-in mice 
would probably not lead to the induction of systemic vasculitis. 
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4.3 The GPA mouse model 
4.3.1 Induction of inflammation by transfer of hPR3 antibodies 
Interaction of PR3-ANCA with neutrophils induces respiratory burst, degranulation of the 
neutrophils and release of cytokines (Falk et al., 1990; Grimminger et al., 1996; Kettritz et al., 
1997). Despite several attempts to assess the pathogenicity of ANCA in a mouse model, direct 
evidence for ANCA pathogenicity is still missing. Differences in the expression of human and 
murine PR3 as well as differences in interactions of FcγRs and IgGs in mice and humans 
complicated the development of a suitable mouse model for GPA. The first indication that 
antibodies against PR3 are able to trigger inflammatory responses was published by Pfister et 
al. in 2004. Antibodies against murine PR3 were generated in PR3/NE double knock-out mice 
and transferred into wildtype mice. A pro-inflammatory activity of these antibodies in 
combination with a primary inflammatory stimuli (LPS or TNFα) was observed (Pfister et al., 
2004). These mice did not develop disease related symptoms, probably due to the weak direct 
interaction of antibodies with mPR3 on murine neutrophils. In another study human 
neutrophils, expressing hPR3 on their surface, were used to enable direct interaction of hPR3-
specific antibodies with neutrophils (Hattar et al., 2010). Here TNFα-primed human 
neutrophils and monoclonal antibodies against hPR3 were injected into isolated rat lungs. The 
direct interaction of the mAb with hPR3 on the surface of neutrophils led to severe vascular 
leakage and edema formation. However, no morphological changes could be observed in 
these lungs. As only an isolated organ system was examined in this study a statement about 
the pathogenicity of ANCA in GPA could not be made. To study the effect of PR3 antibodies 
on the whole organism two different transgenic mouse models, expressing hPR3, were 
already created. In one of these mouse models, however, hPR3 was expressed under the 
control of a podocin promotor and thus expression was redirected and restricted to the kidneys 
(Relle et al., 2013). Injection of mAbs against hPR3 did not lead to morphological changes of 
the kidneys in this model. The expression of hPR3 in the kidneys, however, was only 
analyzed at RNA level. Lack of pathogenic changes in the kidneys could also be due to a lack 
of hPR3 expression. Involvement of the kidneys is a hallmark of the generalized form of 
GPA. In early localized stages of the disease, manifestations in the kidneys are rarely 
observed in patients. Analysis of the mice already five days after injection of the antibodies 
might thus have been too early. 
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To overcome differences in human and murine FcγRs and IgGs and due to the lack of cross-
reactive epitopes between human and mouse PR3, a human hematopoietic system was 
reconstituted in severely immune-compromised mice by injection of human hematopoietic 
stem cells in irradiated, bone marrow-depleted mice (Little et al., 2012). In this model the 
lungs of the mice indeed showed vasculitic changes and hemorrhage after injection of human 
IgG from patients with GPA. Furthermore mild glomerulonephritis with leukocyte infiltration 
was observed in these mice. These findings led the authors to postulate a clear pathogenic role 
of total IgG from GPA-patients in vivo. Nevertheless they admitted that the ability of human 
leukocytes to adhere to the murine endothelium and to transmigrate through mouse blood 
vessels was questionable. Furthermore the majority of recruited leukocytes were murine. Only 
a few human leukocytes infiltrated the tissue. The humanization of the murine immune 
system thus was not complete in this model. Hence it is possible that the present murine 
immune cells disturb the tolerance induction of the human immune cells and lead to a graft 
versus host reaction. Therefore it is likely that the observed immune response is not only 
caused by interaction of antibodies with hPR3 on human neutrophils, but also by an immune 
defense reaction to the human bone marrow graft. 
Due to the many discrepancies in the existing animal models for GPA and due to the lack of 
evidence for the pathogenicity of ANCA a new mouse model was generated within the work 
of this thesis, to analyze the role of ANCA. In the transgenic mouse generated in this study 
the hPR3 is expressed in and on the mouse neutrophils, enabling expression of PR3 under 
natural conditions and direct interaction of hPR3-specific antibodies. Apart from the 
expression of the hPR3 the murine immune system was kept unchanged resulting in normal 
expression of the murine FcγRs and normal effector functions of the immune cells. Hence 
usage of murine mAbs enabled interaction of FcγR and IgG under natural conditions. In 
addition to the antibodies LPS was injected into the transgenic mice, to induce a mild 
inflammation. LPS is an initial trigger to prime neutrophils for degranulation and also induces 
endothelial activation (Li et al., 2010). Furthermore it was already shown by Pfister et al. that 
the proinflammatory effect of the antibodies is increased in combination with a primary 
inflammatory stimulus like LPS (Pfister et al., 2004). Injection of the antibody induced a 
recruitment of immune cells to the lungs in the transgenic mice (Figure 3.18) and an 
inflammatory response. This immune cell infiltration was confirmed by histopathological 
analysis of the lungs, which revealed a strong inflammation in the lung vessels and the lung 
tissue. Hence, it could be shown that hPR3 antibodies indeed have the capacity to induce 
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vasculitis and inflammations in the lungs. However, the effect of the antibody transfer on the 
kidneys has not yet been examined. To gather a complete comprehension of the pathogenicity 
of PR3-specific antibodies this aspect of the model still needs to be investigated in further 
detail.  
4.3.2 The immune response is triggered by properties of immunoglobulins 
The immune response to antibodies is triggered by the interaction of the immunoglobulins 
with the FcγRs on the immune cells. This interaction on one hand is characterized by the 
heterogenicity of the FcγRs, regarding expression pattern, specificity and effector functions. 
On the other hand binding of FcγRs to the immunoglobulins is influenced by the different 
affinities of the IgG subclasses for the receptors. Posttranslational modifications like for 
example glycosylation of antibodies and receptors can further modulate the interaction. 
Abnormalities in one of these factors can favor the development of different diseases. 
Polymorphisms in FcγRs that are known to reduce the immune complex clearance for 
example are a risk factor for Systemic Lupus Erythematosus and GPA (Dijstelbloem et al., 
1999, 2000). The use of mice, which are transgenic for the human FcγR further enabled the 
analysis of the pathological mechanisms and role of the human FcγR. With these mice a 
contribution of the human FcγRs to antibody-mediated disease could be shown (Gillis et al., 
2014). Mice as well as humans have three activating FcγRs and one inhibitory receptor 
(Nimmerjahn and Ravetch, 2012). Despite this general similarity of the receptors in mice and 
men, they exhibit differences in the expression pattern and their binding abilities (Bruhns, 
2012). Thus interaction with the different IgG subclasses can lead to activation of different 
effector functions. These differences have to be considered for the generation of mouse 
models. In the new transgenic mouse model of this thesis these discrepancies have been 
avoided. Only the gene for murine PR3 was replaced in the mice by the human variant. The 
transferred antibodies were murine antibodies, ensuring the correct interaction of the murine 
FcγRs and the immunoglobulins. Usage of human antibodies would nevertheless be possible, 
due the ability of murine FcγRs to bind to human IgG (Bruhns, 2012). However, it is not clear 
if the binding affinities of murine FcγRs to human IgG subclasses differ from the affinities to 
murine IgG subclasses and if therefore other effector functions would be activated. Mice and 
humans have four different IgG subclasses (mice: IgG1, IgG2a, IgG2b and IgG3; humans: 
IgG1, IgG2, IgG3 and IgG4). The most potent subclasses in activating effector responses in 
mice are IgG2a and IgG2b. Therefore these antibody types are most frequently observed in 
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autoimmune diseases (Nimmerjahn and Ravetch, 2005). The different subclasses vary in their 
activation potential towards FcγRs (Kocher et al., 1998; Mulder et al., 1995). Thus the 
functional responses are dependent on the respective subclass. Each IgG subclass has a unique 
activation profile of effector functions and efficacy (Roux et al., 1997). For ANCA it could 
already be shown, that the different subclasses indeed can have a differential influence on 
disease progression. The subclasses differ especially with regard to the activation of 
neutrophils and the induction of inflammatory responses. IgG3 are the most potent mediators 
of neutrophil activation followed by IgG1, which is still more potent than IgG4 (Pankhurst et 
al., 2011). Based on these differences, I decided to inject antibodies of different subclasses 
into the transgenic knock-in mice. IgG2a and IgG2b are able to bind to all activating FcγRs in 
mice. Among the different subclasses IgG2a binds with the highest affinity to the activating 
FcγRs (Bruhns, 2012). Therefore it is not surprising that the PR3-specific antibody 4B12, 
which is an IgG2a antibody, had the strongest effect on immune cell recruitment and 
induction of inflammation (Figure 3.18). In contrast, injection of 7D12 led only to a slight 
recruitment of neutrophils and macrophages. The resulting inflammation was less pronounced 
in comparison to 4B12. 7D12 is an IgG2b antibody. The slightly lower affinity of IgG2b for 
the activating FcγRs probably is the reason for the differences in the immune response to 
these two antibodies. These findings clearly indicate a pathogenic role of the PR3-specific 
antibodies in the development of inflammation and a GPA-like phenotype. According to these 
results pathogenicity of PR3 antibodies seems to depend on the respective subclasses.  
Besides structural differences in immunoglobulins and FcγRs, posttranslational modifications 
can also influence the interaction between receptors and IgGs and thus modulate the immune 
response. IgGs have a conserved N-glycosylation site at Asn297 (Ferrara et al., 2011). The 
attached glycans can change the affinity of the immunoglobulin for the receptors and 
therefore regulate the immune response. Deglycosylation of IgG for example reduces the 
binding to FcγR or complement and thus impairs the activation of the effector functions. Lack 
of fucosylation, by contrast, enhances the interaction with FcγRs. The binding affinity to the 
receptor increases and the effector functions are activated (Krapp et al., 2003). Also an 
influence of glycosylation on autoimmune diseases could already be shown. A reduced 
galactosylation is further known to be associated with ANCA associated vasculitides (Holland 
et al., 2002). Thus it is conceivable, that the development of an immune response in the 
present mouse model can also be influenced by the carbohydrate structure and composition of 
the injected antibodies. 
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4.4 Contribution of ANCA to GPA development and 
disease progression 
4.4.1 Influence of activity modulating ANCA on disease progression 
Enzymes, which are presented on the membrane, are possible targets, as they are directly 
accessible for autoantibodies. Hence, enzymes in neutrophil granules, like for example PR3, 
NE and MPO, which are released upon activation of neutrophils and can be bound to the 
neutrophil surface, are often target antigens in autoimmune diseases. Due to the fact that 
autoantibodies are often directed against proteolytic enzymes it is possible, that their 
pathogenic effect is based on an interference of the antibodies with biological functions of the 
enzymes. Interference of the autoantibodies with the proteolytic activity of the respective 
enzyme, however, is still questionable. Studies to answer these questions were already 
initiated a long time ago. Inhibition of the three major ANCA-autoantigens, PR3, NE and 
MPO, by autoantibodies was not observed in one of the first studies (Chang and Savige, 
1993). It is possible, however, that the assay used for these observations was not sensitive 
enough to detect the low subpopulation of autoantibodies, which interact with the catalytic 
surface region. In another study, conducted by van de Wiel et al., the inhibitory potential of 
PR3-ANCA from eight patients was analyzed. A 45-fold molar excess of total IgG was able 
to reduce the PR3 activity towards Suc-AAPV-pNA and FITC-labeled elastin (van de Wiel et 
al., 1992). The strong inhibitory effect of small amounts of ANCA and the high fraction of 
PR3-specific antibodies (16%), however, was puzzling.  
Besides interference of autoantibodies with enzymatic functions, also correlation of this 
interference with disease progression and severity was in question. Daouk et al. analyzed the 
effect of purified total IgG on PR3 activity towards Boc-A-ONp dependent on disease 
activity. With a 20-fold molar excess of total IgG over PR3, inhibitory ANCA were detected 
in eight out of ten patients with active disease and one out of seven patients in remission. The 
apparent constant determined for the inhibitory effects was pretty high (56.5 µM), suggesting 
that IgG populations with low PR3 affinity accounted for these effects (Daouk et al., 1995). 
Conversely, van der Geld et al. analyzed samples of 26 patients with active disease and 17 
patients in remission and identified inhibitory ANCA in all these samples. For these 
measurements a lower total IgG concentration was used (100 µg/ml). This latter group 
furthermore observed on average higher ANCA titers during relapse phases. The fraction of 
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the non-inhibitory ANCA, however, increased during active disease, whereas the pool of 
inhibitory ANCA did not (van der Geld et al., 2002). According to this study inhibitory 
ANCA did not appear to cause or initiate active disease and were not regarded as a predictor 
for relapses. 
The previous studies, discussed in the last paragraphs, do not give a clear answer to the 
question as to whether inhibitory ANCA correlate with disease activity. The reason for the 
controversial discussions in the literature may be due to differences in the methodologies. 
Based on the uncertainties and technical inadequacies detected in these studies, a new method 
was developed in this thesis to solve this controversy. To determine the allosteric effects of 
autoantibodies on PR3 activity, the properties of the used substrate plays an important role. Its 
interaction with PR3 is dependent on the type and concentration of the substrate. Small 
substrates, like for example Boc-A-ONp, react only with a small region of the active site cleft 
(S1 and S1´ pocket). To assess conformational changes along the entire active site cleft 
extended peptide substrates are necessary, which align with up to eight prime and non-prime 
subsites. Usage of FRET-based reporters increases further the sensitivity to distortions along 
the binding cleft and work at lower concentrations. Due to the high concentrations of total 
IgG required to test the functional properties of ANCA, autofluorescence of IgG in the low 
excitation wavelength range causes a high background and limits sensitivity. To overcome the 
autofluorescence problem, a TAMRA-fluorescein pair was chosen for the newly developed 
assay in combination with a highly sensitive peptide sequence.  
In previous studies the inhibitory capacity of ANCA was directly compared to changes in 
ANCA titers over the course of disease. ANCA titer measurements, which are carried out by 
ELISA, however, identify a different set of antibodies than activity measurements in free 
solution. The direct immobilization of the antigen in ELISA experiments can lead to loss or 
alteration of epitopes, changes in enzymatic or biological activity or generation of new 
epitopes in the antigen. Immobilized antigens are not displayed in the same manner as in 
solution. Hence, indirect ELISA approaches are sometimes preferred. The performed washing 
steps further reduce the level of bound ANCA with lower affinities. Thus only high affinity 
antibodies can be detected. In an activity assay, in contrast, the measurements are performed 
in free solution. For that reason binding of low affinity antibodies is not reduced by washing 
steps and a different set of antibodies can be detected. Measurement of PR3 inhibition could 
only be achieved with concentrated IgG solutions. The low affinity ANCA are recognized in 
these assays, whereas high serum dilutions in ELISA experiments disfavor the binding of 
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these ANCA. Already van der Geld et al. noticed the low concentrations and affinity of 
inhibitory ANCA. Consistent with these findings and the methodological discrepancies, a 
dilution of the IgG samples led to a loss of signal in the activity assay, whereas an ELISA 
signal could be observed at even higher dilutions. Therefore it is not too surprisingly that no 
correlation between ANCA titers and inhibitory capacity was reported (Dolman et al., 1993). 
To detect these low affinity and low concentrated inhibitory ANCA, a high molar excess of 
purified IgG had to be added to a small amount of PR3. In the newly developed assay the IgG 
concentrations after purification were only slightly lower as found in human serum. Already 
at these slightly lower concentrations of ANCA an influence on PR3 activity could be 
determined. Analysis of baseline samples from 180 patients and follow-up samples of 21 
patients revealed that the majority of ANCA was able to inhibit the activity of PR3 (Figure 
3.23). Additionally a group of ANCA was identified, which was able to enhance the activity 
of PR3. As all ANCA were able to bind to PR3-elafin complexes, activity modulating ANCA 
do not appear to directly interact with the active site cleft of PR3 and probably interfere with 
PR3 activity by an allosteric mechanism. Mature PR3 in free solution is able to adopt 
different conformations (Pozzi et al., 2012) as already explained in chapter 4.2.2. For that 
reason, it is likely that PR3 activity enhancing ANCA stabilize the active conformation of 
PR3 and thus shift the conformational continuum of PR3 towards its active conformation.  
As the amount of ANCA in human serum is even slightly higher than in our activity test, it 
can be assumed that ANCA interfere with functions of PR3 in vascular compartments or at 
sites of neutrophil extravasation. Hence, inhibitory ANCA must be considered as a potential 
determinant for disease severity, organ manifestations or disease progression. However no 
correlation between disease activity and PR3 activity modulating ANCA was detectable in the 
present study. Separation of baseline samples into groups according to their type of activity 
modulating ANCA did not reveal differences in the median BVAS (Figure 3.24 A). The 
occurrence of inhibitory ANCA was furthermore not correlated with disease outbreaks 
(Figure 3.24 B) or intensity of disease (Figure 3.24 C). Organ involvement is, as already 
described, a marker for disease severity. Especially involvement of lungs and kidneys occurs 
mostly in patients with severe or generalized GPA. Comparison of the median PR3 inhibition 
in patient groups, subdivided according to the involvement of certain organs, however, did not 
reveal any significant differences (Figure 3.25). In patients with lung involvement PR3 
inhibition was slightly reduced. This reduction of PR3 inhibition was even more pronounced 
in patients with lung nodules. Over extended periods of observation times inhibitory ANCA 
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did not solely occur in phases of active disease, but could also be detected during remission 
(Figure 3.26). No consistent changes in inhibitory capacity were seen at any time over the 
course of the disease (Figure 3.26 A and C). 
One reason for the discrepancy between the present study and the study conducted by Daouk 
et al. might be the low number of samples, especially for remission phases in the latter. Usage 
of the substrate Boc-A-ONp furthermore evaluated only interactions of ANCA with the S1 
site. Thus more subtle allosteric effects were not recognized and could be the reason for the 
lack of inhibitory ANCA in the remission samples. As already explained, in the new activity 
assay the concentration of total IgGs was not kept at a fixed PR3-IgG ratio. In contrast to 
Daouk et al. and van der Geld et al., who used the IgG at a fixed concentration, the 
concentration of total IgG here was close to the IgG concentrations of the respective samples 
and reflected the fluctuations of IgG in the patients. Hence, the detection of inhibitory ANCA 
was more sensitive and inhibitory ANCA could also be detected during remission. Van der 
Geld et al. also noticed inhibitory ANCA during remission. They observed that these 
inhibitory ANCA did not rise at the same extend as non-inhibitory ANCA during active 
disease phases. Similarly, in the present study an increase in the inhibitory potential of ANCA 
could be observed during stable remission phases (Figure 3.26 B and D). In patients, who did 
not display a flare during the time of assessment, 62.5% of patients displayed such an 
increasing inhibitory potential of ANCA over time. In relapsing patients this effect could be 
detected in 58% of patients. As this increase in inhibitory potential could be seen in both 
patient groups no statement can be made about the occurrence of a following relapse. 
In summary no correlation between inhibitory ANCA and active disease could be observed in 
the present study. Inhibitory ANCA occurred also during remission phases and thus cannot be 
seen as harbingers of relapses. A review of previous patient studies furthermore showed, that 
total ANCA titers during remission, can only restrictedly be used for the prediction of relapses 
(Tomasson et al., 2012). In line with these findings no characteristic fluctuations of functional 
ANCA types with predictive value could be observed in this study. Thus it is most likely that 
no close relationship between activity modulating ANCA and overall disease process exists. 
Contribution of ANCA to GPA development and disease progression 
 
92 
 
4.4.2 Interference of activity modulating ANCA with α1PI inhibition of 
PR3 
It is well known that in patients with GPA different subsets of PR3-specific ANCA occur, 
which recognize different epitopes (Sommarin et al., 1995). In this thesis the focus lay on 
ANCA, which were able to modify the catalytic activity of PR3. Inhibitory ANCA as well as 
activity enhancing ANCA were found to bind predominantly to the active site surface of the 
PR3 molecule (Figure 3.27 and 3.28). Due to the location of their binding site, activity 
modulating ANCA interfere with PR3 activity and may thus influence disease development in 
several different ways. Interaction of ANCA with PR3 could for example directly hinder 
access to substrates. However, it could already be shown for one patient sample, that 
inhibition of PR3 rather takes place by an allosteric, non-competitive interaction (Daouk et 
al., 1995). Blocking of the active site cleft of PR3 with elafin did also not influence the ability 
of ANCA to bind to PR3 (Figure 3.29), confirming an interference of activity modulating 
ANCA with PR3 by an allosteric mechanism.  
Binding of activity modulating ANCA could further impair the inhibition of PR3 by α1PI. 
Indirect alterations of the active site cleft by ANCA can hinder interaction with α1PI and thus 
antigen clearance or removal of PR3 from the neutrophil surface. As a consequence 
neutrophil activation via membrane-bound PR3 and via ANCA binding to PR3 and FcγRs 
would be increased, leading to excessive inflammations and development or worsening of 
GPA. Several studies already reported an interference of ANCA with PR3-α1PI interaction 
(Daouk et al., 1995; Dolman et al., 1993; van der Geld et al., 2002; van de Wiel et al., 1992). 
In the experiments conducted by Dolman et al. patient sera were diluted 1:40 and small 
amounts of PR3 were added to measure the inference of ANCA with PR3-α1PI complexation. 
In a RIA the extent of complex formation in presence of ANCA was evaluated after 
30 minutes (Dolman et al., 1993). In this assay the PR3-α1PI complexes were captured with 
the mAb CLB-12.8. Characterization of the mAbs in this thesis, however, revealed that CLB-
12.8 has only poor affinity for covalent α1PI-PR3 complexes (Figure 3.9, see also Kuhl et al., 
2010). Thus it is likely that with this method only the minor fraction of reversible, non-
covalent complexes (Duranton and Bieth, 2003) was precipitated. Therefore the extend of 
complex formation in ANCA sera after addition of external PR3 remains unclear. In a similar 
study by Gross et al. a lack of interference of PR3-ANCA with α1PI complexation was 
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reported. The results of this study, however, were only mentioned in a review of the literature 
(Gross et al., 1993). 
In general it has to be considered that the in vitro experiments to assess the interference of 
ANCA with PR3-α1PI complexation were conducted with specifically designed ratios and 
concentrations of inhibitor, antibodies and PR3. In presence of these low concentrations of 
inhibitor the inhibitory ANCA may be able to change the kinetics of the PR3 interaction. The 
concentration of α1PI in plasma and in epithelial lining fluid, however, is very high and 
inactivates PR3 within milliseconds (Duranton and Bieth, 2003), making a significant 
interference of ANCA with α1PI-inhibition unlikely. Such low concentrations of α1PI, which 
would favor the interference of inhibitory ANCA with PR3-α1PI complexation, are rarely 
seen in patients with GPA. Most GPA-patients have normal levels of α1PI. An exception are 
carriers of the Z-allele. Individuals, who are homozygous for the Z-allele, are known to have a 
slightly higher risk for GPA. With regard to the overall GPA-risk, however, homozygosity for 
the Z-allele only plays a minor role in the Caucasian population. In recent studies it could be 
shown that deficiency of α1PI in general induces excessive activation and degranulation of 
neutrophils via TNFα. This excessive degranulation additionally was detected to favor the 
development of autoantibodies against granule proteins like for example lactoferrin (Bergin et 
al., 2014). It is already known that α1PI deficiency worsens the clinical presentation and 
outcome of GPA patients (Segelmark et al., 1995). Biosynthesis of the mutated Z-variant by 
liver cells and primary airway epithelial cells lead to aggregation of α1PI. This aggregation 
can trigger stress responses via pro-inflammatory signaling and may lower the threshold for 
the adaptive immune response. However PR3- or MPO-positive ANCA are only rarely found 
in homozygous healthy carriers of the Z-allele, indicating that other factors, not the clearance 
of PR3 by α1PI, are important for PR3-directed immune response (Audrain et al., 2001). Thus 
Audrain et al. postulated that α1PI deficiency rather acts as an amplifying factor in GPA. 
4.4.3 Activity modulating ANCA inhibit PR3 by different allosteric 
mechanisms 
For the better understanding of the pathogenic potential of ANCA, the specific molecular 
interactions between ANCA and PR3 need to be understood. A potential interference of 
antibodies with PR3 activity could be shown with the mAb MCPR3-7. In addition to the 
preferential binding of this mAb to the proform of PR3 it is able to induce a conformational 
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transition of mature PR3. This conformational alteration of PR3 affected furthermore the 
interaction with α1PI. Due to these unique properties of MCPR3-7, I decided to search for 
ANCA subtypes, which displayed MCPR3-7 like properties, to characterize the interaction of 
ANCA and PR3 further. Therefore the excess of epitope sharing between ANCA and 
MCPR3-7 was analyzed. In some patients an overlap with the MCPR3-7 epitope occurred in 
parallel with strong inhibitory capacity (Figure 3.30 B and D). In other patients, however, the 
inhibitory ANCA showed strong binding to the remaining epitopes in the MCPR3-7 capture 
ELISA (Figure 3.30 A and C). Furthermore comparison of the proportion of activity 
modulating ANCA in general in relation to the MCPR3-7 epitope did not reveal any 
differences (Figure 3.31). These results argue for at least two different mechanisms of 
interference with PR3 activity. MCPR3-7 is further known to have a higher affinity to 
proPR3. ProPR3 was able to neutralize the inhibitory effect of MCPR3-7 towards PR3 
(Figure 3.32 A). Hence, the inhibitory capacity of ANCA with MCPR3-7 like properties 
should also be influenced by proPR3. ProPR3 could only partly reverse the inhibitory effect 
of ANCA, which showed a high affinity for the proform. Only in two from the three analyzed 
samples the inhibitory fraction was neutralized by proPR3 (Figure 3.32 B). These findings 
indicate that only a small proportion of ANCA inhibit PR3 by a similar mechanism as 
MCPR3-7. The vast majority of ANCA, however, probably regulate the activity of PR3 by an 
allosteric alteration of its mature conformation. 
4.5 Conclusions 
The aim of this thesis was to explore whether antibodies against hPR3 play a pathogenic role 
in the development of GPA and by which mechanisms these antibodies could contribute to the 
disease progression. Based on the literature, antibodies, which are able to inhibit the 
proteolytic activity of PR3, were thought to influence the development of relapses. Analysis 
of a large GPA patient cohort, however, revealed that activity modulating antibodies, despite 
their high occurrence rate among the patients, do not correlate with active disease and do not 
influence the disease progression. Due to shared interaction sites of activity modulating 
antibodies and α1PI on the PR3 molecule, it is likely that these antibodies impair the 
inhibition by α1PI and thus also the clearance of PR3. As these antibodies were not found to 
correlate with active disease in this study, the interference with α1PI inhibition, however, can 
only be seen as amplifying factor and not as a causative trigger of relapses. Due to the missing 
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evidence of the higher pathogenicity of inhibitory antibodies PR3-specific antibodies with 
different IgG subclasses were used for the generation of a GPA mouse model. The PR3-
specific antibodies were indeed able to induce an inflammatory response in the mice, proofing 
their pathogenic potential. After recruitment of immune cells, activation and degranulation of 
neutrophils led to a local type of lung vasculitis and pulmonary lesions. The development of a 
GPA-like phenotype in this model, however, seemed to be dependent on the IgG subclass, as 
IgG2a antibodies were able to elicit a stronger inflammatory response than IgG2b antibodies. 
In future further optimization of this model and injection of different types of antibodies 
opens the possibility to investigate the pathogenicity of different hPR3-specific antibody 
subsets, with regard to their subclass identity, in ANCA associated vasculitis in more detail. 
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6. Abbreviations 
 
α1PI Alpha-1-proteinase inhibitor 
AAV ANCA-associated vasculitis 
Abu Aminobutyric acid 
ANCA Anti-neutrophil cytoplasmic antibody 
APS Ammonium persulfate 
BCA Bicinchonic acid 
Boc Tert-butoxycarbonyl 
BSA Bovine serum albumin 
CDR Complementarity determining region 
CG Cathepsin G 
CMK Chloromethyl ketone 
CSS Churg-Strauss Syndrome 
DMSO Dimethyl sulfoxide 
dNTP Deoxyribonucleotide triphosphate 
DPPI Dipeptidyl aminopeptidase I 
EDTA Ethylenediaminetetraacetic acid 
FcγR Fcγ receptor 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
FRET Fluorescence/Förster resonance energy transfer 
gibPR3 Gibbon PR3 
GPA Granulomatosis with Polyangiitis 
GWAS Genome wide association study 
HBSS Hank’s Balanced Salt solution 
HEK Human embryonic kidney cell line 
hNE Human NE 
hPMNs Human PMNs 
hPR3 Human PR3 
hPR3+/+ Human PR3 knock-in 
HRP Horseradish peroxidase 
IgG Immunoglobulin G 
IL Interleukin 
IVIG Intravenous Immunoglobulin 
λAb Absorption wavelength 
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λEm Emission wavelength 
λEx Extinction wavelength 
LPS Lipopolysaccharide 
mAb Monoclonal antibody 
MMP Matrix metalloproteinase 
mNE Mouse NE 
MPA Microscopic polyangiitis 
mPMNs Murine PMNs 
MPO Myeloperoxidase 
mPR3 Mouse PR3 
NE Neutrophil elastase 
NET Neutrophil extracellular trap 
NSP Neutrophil serine protease 
NSP4 Neutrophil serine protease 4 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
PEI Polyethylenimine 
PFA Paraformaldehyde 
PMA Phorbol-12-myristate-13-acetate 
PMNs Polymorphonuclear cells 
PR3 Proteinase 3 
proPR3 Proform of PR3 
PVDF Polyvinylidene difluoride 
RFU Relative fluorescence unit 
ROS Reactive oxygen species 
RPMI Roswell Park Memorial Institute medium 
RT-PCR Reverse transcription polymerase chain reaction 
SBzl Thiobenzyl ester 
SD Standard deviation 
SDS Sodium dodecyl sulfate 
SEM Standard error of the mean 
SigIgκ Signal peptide derived from Igκ 
TNFα Tumor necrosis factor α 
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7. Appendix 
7.1 Vector maps 
7.1.1 pcDNA5/FRT/V5-His-TOPO® 
 
Vector 7.1: Vector map of the pcDNA5/FRT/V5-His-TOPO vector. The pcDNA5 vector 
contains a promotor of the cytomegalovirus (CMV), two different polyadenylation signals 
(BGH and SV40), an E. coli origin of replication (pUC ori) and two resistance genes 
(Ampicillin and Hygromycin) for selection in E. coli. All relevant recognition sites of 
restriction enzymes, the V5 epitope and the 6 × His tag are depicted. The vector was 
purchased from life technologies. 
Vector maps 
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7.1.2 pTT5 
 
Vector 7.2: Vector map of the pTT5 vector. The important components of the pTT5 vector 
are an E. coli origin of replication (pMB1ori) and an EBV specific origin of replication 
(OriP), a promotor of the cytomegalovirus (CMV), an adenovirus tripartite leader (TPL), a 
major late promotor (MLP), a rabbit beta-globin polyadenylation signal (pA) and an 
ampicillin resistance gene for selection in E. coli. All important recognition sites of restriction 
enzymes are depicted. The vector was procured from the NRC Biotechnology Research 
Institute. 
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7.2 Sequences 
7.2.1 SigIgκ-proPR3-H6 
The amino acid sequence is shown in single letter code. The sequence begins with the SigIgk 
signal peptide, the N-terminal S-tag is displayed in bold and underlined. The enterokinase 
cleavage site was underlined. The sequence of the mature PR3 is displayed in bold. The C-
terminal 6 × His-tag is marked in italics and the stop codon is represented by a star (*). 
  1  ATGGAGACAGACACACTCCTGCTATGGGTACTGCTGCTCTGGGTACCAGGTTCCACTGGT   60 
  1  M  E  T  D  T  L  L  L  W  V  L  L  L  W  V  P  G  S  T  G     20 
 
 61  GACGTGAAAGAAACCGCTGCTGCTAAATTCGAACGCCAGCACATGGACAGCGGAAGCGGT  120 
 21  D  V  K  E  T  A  A  A  K  F  E  R  Q  H  M  D  S  G  S  G     40 
 
121  GGACACGTGGATGACGACGACAAAATCGTGGGCGGTCACGAGGCGCAGCCACACTCCCGG  180 
 41  G  H  V  D  D  D  D  K  I  V  G  G  H  E  A  Q  P  H  S  R     60 
 
181  CCCTACATGGCCTCCCTGCAGATGCGGGGGAACCCGGGCAGCCACTTCTGCGGAGGCACC  240 
 61  P  Y  M  A  S  L  Q  M  R  G  N  P  G  S  H  F  C  G  G  T     80 
 
241  TTGATCCACCCCAGCTTCGTGCTGACGGCCGCGCACTGCCTGCGGGACATACCCCAGCGC  300 
 81  L  I  H  P  S  F  V  L  T  A  A  H  C  L  R  D  I  P  Q  R    100 
 
301  CTGGTGAACGTGGTGCTCGGAGCCCACAACGTGCGGACGCAGGAGCCCACCCAGCAGCAC  360 
101  L  V  N  V  V  L  G  A  H  N  V  R  T  Q  E  P  T  Q  Q  H    120 
 
361  TTCTCGGTGGCTCAGGTGTTTCTGAACAACTACGACGCGGAGAACAAACTGAACGACATT  420 
121  F  S  V  A  Q  V  F  L  N  N  Y  D  A  E  N  K  L  N  D  I    140 
 
421  CTCCTCATCCAGCTGAGCAGCCCAGCCAACCTCAGTGCCTCCGTCGCCACAGTCCAGCTG  480 
141  L  L  I  Q  L  S  S  P  A  N  L  S  A  S  V  A  T  V  Q  L    160 
 
481  CCACAGCAGGACCAGCCAGTGCCCCACGGCACCCAGTGCCTGGCCATGGGCTGGGGCCGC  540 
161  P  Q  Q  D  Q  P  V  P  H  G  T  Q  C  L  A  M  G  W  G  R    180 
 
541  GTGGGTGCCCACGACCCCCCAGCCCAGGTCCTGCAGGAGCTCAATGTCACCGTGGTCACC  600 
181  V  G  A  H  D  P  P  A  Q  V  L  Q  E  L  N  V  T  V  V  T    200 
 
601  TTCTTCTGCCGGCCACATAACATTTGCACTTTCGTCCCTCGCCGCAAGGCCGGCATCTGC  660 
201  F  F  C  R  P  H  N  I  C  T  F  V  P  R  R  K  A  G  I  C    220 
 
661  TTCGGAGACTCAGGTGGCCCCCTGATCTGTGATGGCATCATCCAAGGAATAGACTCCTTC  720 
221  F  G  D  S  G  G  P  L  I  C  D  G  I  I  Q  G  I  D  S  F    240 
 
721  GTGATCTGGGGATGTGCCACCCGCCTTTTCCCTGACTTCTTCACGCGGGTAGCCTTCTAC  780 
241  V  I  W  G  C  A  T  R  L  F  P  D  F  F  T  R  V  A  L  Y    260 
 
781  GTGGACTGGATCCGTTCTACCCTGAAAACCGGTCATCATCACCATCACCATTGA        834 
261  V  D  W  I  R  S  T  L  K  T  G  H  H  H  H  H  H  *          278 
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7.2.2 ∆hPR3-S195A 
The amino acid sequence is shown in single letter code. The sequence begins with the signal 
peptide. This mutant lacks the codons for the amino-terminal propeptide, starting directly with 
the sequence of the mature PR3, which is displayed in bold. The S195A mutation is marked 
bold and underlined. The C-terminal 6 × His-tag is marked in italics and the stop codon is 
represented by a star (*). 
  1  ATGGCTCACCGGCCCCCCAGCCCTGCCCTGGCGTCCGTGCTGCTGGCCTTGCTGCTGAGC   60 
  1  M  A  H  R  P  P  S  P  A  L  A  S  V  L  L  A  L  L  L  S     20 
 
 61  GGTGCTGCCCGAGCTATCGTGGGCGGTCACGAGGCGCAGCCACACTCCCGGCCCTACATG  120 
 21  G  A  A  R  A  I  V  G  G  H  E  A  Q  P  H  S  R  P  Y  M     40 
 
121  GCCTCCCTGCAGATGCGGGGGAACCCGGGCAGCCACTTCTGCGGAGGCACCTTGATCCAC  180 
 41  A  S  L  Q  M  R  G  N  P  G  S  H  F  C  G  G  T  L  I  H     60 
 
181  CCCAGCTTCGTGCTGACGGCCGCGCACTGCCTGCGGGACATACCCCAGCGCCTGGTGAAC  240 
 61  P  S  F  V  L  T  A  A  H  C  L  R  D  I  P  Q  R  L  V  N     80 
 
241  GTGGTGCTCGGAGCCCACAACGTGCGGACGCAGGAGCCCACCCAGCAGCACTTCTCGGTG  300 
 81  V  V  L  G  A  H  N  V  R  T  Q  E  P  T  Q  Q  H  F  S  V    100 
 
301  GCTCAGGTGTTTCTGAACAACTACGACGCGGAGAACAAACTGAACGACGTTCTCCTCATC  360 
101  A  Q  V  F  L  N  N  Y  D  A  E  N  K  L  N  D  V  L  L  I    120 
 
361  CAGCTGAGCAGCCCAGCCAACCTCAGTGCCTCCGTCGCCACAGTCCAGCTGCCACAGCAG  420 
121  Q  L  S  S  P  A  N  L  S  A  S  V  A  T  V  Q  L  P  Q  Q    140 
 
421  GACCAGCCAGTGCCCCACGGCACCCAGTGCCTGGCCATGGGCTGGGGCCGCGTGGGTGCC  480 
141  D  Q  P  V  P  H  G  T  Q  C  L  A  M  G  W  G  R  V  G  A    160 
 
481  CACGACCCCCCAGCCCAGGTCCTGCAGGAGCTCAATGTCACCGTGGTCACCTTCTTCTGC  540 
161  H  D  P  P  A  Q  V  L  Q  E  L  N  V  T  V  V  T  F  F  C    180 
 
541  CGGCCACATAACATTTGCACTTTCGTCCCTCGCCGCAAGGCCGGCATCTGCTTCGGAGAC  600 
181  R  P  H  N  I  C  T  F  V  P  R  R  K  A  G  I  C  F  G  D    200 
 
601  GCCGGTGGCCCCCTGATCTGTGATGGCATCATCCAAGGAATAGACTCCTTCGTGATCTGG  660 
201  A  G  G  P  L  I  C  D  G  I  I  Q  G  I  D  S  F  V  I  W    220 
 
661  GGATGTGCCACCCGCCTTTTCCCTGACTTCTTCACGCGGGTAGCCCTCTACGTGGACTGG  720 
221  G  C  A  T  R  L  F  P  D  F  F  T  R  V  A  L  Y  V  D  W    240 
 
721  ATCCGTTCCACGCTGCGCCGTGTGGAGGCCAAGGGCCGCCCCGGGCCCTTCGAACAAAAA  780 
241  I  R  S  T  L  R  R  V  E  A  K  G  R  P  G  P  F  E  Q  K    260 
 
781  CTCATCTCAGAAGAGGATCTGAATATGCATACCGGTCATCATCACCATCACCATTGA     837 
261  L  I  S  E  E  D  L  N  M  H  T  G  H  H  H  H  H  H  *       279 
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